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Abstract 
 
Ovarian cancer is a disease which is fatal in the majority of cases. The 
evolution of surgery and chemotherapy over the past 30 years has resulted in 
improvements in overall and progression-free survival. However, the rate of 
relapse in ovarian cancer is very high, suggesting that current treatment 
strategies are ineffective. Therefore, to overcome the poor prognosis of 
ovarian cancer, immunotherapeutic strategies have been devised such as the 
use of anti-CTLA-4 antibody therapy in melanoma. The principle that the 
immune system can affect either cancer development or clearance has been 
the subject of debate for over a century.  Clinical results of novel 
immunotherapeutic approaches that aim to exploit and enhance this 
immunogenicity have had mixed success such as IL-2 therapy in renal cell 
carcinoma. It is clear that whilst many tumours possess antigenic component 
in their make-up, they do not stimulate durable and effective immune 
responses In vivo. This may reflect the fact that tumours develop a network of 
escape mechanisms to circumvent tumour-specific immunity.   
Due to the ineffectual nature of current treatment options and the complexity 
of the tumour microenvironment a coherent stratagem needs to be 
composed.  This thesis explores, in principle, a contemporary strategy to 
propagate an anti-tumour immune response within ovarian cancer by using 
existing drugs in combination to target three different facets of ovarian cancer 
immunity; Regulatory T cell (Treg) migration, poor release of the tumour-
associated antigen, MUC1, and reduced cytotoxic T cell (CTL) proliferation. 
The migration of Regulatory T cell (Treg) to ovarian cancer is principally 
mediated by the CCR4-CCL22 chemokine receptor-chemokine axis. AZ1, a  
specific antagonist for the chemokine receptor CCR4, which is highly 
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expressed on Treg, abrogated the migration of these cells to the chemokine. 
This compound did not alter Treg function suggesting that its activity was 
specifically against Treg migration.   
In order to induce an adequate T cell response, sufficient antigen needs to be 
provided. Camptothecin, a classical topoisomerase inhibitor, demonstrated 
effective tumour cell death and release of the tumour-associated antigen, 
MUC1. The increase in tumour antigen release and decrease in tumour load 
was offset by significant immune toxicity. The incorporation of Camptothecin 
into a synthetic drug delivery system led to a decrease in immune toxicity 
ZKLOHUHWDLQLQJWKHGUXJ¶VDQWL-tumour activity.     
Finally, in order to take advantage of tumour antigen release, it would be 
desirable to stimulate CTL. Imiquimod, the toll-like receptor 7 agonist, widely 
used in basal-cell carcinoma and melanoma was able to demonstrate a 
potential enhancement of an anti-tumour response in three ways. Firstly, the 
drug enhanced the activation and antigen uptake capacity of plasmacytoid 
dendritic cells. It also had a direct effect on CTL themselves whilst also 
reducing the suppressive effect of Treg. 
This thesis illustrates, in principle, the possibility that a poly-pharmaceutical 
approach can be taken to target ovarian cancer. It indicates that readily 
available compounds, when used in the correct combination, could be key in 
developing effective anti-cancer therapy. Future work in this area should 
focus on using existing chemotherapeutic  and immunotherapeutic drugs in 
combination to illicit enhanced anti-tumour cytotoxicity. Critically, the next step 
in developing this strategy is to acquire suitable in vivo models. This is key as 
there is conflicting evidence regarding the efficacy of certain drugs in mice 
compared to man.  
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Chapter 1 
General Introduction 
1.1 Ovarian Cancer 
Ovarian cancer is fatal in the majority of cases. The lifetime risk of ovarian 
cancer is approximately 2% and it is the fourth most common cause of 
cancer-related death in women within the UK, although its incidence 
worldwide is slightly less (1). In 2009 almost 7,000 cases of ovarian cancer 
were diagnosed, and it is considered one of the most common forms of 
gynaecological malignancy. The incidence of ovarian cancer appears to be on 
the rise (2), with rates of 15 and 17 per 100,000 women in 1975 and 2005 
respectively, which may simply reflect the proportionally older population in 
the UK compared with 30 years ago (3).  Ovarian cancer is predominately a 
disease of older, postmenopausal women. The incidence increases rapidly 
after the age of 50, with over 85% of ovarian cancers occurring above that 
age (4). Less than 1% of epithelial ovarian cancers occur below the age of 20, 
with two thirds of the ovarian malignancies in these young patients being 
germ cell tumours (5). Since germ cell tumours represent less than 5% of 
ovarian cancers and tend to present at an earlier stage, they make minimal 
impact on incidence and mortality rates (4).   
The impact of age in ovarian cancer is not limited to incidence alone, 
increasing age is coupled to decreasing chemotherapeutic performance 
status which may limit the extent to which the most aggressive treatments can 
be initiated or sustained. Hence, increasing age and reduced 
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chemotherapeutic performance status have been linked with poor prognosis 
(1), which is independent of other prognostic factors (6). 
Worldwide there are almost 200,000 new cases of ovarian cancer annually 
(4). Incidence rates vary considerably with the highest rates in Northern 
Europe and the USA and lowest rates in Africa and Asia. The Office for 
National Statistics recorded an incidence rate of  16.7 cases  per 100,000 
women in the United Kingdom (2). 
 
1.2 The Hallmarks of Cancer 
In order for a tumour to first develop, and secondly progress, dysregulation of 
DQXPEHURISDWKZD\VDSWO\WHUPHGWKH³KDOOPDUNVRIFDQFHU´ are necessary. 
Originally, these included sustaining proliferative signalling, resisting cell 
death, evading growth suppressors, inducing angiogenesis, enabling 
replicative immortality and activating invasion and metastasis (7). However, 
UHFHQWDGGLWLRQV WR WKHVH µKDOOPDUNV¶ LQFOXGHGHUHJXODWLQJFHOOXODUHQHUJHWLFV
and avoiding immune destruction (8) (Figure 1.1). 
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Figure 1.1 ± The Hallmarks of Cancer. A ± 7KHRULJLQDOµKDOOPDUNV¶DVGHVFULEHGE\
(7). B ± $GGLWLRQ RI WZR H[WUD µKDOOPDUNV¶ GHUHJXODWLQJ FHOOXODU HQHUJHWLFV DQG
avoiding immune destruction as described by (10). Reprinted with permission 
(License number 2812690309460), Elsevier Ltd. 
 
 
4 
 
1.2.1 Sustaining Proliferative Signalling 
One of the most obvious properties of cancer cells is the capacity for 
uncontrolled growth. Tumour cell independence from normal growth factor 
control is in part due to the generation of its own growth factors. This is in 
contrast to normal cells which only respond to exogenous growth factor 
stimuli (7). There are three molecular strategies by which tumours achieve 
growth autonomy. These include alteration in extra cellular growth signals, 
receptor transducers of these signals and alteration of intracellular pathways 
which translate these signals into cellular events. Two examples of tumours 
secreting and responding to their own growth factors in a positive feedback 
loop involve platelet derived growth factor and tumour growth factor-alpha (8).  
Receptor over-expression may enable tumour cells to be hypersensitive to 
haemostatic levels of growth factor. For example, epidermal growth factor 
receptor 1  is over expressed in ovarian cancer, with a subsequent negative 
impact on prognosis (9).  
Downstream cytoplasmic pathways can be altered, resulting in abnormally 
prolonged stimulation of cells following receptor signalling which is often 
related to the Ras pathway. The Ras pathway involves numerous proteins 
involved with cell proliferation (10).  
 
1.2.2 Evading Growth Suppressors 
Within normal tissue, multiple anti-proliferative signals operate to maintain 
cellular homeostasis. The retinoblastoma protein acts as a central coordinator 
of anti-proliferative signals. Retinoblastoma protein blocks proliferation by 
sequestering and inactivating transcription factors from the E2F group of 
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genes which are involved in cell cycle regulation. These control the 
expression of genes essential for progression from G1 into S phase (11).  
Disruption of the retinoblastoma protein pathway liberates E2F, thus allowing 
cellular proliferation and rendering cells unresponsive to anti-proliferative 
signals. Transforming growth factor-beta (TGF-ȕUHSUHVHQWVDwidely studied 
anti-proliferative factor, which prevents phosphorylation and subsequent 
inactivation of retinoblastoma protein. TGF-ȕ EORFNV SKRVSKRU\ODWLRQ RI
retinoblastoma protein by stimulation of p15INK4B and p21, which block 
cyclin:CDK complexes which are responsible for pRb phosphorylation (12). 
Loss of TGF-ȕUHVSRQVLYHQHVVKDVEHHQGHPRQVWUDWHGLQWXPRXUVYLDGRZQ-
regulation of TGF-ȕUHFHSWRUV(8).  
 
1.2.3 Resisting Cell Death 
Apoptotic machinery is present in all cells and is divided into sensors and 
effectors. The sensors include cell surface receptors that bind to survival (e.g. 
IGF-1, IGF-2 and IL-3) and death factors (Fas ligand, TNF-ĮDQG75$,/(13). 
Many apoptotic signals converge on the mitochondria which produce 
cytochrome c, a potent catalyst of apoptosis. The release of cytochrome c is 
controlled through the Bcl-2 family of proteins which have either pro-apoptotic 
(Bax) or anti-apoptotic effects (Bcl-2 and Bcl-XL) (14). The ultimate inducers 
of apoptosis are the caspases which can be stimulated through cytochrome c 
or death receptors. 
Tumour cells all develop strategies to avoid apoptosis. One of the most 
common involves mutations and ultimately inactivation of p53, which is seen 
in over 50% of human cancers (15). Physiologically, p53 is a potent 
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coordinator of apoptosis resultant from DNA damage, hypoxia and oncogene 
overexpression (12). Defects in the TRAIL pathway, the major p53 
independent pathway for apoptosis, can also occur with disruptions to the 
TRAIL receptor and downstream signalling pathways (16). In addition, over 
activity of anti-apoptotic pathways can inhibit cell death. For example, the 
PI3kinase-AKT/PKB pathway can be over-stimulated through extracellular 
factors such as IGF1/2 and IL-3 and intracellular factors, for example Ras and 
via loss of pTEN (a tumour suppressor gene) (17). A mechanism that inhibits 
cell death through Fas, involving upregulation of decoy death receptors, has 
also been demonstrated in tumour cells (18).  
1.2.4 Enabling Replicative Immortality 
Normal cells have a limited number of possible cell divisions before they enter 
a state of senescence. Tumour cells have been shown in vitro to be 
immortalised with limitless replicative potential. This is thought to be in part 
due to defects in the retinoblastoma protein and p53 tumour suppressor 
systems (19), although effects on telomere maintenance may play a more 
significant role. Telomeres represent the ends of chromosomes and 
essentially act as the counting device for cell division. Each cell division leads 
to progressive loss of base pairs from the telomere and this erosion 
eventually leads to loss of protection of the chromosomal DNA.  
This in turn leads to fusion of chromosomal ends producing severe karyotype 
abnormalities resulting in cell death (20). Telomere maintenance is seen in 
most cancer cells, with the upregulation of telomerase enzymes which add 
base pairs to the telomere.  
This preservation of the telomere effectively inactivates the cells usual 
counting mechanism for cell division (21). 
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1.2.5 Inducing Angiogenesis  
The oxygen and nutrients supplied by tissue vasculature are crucial for cell 
function and survival, necessitating that all cells are within a short distance of 
a blood capillary. The process by which new vessels form to ensure adequate 
blood supply to developing tissue, angiogenesis, is controlled by stimulatory 
signals such as vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF).  
The rapid growth of tumours requires a high level of angiogenesis. This has 
been demonstrated to be strongly associated with VEGF, since neutralising 
antibodies to VEGF inhibited tumour angiogenesis in mice models (22). 
Tumours appear to activate the angiogenic switch through increased 
expression of VEGF and FGF with reduced expression of angiogenesis 
inhibitors such as thrombospondin-1 (23).  
 
1.2.6 Activating Tissue Invasion and Metastasis 
A characteristic of tumour cells, which makes them different from normal 
cells, is the ability to invade tissue stroma and metastasise. Tumours utilise 
extra-cellular proteases and changes to the physical coupling of cells to 
achieve this. The multistep process of invasion and metastasis has been 
described as a sequence of discrete steps, often termed the invasion-
metastasis cascade (24,25). This depiction envisions a succession of 
changes, beginning with local invasion, then intra-vasation by cancer cells 
into nearby blood and lymphatic vessels, transit of cancer cells through the 
lymphatic and vascular systems, followed by escape of cancer cells from the 
lumina of such vessels into the parenchyma of distant tissues (extra-
vasation), the formation of small nodules of cancer cells (micrometastasis), 
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and finally the growth of micrometastatic lesions into macroscopic tumours, 
WKLVODVWVWHSEHLQJWHUPHGµµFRORQLVDWLRQ¶¶ 
 
1.2.7 Deregulating Cellular Energetics 
The chronic and often uncontrolled cell proliferation that represents the 
essence of malignant disease involves not only deregulated control of cell 
proliferation but also, corresponding adjustments of energy metabolism in 
order to fuel cell growth and division. Under aerobic conditions, normal cells 
process glucose, first to pyruvate via glycolysis in the cytosol and thereafter to 
carbon dioxide in the mitochondria; under anaerobic conditions, glycolysis is 
favoured and relatively little pyruvate is dispatched to the oxygen-consuming 
mitochondria. The altered metabolism of cancer cells has been documented 
since the 1930s. Otto Warburg first observed an anomalous characteristic of 
cancer cell energy metabolism (26,27): even in the presence of oxygen, 
cancer cells can reprogram their glucose metabolism, and thus their energy 
production, by limiting their energy metabolism largely to glycolysis, leading to 
D VWDWH WKDW KDV EHHQ WHUPHG µµDHURELF JO\FRO\VLV¶¶ 7KH H[LVWHQFH RI WKLV
metabolic switch in cancer cells has been substantiated in the ensuing 
decades. They do so, in part, by upregulation of glucose transporters, notably 
GLUT1, which substantially increases glucose uptake into the cytoplasm (28-
30). Indeed, markedly increased uptake and utilisation of glucose have been 
documented in many human tumour types, most readily by non-invasively 
visualising glucose uptake using positron emission tomography (PET) with a 
radiolabelled analogue of glucose (18F-fluorodeoxyglucose, FDG) as a 
reporter. Tumours, being heterogeneous, have been found to contain multiple 
populations of cells that differ in their energy-generating pathways. One 
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subpopulation consists of a glucose-dependent sub-population of cells that 
secrete lactate, whereas cells of the second sub-population preferentially 
import and utilise the lactate produced by their neighbours as their main 
energy source, employing part of the citric acid cycle to do so (31-33). These 
two populations evidently function symbiotically: the hypoxic cancer cells 
depend on glucose for fuel and secrete lactate as waste, which is imported 
and preferentially used as fuel by their better-oxygenated brethren. 
Additionally, it is becoming apparent that oxygenation, ranging from normoxia 
to hypoxia, is not necessarily static in tumours but instead fluctuates 
temporally and regionally (34). This is a likely result due to the instability and 
chaotic organisation of the tumour-associated vasculature.  
 
1.3 Avoiding Immune Destruction ± Principles of Immunoediting 
Cancer immunoediting is an extrinsic tumour suppressor mechanism that 
engages after cellular transformation has occurred and intrinsic tumour 
suppressor mechanisms have failed. The notion that the immune system not 
only protects the host against tumour formation but also shapes tumour 
immunogenicity is the basis of the cancer immunoediting hypothesis, which 
stresses the dual host-protective and tumour-promoting actions of immunity 
on developing tumours. It has been suggested that immunoediting exists in 
thrHHSKDVHVWKDWKDYHEHHQWHUPHG³HOLPLQDWLRQ´³HTXLOLEULXP´DQG³HVFDSH´
(Figure 1.2) (35).  
1.3.1 Elimination 
The elimination phase is best described as when the immune system detects 
the presence of a developing tumour and destroys it before it becomes 
clinically apparent. The mechanisms by which the immune system is alerted 
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to the presence of a developing tumour are not fully understood. Among the 
possibiliWLHVDUHWKHFODVVLFDO³GDQJHUVLJQDOV´VXFKDV7\SH,,)1VHJ,)1-
ĮDVRULJLQDOO\GHVFULEHGE\0DW]LQJHU (36), which exist during early tumour 
development. These cytokines activate dendritic cells and promote induction 
of the adaptive anti-tumour immune responses. Damage-associated 
molecular pattern molecules (DAMPs) such heat-shock 90 protein  could also 
be a trigger because they are released directly from dying tumour cells 
(37,38).  The induction of an immune response on the basis of tumour cell 
death is of significant interest in this thesis and is highlighted as such in 
Chapter 2 and Chapter 5.  
 Stress ligands such as RAE-1 and H60 (mouse) or MICA/B (human) are 
frequently expressed on the surface of tumour cells. Such ligands bind to 
activating receptors on innate immune cells, leading to the release of pro-
inflammatory and immune modulatory cytokines, which in turn establish a 
microenvironment that facilitates the development of a tumour-specific 
adaptive immune response (39). In literature, the most effective cancer anti-
tumour immune responses require the additional expression of tumour 
antigens capable of propagating the expansion of CD4+ and CD8+ effector T 
cells. Therefore, it can be suggested that an enhancement of an adaptive 
immune response is needed to protect the host against a developing tumour.  
1.3.2 Equilibrium 
In the equilibrium phase, the immune system maintains residual tumour cells 
in a functional state of dormancy, a term used to describe latent tumour cells 
that may reside in patients for decades before eventually resuming growth as 
either recurrent primary tumours or distant metastases (40).  Equilibrium thus 
represents a type of tumour dormancy in which the growth of tumours is 
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specifically controlled by immunity. Studies with different mouse tumour 
models confirmed the capacity of the immune system to control the growth of 
primary carcinomas and metastases for extended periods of time (41,42). In 
the low-GRVH ¶-methylcholanthrene system, equilibrium appears to be the 
result of both the growth inhibitory and cytocidal effects of  the immune 
response against residual tumour cells (43). However, there could be some 
doubt as to the duration of an equilibrium state as 
chemo/radio/immunotherapeutic regimens are more than likely to alter the 
balance of the tumour-immune infiltrate and thus drive the development of 
either an elimination or escape phase.  
 
1.3.3 Escape  
In the escape phase, tumour cells that have acquired the ability to circumvent 
immune recognition and/or destruction emerge as growing, visible tumours. 
Progression from equilibrium to the escape phase is likely to occur because 
the tumour cell population changes as there is increased cancer-induced 
immune suppression or immune system deterioration.  At the tumour cell 
level, alterations leading to reduced immune recognition (such as a loss of 
antigens) promote tumour growth. Loss of tumour antigen expression is one 
of the best-studied escape mechanisms, and it can occur in at least three 
ways: (i) through emergence of tumour cells that lack expression of strong 
rejection antigens, (ii) through loss of major histocompatibility complex (MHC) 
class I proteins that present these antigens to tumour-specific T cells, or (iii) 
through the loss of antigen processing function within the tumour cell (10,44).  
Alternatively, escape may result from the establishment of an immune 
suppressive milieu within the tumour microenvironment (45). Tumour cells 
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can promote the development of such a state by producing immune 
suppressive cytokines such as VEGF, TGF±ȕ JDOHFWLQ RU H[SUHVVLQJ
indoleamine 2,3-dioxygenase and/or by recruiting regulatory immune cells 
that function as mediators of effector T cell proliferation. Regulatory T cells 
(Treg) and myeloid-derived suppressor cells (MDSCs) are two major types of 
immune suppressive cell that play key roles in inhibiting host-protective anti-
tumour immune responses (45).  
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Figure 1.2 - The Cancer Immunoediting Concept. In its most complex form, cancer 
immunoediting consists of three sequential phases: elimination, equilibrium, and 
escape. In the elimination phase, innate and adaptive immunity work together to 
destroy developing tumours long before they become clinically apparent. If, however, 
a cancer cell is not destroyed in the elimination phase, it may then enter the 
equilibrium phase, in which its growth is prevented by immunologic mechanisms. 
Editing of tumour immunogenicity occurs in the equilibrium phase. Over time, tumour 
cell variants may emerge that (i) are no longer recognised by adaptive immunity 
(antigen loss variants or tumours cells that develop defects in antigen processing or 
presentation), (ii) become insensitive to immune effector mechanisms, or (iii) induce 
an immunosuppressive state within the tumour microenvironment. These tumour cells 
may then enter the escape phase, in which their outgrowth is no longer blocked by 
immunity. Adapted from (35).  Reprinted with permission (License number OP-
00023894), AAAS Ltd. 
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1.4 Evidence for the Role of Immunoediting Against Human 
Ovarian Cancer 
Evidence of the role of immunoediting in human ovarian cancer comes from 
the presence of tumour-infiltrating lymphocytes, which correlated positively 
and strongly with patient survival. Zhang et al. (46) assessed the distribution 
of tumour infiltrating lymphocytes in 186 frozen specimens from stage III or IV 
ovarian cancers and conducted clinical outcome analyses. In this study, CD3+ 
T cells were detected within tumour-cell islets in 102 of the 186 tumours. They 
also assessed the number of CD4+ and CD8+ T cells in 30 tumours. The data 
showed that intratumoural CD4+ and CD8+ cells were either both present or 
both absent. Patients whose tumours contained tumour infiltrating 
lymphocytes had five-year survival rates of 38%, whereas patients whose 
tumours lacked this only had a five-year survival rate of 4.5%. The five-year 
progression-free survival rates for patients whose tumours had tumour 
infiltrating lymphocytes was 31%. In comparison, those that were tumour 
infiltrating lymphocyte negative had a progression free survival rate of just 
8.7%. Other studies have confirmed that the intraepithelial CD3+ T cell count 
was a significant prognostic factor in epithelial ovarian cancer. Tomsova et al. 
(47) showed improved overall survival among 116 patients with higher versus 
lower counts of intraepithelial CD3+ T cells. Thus, overall and progression-
free five-year survival rates were significantly prolonged in the patients whose 
tumours contained higher numbers of tumour infiltrating lymphocytes 
compared to the patients whose tumours did not contain these cells. 
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1.5 The TumRXU,PPXQRORJ\µ7XEH0DS¶7KH,PPXQH6\VWHPLQ
Cancer Explained  
As described earlier, the immune system has a significant role in the 
development of tumours. Within the structure of a tumour, stromal cells 
including immune cells (35), often outnumber cancer cells. The complex 
immune milieu which is present at the tumour site influences both the 
potential for immune elimination or immune escape. Extensive 
characterisation using immunohistochemical, cytofluorometric and micro array 
techniques have been performed on multiple human carcinomas. These 
studies suggest that dendritic cells, M1 macrophages, cytotoxic CD8+ T cells, 
Th1 CD4+ T cells, NK cells and Th17 CD4+ T cells present in the tumour bed 
can induce immune-mediate tumour elimination. In contrast, neutrophils, M2 
macrophages, myeloid-derived suppressor cells, Th2 CD4+ T cells and 
CD4+FOXP3+ Treg are suspected to aid tumour-immune escape. The 
interactions between these different populations can be represented as a 
µPDS¶)LJXUH7KHLQWULFDWHUHODWLRQVKLSEHWZHHQERWKWXPRXU-eliminating 
or tumour-escaping immune populations means that selective targeting of a 
particular cell type or receptor can be either circumvented by the tumour or 
lead tR DGYHUVH V\VWHPLF HIIHFWV RQ WKH SDWLHQW 7KH µPDS¶ EHORZ KDV WKH
capacity to highlight areas which may provide avenues for improved 
immunotherapy.
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Figure 1.3 ± 7KH7XPRXU,PPXQRORJ\µ7XEH0DS
± A schematic which incorporates chemokines, cytotoxic CD8+ T cells, helper T cells, tumour-associated 
macrophages, dendritic cells, natural killer cells and tumour cells.   The rationale behind the 'tube map' is to identify key interactions within the tumour and 
thus gain a greater understanding of the complexity of the environment 
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1.5.1 Tumour Cells 
Tumours contribute to the immune suppressive milieu in a variety of ways. 
These include alterations to antigen presentation machinery, defects in 
proximal TCR signalling, secretion of immune suppressive and pro-apoptotic 
factors, activation of negative regulatory pathways and specific recruitment of 
regulatory cell populations (48-51). These mechanisms work synergistically in 
advanced stages of cancer to attenuate both native and therapy-induced anti-
tumour immune responses (52).  
One of the best studied mechanisms used by tumours to avoid T cell 
recognition is the impairment of antigen presentation (53). It has been 
observed that the continuous generation of tumour variants by an increased 
frequency of mutations and/or genetic deletions can result in escape from T 
cell recognition (50). In this regard, cancer cells that no longer express the 
tumour antigen may escape destruction by cytotoxic T cells and grow 
progressively. However, there are indications that cytotoxic T cells may 
indirectly eliminate these tumour variants when tumour cells express sufficient 
antigen to be effectively cross-presented (54). 
In addition to the generation of antigen loss variants, downregulation of 
antigen processing machinery has been documented extensively at different 
levels in a wide variety of tumours and has been considered as the most 
common strategy exploited to escape T cell control (48,53). Complete 
absence of MHC-I expression cDXVHG E\ PXWDWLRQV RI WKHȕ PLFURJOREXOLQ
ȕ0JHQHRUGHFUHDVHG0+&-I expression due to transcriptional regulation 
(55-58) prevents recognition by cytotoxic T cells. Furthermore, point 
mutations and genetic deletions lead to selective loss of individual HLA alleles 
(59),  which further facilitates immune evasion from T cells. These changes 
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have been frequently observed in renal cell carcinoma, colorectal carcinoma, 
melanoma (53,56) and ovarian cancer (60).  
Tumours also alter the extracellular environment in order to establish immune 
suppression. The  immune-regulatory enzyme indoleamine 2,3-dioxygenase 
(IDO) catalyses the degredation of the essential amino acid tryptophan, via 
the kynurenine pathway (61). The lack of tryptophan and the subsequent 
increase in kynurenine derived metabolites leads to attenuated T cell 
proliferation (62). This effect was confirmed by in vitro observations showing 
inhibition of T cell proliferation and antagonism of cell cycle progression by 
tryptophan depletion (63). The fact that IDO is also expressed by different 
tumour cells prompted Uyttenhove et al. (64) to investigate the role of IDO in 
the establishment of tumour-immune escape. They demonstrated that 
immunogenic tumours engineered to overexpress IDO grew more 
aggressively in immune competent hosts and this effect correlated with a 
decreased accumulation of activated T cells at the tumour site (64).  Since 
this work, the prognostic significance of IDO has been investigated with 
changes in prognosis seen in prostate (65), leukaemia (66), endometrial (67) 
and ovarian cancer (68). Importantly, in vivo administration of the IDO 
inhibitor 1-methyltryptophan resulted in reduced tumour mass and stimulation 
of anti-tumour cytotoxic immune responses (64).  
Whether IDO plays a physiological role in peripheral T-cell tolerance still 
remains to be elucidated. In contrast to other homeostatic mediators such as 
CTLA-4, IDO-deficient mice do not display  autoimmunity (62), suggesting 
that IDO might be predominantly involved in the generation of local immune 
tolerance at selected sites of immune privilege, such as the  tumour 
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microenvironment. Thus, pharmacological antagonism of IDO may be an 
important component of combinatorial immunotherapy strategies. 
The disordered growth of an expanding tumour often outstrips the 
development of a supportive vascular bed, which leads to a reduction in 
oxygen levels throughout much of the tumour mass (69,70). For example, the 
hypoxic fraction in squamous cell carcinomas of the cervix and head and 
neck can be as high as 20-32% (71). Whereas in ovarian cancer, an increase 
in tumour hypoxia has been linked with increased resistance to Paclitaxel 
therapy (72). Adenosine is present at elevated levels in hypoxic tissues 
because of increased intracellular adenosine production and release from the 
cells. This is the result of oxygen deprivation and cellular ATP depletion (73) 
by activation of the 5'-nucleotidase pathway (74) and inhibition of adenosine 
kinase (75). Bidirectional nucleoside transporters in the membrane are 
responsible for exporting intracellular adenosine to the extracellular 
compartment (76).  
As expected, hypoxia has been shown to stimulate adenosine production in 
cultures of 3LL Lewis lung carcinoma cells (77). Moreover, analysis of mouse 
and human colorectal cancer has shown that the concentration of 
extracellular adenosine is 10-20-fold higher than those measured in 
surrounding normal tissue (78,79). It is important to note that extracellular 
adenosine levels in solid tumours can be further supplemented or modified by 
ecto-enzymes that mediate adenosine production or degradation at the cell 
surface. Adenosine-producing ecto-enzymes that are expressed by both 
lymphocytes and cancer cells include NTPDase 1 (CD39)  and ecto-5'-
nucleotidase (CD73) (80-84).  
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1.5.2 Tumour-associated Macrophages 
Macrophages are highly versatile, multifunctional cells that are characterised 
by their ability to engulf invading microbes or cell debris from injured sites, 
secrete a wide array of immune-modulatory cytokines, present antigens to T 
cells and act as accessory cells in lymphocyte activation. They display a high 
degree of plasticity, altering their phenotype to suit the microenvironment in 
which they reside. The conventional understanding is that macrophages can 
be subdivided into M1 (classically activated) or M2 (alternatively activated) 
phenotypes. M1 macrophages exhibit a pro-inflammatory phenotype and are 
activated by lipopolysaccharide and interferon-Ȗ ,)1-Ȗ WR VHFUHWH
bactericidal factors and promote Th1 responses. In contrast, M2 
macrophages have an immune suppressive phenotype and release cytokines 
that promote Th2 responses (85). 
Macrophages in tumours ² usually termed tumour-associated macrophages 
(TAM) ² often express many of the characteristics typical of the M2 
phenotype (86,87) DQG KDYH WKHUHIRUH EHHQ GHVFULEHG DV µ0-VNHZHG¶
However, recent evidence has suggested that the phenotype of TAM varies 
with the stage of tumour development, with M1-like cells often predominating 
at sites of chronic inflammation where tumours can develop, then switching to 
a M2-like phenotype as the tumour begins to invade, vascularise and develop 
(88,89). There are usually higher numbers of TAM in malignant tumours than 
surrounding normal tissues (90). These cells initially enter the tumour 
vasculature as monocytes from the blood, starting to differentiate into TAM as 
they do so (91). Monocyte recruitment is driven by chemokines secreted by 
both malignant and stromal cells in tumours as discussed below.  
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TAM have a profound influence on the regulation of tumour angiogenesis. 
Several clinical studies have shown a correlation between a high number of 
TAM in human tumours and increased micro-vessel density, suggesting that 
these cells might promote tumour angiogenesis (92-96). Depletion of 
macrophages in a transgenic mouse mammary tumour virus model that 
expresses Polyoma Middle T antigen (MMTV-PyMT) resulted in a 50% 
reduction in vascular density, causing delayed tumour progression and 
metastasis. Reintroduction of macrophages into these knockout mice led to a 
significant increase in vascular density and enhanced tumour progression 
(97). Further evidence of the importance of TAM has come from studies in 
which monocytes were removed from the circulation using Clodronate 
liposomes. This was shown to significantly reduce TAM numbers and 
angiogenesis in Lewis lung carcinoma xenografts (98). 
TAM express many pro-angiogenic and angiogenesis-modulating factors in 
vitro, such as VEGF, basic fibroblast growth factor (bFGF, also known as 
FGF2), tumour necrosis factor  (TNF), interleukin 1 (IL-1), chemokine (C-X-C 
motif) ligand 8 (CXCL8; also known as IL-8), cyclooxygenase-2 (COX-2), 
plasminogen activator, urokinase, platelet derived growth factor  (PDGF), 
matrix metalloproteinase 7 (MMP7), MMP9 and MMP12. The tumour 
microenvironment is now known to stimulate the pro-angiogenic functions of 
macrophages. For example, TNF secreted by ovarian tumour cells enhances 
the release of VEGF, MMP9 and other important pro-angiogenic factors by 
macrophages (89).  
A number of recent findings have shown that in such hypoxic areas TAM 
have a marked effect on tumour angiogenesis. Macrophages are known to 
respond to hypoxia by up-regulating hypoxia-inducible transcription factors 
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(mainly hypoxia-inducible factors HIF1 and HIF2) (99-101), the activation of 
which leads to increased transcription of many genes that regulate cell 
proliferation, metabolism and angiogenesis (102). Moreover, human TAM 
express VEGF almost exclusively in hypoxic and/or peri-necrotic areas of 
breast carcinomas (103,104).  
The fact that TAM also upregulate the pro-angiogenic matrix 
metalloproteinase MMP7 in hypoxic areas of tumours (100) might have 
relevance not only to tumour angiogenesis but also the newly identified role of 
TAM in metastasis. Recent work has indicated that TAM (possibly in 
conjunction with other inflammatory cells such as T cells) can express high 
levels of RANKL (also known as TNFSF11) that directly stimulate tumour 
cells to express a more metastatic phenotype (105). MMP7 cleaves an active 
form of RANKL from the cell surface (106), so increased expression of MMP7 
could enhance the release of RANKL by macrophages and T cells and drive 
tumour progression. 
Recent studies have also suggested that monocytes can differentiate into 
endothelial cells when exposed to the sustained stimulation by angiogenic 
growth factors (107,108). Whether monocytes newly recruited into tumours or 
differentiated into TAM directly contribute to the formation of new tumour 
blood vessels in this way remains to be determined. 
 
1.5.3 Dendritic Cells 
Dendritic cells (DC) are developed in the bone marrow from hematopoietic 
progenitor cells under the control of a complex network of soluble and cell-
bound molecules produced and expressed by bone marrow stroma (109). 
Most DC differentiate along the myeloid lineage, and precursors of DC 
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include common myeloid progenitor cells and immature myeloid cells. DC can 
also differentiate from common lymphoid progenitor cells. The proportion of 
lymphoid DC is substantially lower than that of myeloid DC, and most of these 
cells belong to a relatively rare subset of DC known as plasmacytoid DC 
(pDC). pDC express lymphoid antigens and produce large amounts of type-I 
IFN in response to viruses. They have a lower ability to process and present 
antigen and stimulate T cells than myeloid DC. In humans, myeloid DC are 
characterised by a lack of expression of lineage-specific markers and the 
expression of CD11c, whereas pDC do not express lineage-specific markers 
or CD11c, but express a receptor for IL-3 (CD123). In vitro, myeloid DC are 
dependent on Granulocyte Macrophage-colony stimulating factor (GM-CSF), 
whereas pDC are dependent on IL-3 and IFN-Į IRU VXUYLYDO (110). DC that 
leave the bone marrow are defined as immature DCs (iDC). iDC have little or 
no expression of co-stimulatory molecules such as CD80, CD86 and CD40 on 
the surface and produce little or no IL-12, which is required to support T cell 
proliferation.  
However, these cells are capable of taking-up and processing various 
molecules and micro-organisms. In tumour tissues, antigens may come from 
dying tumour cells. DC can engulf apoptotic or necrotic tumour cells, and 
process and present tumour-associated antigens on their surface. This effect 
is clearly manifested by upregulated expression of MHC-II and co-stimulatory 
molecules, increased IL-12 production and enhanced stimulation of antigen-
specific T-cell responses (111,112). DC are critically important for the 
generation and maintenance of anti-tumour immune responses (109). It is 
now well established that tumour cells contain a large number of antigens that 
can be recognised by the host immune system. DC can take up, process, and 
present tumour antigens to activate a tumour-specific T cell response. 
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However, this does not happen in most types of cancer or in animal models 
with spontaneously arising tumours. Data from many laboratories obtained 
during the past few years indicates that defects in the DC system are one of 
the main factors responsible for tumour escape, which contributes in various 
ways to the T cell defects seen in cancer. These abnormalities manifest in 
several major phenomena. 
 
1.5.3.1 Lack of Competent DC 
Tumour-bearing mice have been shown to have decreased numbers and 
function of DCs in lymph nodes, spleen and skin (113,114). Large numbers of 
studies in ovarian (115), breast (116,117) and prostate cancer (118) patients 
have found similar effects. In these studies, both myeloid and lymphoid 
populations of DCs were investigated. A significant decrease was observed 
only in the myeloid population of DC, whereas pDC were not affected. 
Several clinical studies have provided clear evidence that surgical removal of 
tumours can increase the number of DCs in the peripheral blood of patients 
with cancer. Almand et al.(119) demonstrated an increase in the total DC 
population in patients with breast and prostate cancer after surgery. The 
functional consequences of a decreased number of functionally competent 
DC in patients with cancer are obvious: a decreased number of DC makes 
immune stimulation less effective. However, it is likely that other defects in 
DC differentiation and activation have more of a profound effect on anti-
tumour immune responses. 
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1.5.3.2 Accumulation of Immature DC 
Immature DC have reduced capacity to capture antigens and elicited poor 
proliferation and IFN-ȖVHFUHWLRQE\7FHOOV (120). In patients with cancer, it 
has been repeatedly shown that tumours contain cells with the phenotype of 
iDC. Data from renal cell carcinoma (121), melanoma metastases (122) and 
basal-cell carcinoma (123) suggests that DC are not recruited to tumours in 
large numbers and those that are recovered from the tumour site have low 
levels of co-stimulatory molecules and have reduced T cell stimulatory 
activity. Importantly, the addition of GM-CSF and TNF-ĮRU&'/WRin vitro 
cultures, all of which are normally potent stimulators of CD80/CD86 
expression, did not induce CD80 expression on tumour-infiltrating DC. This 
indicates that the lack of CD80/CD86 expression does not simply result from 
a lack of activation of these cells in the tumour microenvironment but might be 
caused by defects in cell differentiation (124).  
Consistent with these observations, an increased proportion of iDC with 
reduced expression of co-stimulatory molecules was found in the peripheral 
blood of patients with breast, head and neck, lung, and oesophageal cancers 
(114,118-126). Immature DC are unable to induce anti-tumour immune 
responses and can induce T-cell tolerance. It has been shown that if APCs 
fail to provide an appropriate co-stimulatory signal for T cells, tolerance or 
anergy can develop (27, 140). DC derived from colon cancer tissue or 
melanoma-associated DC were not only significantly less potent inducers of T 
cell proliferation, but also induced T cell anergy (122-124). This suggests that 
DC can significantly contribute to the anergic environment found within the 
tumour. 
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1.5.3.3 Accumulation of Suppressive DC 
In addition to accumulation of iDC, a number of studies reported the presence 
in tumour tissues of subsets of DC with potential to suppress T cells. Most 
prominent of them are pDC (127). As described above, in contrast to myeloid 
DC, the number of circulating pDC in patients with different types of cancer 
was not altered. Furthermore, accumulation of pDC were found inside ovarian 
tumours (115,128). This accumulation was attributed to stromal-derived 
factor-1 (SDF-1) secreted by malignant cells (115,129). Tumour associated 
pDC induced IL-10 production by T cells (115,130,131). The ability of these 
pDC to produce IFN-Į ZDV GLPLQLVKHG 7XPRXU-induced down-regulation of 
TLR9 was identified as one mechanism probably contributing to impaired 
pDC function within the tumour environment (132). Accumulation of pDC was 
also found in peri-tumoural areas of primary melanomas (133). It has been 
shown that mouse tumour-draining lymph nodes contained a subset of pDC 
that constitutively expressed immunosuppressive levels of the enzyme IDO 
(134). This may prevent the clonal expansion of T cells and promote T cell 
anergy.  The accumulation of pDC in ovarian cancer is of interest and is 
discussed in greater detail later in this thesis. 
 
1.5.4 Natural Killer Cells 
Natural Killer cells (NK) are a type of lymphocyte defined by the expression of 
CD56 and the absence of CD3. NK play an important role in innate immunity 
by mediating direct cytotoxicity and secreting cytokines such as  IFN-Ȗ,/-10,  
IL-13 and TNF-Į (135,136). NK activity is dependent on a complex balance 
between inhibitory and stimulatory receptors which interact through MHC 
class molecules on potential target cells. Ultimately NK will be triggered or 
inhibited depending on the balance of these signals. The loss or absence of 
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HLA class I molecules on the surface of the target cell tends to produce 
triggering of NK (135). Once activated NK trigger apoptosis in the target cell 
through initiation of the caspase cascade. Apoptosis may also be induced 
through interaction of FasL and TNF Related Apoptosis Inducing Ligand 
(TRAIL) with the respective death receptors (137). NK are able to respond to 
human tumours through NKG2D and its related ligands MICA and MICB. The 
activation of human NK by tumours also largely depends on the natural 
cytotoxicity receptors (NCR), which include three members: NKp46, NKp44 
and NKp30 (138,139). The NCR is unique in its expression pattern and is 
almost exclusively confined to NK. However, very little is known about the 
identity of NCR ligands, particularly with respect to tumours. Recently, it has 
also been suggested that the DNAX accessory molecule 1 may also play a 
role in tumour immune surveillance as either an activating receptor or co-
stimulatory molecule (140).  
Killer immunoglobulin-like receptors (KIR) of NK activity include the killer-like 
immunoglobulin family and the CD94-NKG2 complexes that bind to specific 
MHC-HLA alleles. Since NK activity is controlled by a balance of inhibitory 
and activating receptor signalling, the inhibitory receptors represent targets to 
effectively enhance NK cytotoxicity against tumours. Antibodies that inhibit 
KIR/MHC binding have been minimally studied in mice (141) and has only just 
entered clinical trials (142). Interestingly, specific inhibitory KIR/HLA ligand 
pairs decrease the risk of developing human cervical neoplasia while the 
presence of the activating KIR3DS1 results in increased risk of disease (143). 
It is therefore essential to thoroughly understand what role NK are playing in 
each neoplastic disease (inflammatory versus protective) before considering 
intervention. The effector molecules, TRAIL, perforin/granzymes, and the 
cytokine IFN-Ȗ KDYH DOO EHHQ LPSOLFDWHG LQ WXPRXU VXSSUHVVLRQ E\ 1. FHOOV
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(144). However, until the means to specifically and conditionally mutate genes 
in NK become available, the importance of these pathways cannot be 
elegantly tested. With the knowledge gained in recent years regarding 
suppressive tumour-immune infiltrates e.g. Treg and MDSC, it is important to 
recognise the potential for the attenuation of NK efficacy (145,146).  
Collectively, these mechanistic insights into how NK contribute to tumour 
suppression provide attractive new targets to formulate potential cancer 
therapies based in part upon NK activation. 
 
1.5.5 Cytokines and Chemokines 
Mounting evidence supports the idea that immune cells and inflammatory 
mediators (cytokines, chemokines) within the tumour microenvironment, can 
either be beneficial or detrimental for tumour progression (Figure 1.4) (147). 
Initially, tumour cells and cells of the tumour microenvironment, respond to 
tumour hypoxia and necrosis secondary to excessive tumour cell proliferation, 
by releasing a number of growth factors and cytokines that are 
chemoattractive for monocytes and macrophages, including colony 
stimulating factor-1 (CSF-1), GM-CSF, TGF-ȕ DQG FKHPRNLQHV HJ &&/
CCL3, CCL4, CCL5) (148). In turn, recruited macrophages secrete growth 
factors that affect tumour cell behaviour (e.g. induction of motility), activate 
tumour endothelium and propagate inflammation (149-151). Factors released 
by recruited monocytes/macrophages include VEGF, basic fibroblast growth 
factor (bFGF), tumour necrosis factor (TNF), hepatocyte growth factor (HGF), 
epidermal growth factor (EGF) family members, platelet- derived growth 
factor (PDGF), and chemokines such as CXCL12 and IL-8 (148,152,153).  
Monocytes and macrophages also bring in much of the cyclooxygenase-2 
(COX-2) present in the tumour environment (154,155). COX-2 expression and 
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prostaglandin production within the tumour environment stimulate tumour cell 
proliferation, survival and motility but also tumour angiogenesis (154-157).  
Chemokines play an important role in coordinating the stromal response to 
cancer, including the polarisation of the immune responses to the tumour, the 
determination of the composition of the cellular infiltrate, and the induction of 
angiogenesis. Chemokine receptors have been detected on cancer cells and 
the relevant ligands were found expressed at the primary tumour site and at 
sites of tumour metastasis, suggesting a direct role for 
chemokines/chemokine receptors in tumour growth and metastasis (158). 
Inflammatory insults lead to upregulation of CCL22, a macrophage-derived 
chemokine that is an attractant for Treg (159). This particular migratory 
pathway is of interest in this thesis.  
TGF-ȕ LV D SOHLRWURSLF LPPXQH VXSSUHVVLYH F\WRNLQH WKDW LQKLELWV 7 FHOO
activation, proliferation and differentiation (160,161). In addition to TGF-ȕ
other cytokines are present in the tumour microenvironment and have been 
shown to impair immune cell function including IL-10 (162), prostaglandin-E2 
(163) and sialomucins (164). IL-10 is abundant in the tumour 
microenvironment, impairs DC functionality (162,165,166) and protects 
tumour cells from cytotoxic T cell-mediated cytotoxicity by downregulating 
TAP1 and TAP2 (162). However, in contrast to previous assumptions, recent 
evidence indicates that IL-10 may also be immune-stimulatory. Unexpectedly, 
overexpression of IL-10 in the tumour microenvironment synergizes with other 
cytokines to promote tumour rejection instead of inducing immune 
suppression (167,168).  
Such unresolved chronic inflammation is associated with increased 
conversion of normal cells to pre-neoplastic foci. Accumulation of somatic 
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mutations can change pre-neoplastic foci into foci of fully transformed cells 
with tumour initiation capacities. It is this constant chronic inflammation that 
contrLEXWHV WR WKH GHYHORSPHQW RI WXPRXU FHOO YDULDQWV ZKLFK FDQ ³HVFDSH´
immune detection (35). 
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Figure 1.4 - Role of Major Cytokines in the Tumour Microenvironment. Tumour cells co-exist with immune cells: tumour-associated macrophages (TAM), 
regulatory T cells (Treg) and dendritic cells (DC). TAM and Treg are major sources of anti-inflammatory Th2 cytokines (e.g. IL-4, IL-10 and IL-13) and 
transforming growth factor-ȕ7*)-ȕZKLFKVXSSUHVVWKHDQWL-tumour immune response which is mediated by natural killer cells, cytotoxic CD8+ T cells and 
pro-inflammatory cytokines (e.g. IL-2 and interferon-Ȗ6LPXOWDQHRXVO\WXPRXUFHOOVGLUHFWO\H[SORLt activated immune cells for their growth and development. 
In an immunosuppressed environment various cytokines produced by innate immune cells and cancer cells directly promote the growth of cancer cells. 
Adapted from (267). Reprinted with permission (License number 2812710846009), Nature Publishing Group. 
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1.5.6 T Cells 
The role of T cell infiltrates in tumour immunoediting has been widely 
discussed. T cells can be divided into two main groups; those expressing 
CD8 molecules, cytotoxic T lymphocytes, and those expressing CD4 
molecules, helper T cells (Th).  CD4+ and CD8+ T cells are the principal 
helper and effector cells, respectively, of adaptive cellular immunity, and 
many immunotherapy strategies are aimed at activating these cells to 
promote anti-tumour immunity and long-term immune memory against the 
recurrence of primary disease or development of metastases. T helper 1 
CD4+ T cells (Th1) facilitate tissue destruction and tumour rejection by 
providing help to cytotoxic CD8+ T cells, while T helper 2 CD4+ T cells T (Th2) 
facilitate antibody production by B cells and polarise immunity away from a 
beneficial cell-mediated anti-tumour response.  
1.5.6.1 Cytotoxic CD8+ T Cells 
These cytotoxic T-cells have a T cell receptor which binds to HLA class I 
molecules on the surface of cells displaying peptides which are typically from 
viral infection or abnormal cellular functioning. Their mechanism of cell killing 
is similar to NK (e.g. Perforin/Granzyme, IFN-Ȗ75$,/)DV/7KH\DUHVHHQ
as key prognostic indicators in several disease settings (169-173).  
1.5.6.2 Helper T Cells 
T (Th) cells, are the key players in steering the immune responses. Th cell 
differentiation is characterised by the acquisition of cytokine production. Since 
the establishment of the Th1±Th2 paradigm, the function and regulation of 
effector T cells has been a subject of intense investigation. The Th1 cell, one 
of the first described Th cells that produces IFN-Ȗ 71)-Į DQG 71)-ȕ WR
stimulate innate and T-cell immune responses. The most important function of 
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Th1 cells is to promote cell-mediated immunity characterised by CD8+ T cell 
induced-cytolytic activity. Th1 cells are important in protection of the host from 
obligate intracellular pathogens. Over-exuberant pro-inflammatory activities of 
Th1 cells cause tissue damage and elicit unwanted inflammatory disease and 
self-reactivity including inflammatory bowel disease (174) and graft-versus-
host disease (175). 
 T helper type 2 cells were identified at the same time as Th1 cells in the early 
1980s. They are defined as producers of IL-4, IL-5, IL-9, IL-10 and IL-13. The 
Th2 response is often associated with the humoral response and is important 
in resistance against extracellular forms of pathogens. Th2 cells are also 
important for mucosal immunity in the lung. Aberrant elevation of the Th2 
response often leads to chronic inflammatory airway diseases, such as atopic 
asthma and allergy (176-178). 
In the peripheral blood of patients with bladder and colorectal cancer, the 
proportion of Th1 cells, identified by intracellular production of IFN-ȖRU ,/-2, 
was markedly reduced, whereas the proportion of Th2 cells producing IL-4, 
IL-6 and/or IL-10 were significantly elevated, as compared with the proportion 
of Th1 and Th2 in otherwise healthy patient populations (179,180). In human 
cervical carcinomas, CD3+ tumour infiltrating T cells display enhanced Th2 
cytokine profiles, specifically increased IL-4 and reduced IFN-Ȗ SURGXFWLRQ
(181). 
CD4+ Th17 cells (182,183), may have a role the anti-tumour immune 
response. Th17 cells are induced by IL-23, a cytokine closely related to IL-12 
(184). Upon activation by IL-23, Th17 cells produce IL-17 which exacerbates 
inflammation by inducing IL-6, TNF-Į*-CSF, and other acute phase proteins 
(185). Controversy surrounds the role of Th17 cells in tumour immunity 
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(186,187). IL-23 itself, has been shown to reduce CD8+ T cell infiltration into 
tumours, thereby promoting tumour growth (184). Recent work however, has 
shown that Th17 cells could be beneficial in propagating an anti-tumour 
response (183,188,189). This ambiguity may be explained by a recent study 
showing that Th17-induced IL-6 inhibits Treg function (189-191). Additional 
experiments are clearly necessary to clarify the roles of IL-17, IL-23 and the 
plasticity between Th17 cells and Treg in tumour progression. 
Despite the mounting evidence of CD8+ T cell, Th1/Th2/Th17 and NK cell 
tumour infiltration; there is still minimal tumour elimination. This is due to the 
immune suppressive environment which is generated by the tumour. There is 
intense debate as to how tumour-T cell tolerance is achieved. It was initially 
considered that the lack of effector T cell efficacy in controlling tumour growth 
MXVWUHIOHFWHG³WXPRXU LJQRUDQFH´VLQFHDQWLJHQ-specific cytotoxic responses, 
proliferation and cytokine production could be measured upon in vitro re-
stimulation or secondary immunisation against tumour antigen (192,193). 
Other studies have indicated that CD8+ T-cells are, indeed, rendered tolerant 
to tumour antigens (194-197). The delivery of large amounts of antigen could 
be deleterious for mounting reactive effector T cells. It has been shown that 
there is a direct correlation between the amount of antigens that are 
expressed in the periphery, the degree of T cell proliferation and the number 
of antigen-specific CD8+ T cells in the draining lymph nodes (198).  
Given the profound impairment in the function of tumour-antigen specific T 
cells, as determined by their blunted proliferation and cytokine production, it 
was assumed that the whole tumour-T cell infiltrate was rendered anergic by 
the growing malignancy. However, a more detailed analysis revealed a more 
complex picture of tumour-immune responses. In particular, the emergence of 
35 
 
Treg in tumour immunology and its subsequent role in conferring tolerance on 
a tumour is of major interest. 
 
1.6 Introduction to Regulatory T Cells 
As mentioned above tumours develop an environment which is conducive to 
their survival. In addition, this tumour-associated milieu supports a network of 
immunosuppressive adaptations favouring the generation of a subset of 
regulatory T lymphocytes (Treg); potent suppressors of CD8+ T cell-mediated 
cytotoxicity (199).  
Several subtypes of Treg have been described (Table 1.1) and represent an 
important control mechanism of the adaptive immune response functioning to 
restrict the duration and intensity of an acute immune response, preventing 
the induction of autoimmunity and limiting the development of chronic 
inflammation (200,201). This thesis will focus on CD4+CD25+FOXP3+ µQDWXUDO¶
Treg as these have been implicated in the suppression of anti-tumour 
immunity and have been repeatedly identified in several clinical settings to 
correlate with negative outcome (202). Forkhead box P3 (FOXP3) is a key 
transcription factor and marker of Treg in mouse and man (203,204). In 
contrast to experiments in the mouse, the expression of FOXP3 alone does 
not confer a regulatory phenotype in man (205) as FOXP3 is also expressed 
transiently on activated T cells that do not exhibit regulatory function (206).  
An increase in tumour infiltrating Treg has been well documented in several 
disease settings, including oesophageal cancer, gastric cancer (207), 
hepatocellular carcinoma (208), leukaemia (209), lung cancer (210),  
lymphoma (209,211) and melanoma (212) (Table 1.2).  In a study of 104 
patients with ovarian cancer Curiel et al. (213) demonstrated that specific 
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recruitment of Treg via the chemokine CCL22 supported tumour growth and 
predicted reduced survival. This study demonstrated that at later stages of 
disease CD4+ CD25+ FOXP3+ cells accumulated in tumours but rarely 
migrated to draining lymph nodes. Further, approximately 75% of Treg in the 
tumour masses were in proximity to infiltrating CD8+ T cytotoxic cells. Several 
other studies have examined the prognostic significance of Treg in cancer 
(summarised in Table 1.2), with the vast majority demonstrating that high 
Treg numbers have a negative impact on disease free- and overall survival.  It 
is because of this mounting evidence that Treg are the main focus of this 
thesis. 
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Table 1.1 ± Immune Suppressive T cell Populations. 
Subsets of 
regulatory T cells 
Cellular targets of 
suppression 
Present in : - Reference 
CD4+CD25- Tregs T and B cells Rat, Mice (214,215) 
CD4+CD25+ 
FOXP3+ Tregs 
T cells Rat, Mice, 
Human 
(199,216,217) 
Qa-1-restricted 
CD8+ Tregs 
Antigen-activated T cells 
differentially expressing Qa-
1-self-peptide complexes. 
Mice (218) 
CD8+CD28- Tregs Dendritic cells Human (219) 
CD8+FOXP3+ 
Tregs 
CD4+CD25- T cells Human  (220) 
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Table 1.2 ± Prognostic Significance of Treg
 
in Cancer  
Cancer Type Study 
Size 
(n = ) 
Treg
 
population 
Other 
Observations 
Prognosis Ref. 
Breast  299  
(pure 
ductal 
carcinom
a in situ, n 
= 62; 
invasive 
breast 
cancer, n 
= 237)  
Increase in 
FOXP3+ cells in 
invasive 
tumours 
compared to 
control 
High Treg 
numbers within 
oestrogen 
receptor positive 
tumours 
identified high 
risk patients  
Higher 
intratumoural 
Treg numbers 
correlate to 
decreased 
overall survival 
and relapse-free 
survival 
(221) 
28 
(Stage I + 
II, n = 12; 
Stage III 
+ IV, n = 
16) 
Increased 
CCR6+  FOXP3+ 
T cells found 
within tumour 
masses 
CCR6+ Treg 
appear to be the 
major population 
within tumour 
Increased 
intratumoural 
CCR6+ Treg 
predicts reduced 
survival 
(222) 
Ovarian  360 
(FIGO 
stage I- 
IV)  
Increase in  
FOXP3+ T cells 
in omental 
metastases 
compared to 
intratumoural 
ovarian tissue 
High CD45RO+ 
linked to 
increased 
disease specific 
survival 
High 
CD8+/Foxp3+ 
correlates with 
increased 
disease specific 
survival. 
(223) 
99 
(FIGO 
stage I, n 
= 18; 
stage II, n 
= 4; stage 
III, n = 62; 
stage IV, 
n = 15) 
Increased  
FOXP3+  
expression in 
tumour tissue 
compared to 
healthy tissue 
High IFN-Ȗ
FOXP3+ ratio 
associated with 
improved overall 
survival 
High 
intratumoural 
FOXP3+ T cell 
number 
associated with 
poor overall 
survival and 
disease free 
survival 
(224) 
 
117 
(FIGO 
stage I, n 
= 5; 
FIGO 
stage II, n 
= 7; 
FIGO 
stage III, 
n = 93; 
FIGO 
stage IV, 
n = 12) 
Increased 
intratumoural 
CD25+ FOXP3+ 
T cell number 
High CD8+ T cell 
infiltrate 
associated with 
improved overall 
survival 
High 
CD8+/FOXP3+ 
correlates with 
increased 
disease specific 
survival 
(225) 
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Renal cell 125 (clear 
cell) 
Higher 
CD4+CD25+ 
FOXP3 
numbers found 
in peritumoural 
areas compared 
to intratumoral 
sites 
Increase in Treg 
also correlated 
with an increase 
in COX-2 
expression and 
associated with 
TNM stage and 
tumour size 
High peritumoral 
Tregs 
associated with 
decreased 
overall survival 
and disease-
free survival 
(226) 
Colorectal 967 
(stage II, 
n = 593; 
stage III, 
n = 374) 
Treg density 
higher in tumour 
tissue compared 
with normal 
colonic mucosa 
Lower CD8+ and 
CD45RO+ cell 
densities in 
tumour 
compared to 
normal colonic 
mucosa 
High Treg 
density in 
normal mucosa 
associated with 
worse 
prognosis. 
In contrast,a 
high density of 
Treg in tumour 
tissue was 
associated with 
improved 
survival 
(227) 
94 
(stage 
I+II, n = 
43; 
Stage III 
+ IV, n = 
51) 
High  FOXP3+ 
number 
compared to 
normal tissue 
High TGF-ȕ
expression 
correlated with 
high FOXP3+ 
cells 
High CD8+/ 
FOXP3+ ratio 
correlates with 
improved 
survival and 
longer disease 
free period 
(228) 
40 
(stage I, n 
= 1;stage 
II,  n = 20; 
stage III, 
n= 6; 
stage IV, 
n = 13 
Higher  FOXP3+ 
number 
compared to 
normal tissue 
Tumour 
infiltration by 
Treg higher in 
limited disease 
compared to 
metastatic 
disease  
No correlation 
found between 
high Treg 
number or high 
CD8+/ FOXP3 
ratio and 
survival 
(229) 
160 
(stage II, 
n = 24; 
Stage III, 
n = 136) 
High  FOXP3+ 
number within 
tumour 
intraepithelia 
and stroma 
compared to 
normal tissue 
Reduced CD3+ 
T cell density 
associated with 
reduced disease 
free survival 
Low CD3+/ 
FOXP3+ cell 
ratio predicted 
reduced disease 
free survival 
(230) 
Anal 
squamous cell 
carcinoma 
38 
(stage I/II, 
n = 24; 
stage 
III/IV, n = 
14) 
High 
intratumoural  
FOXP3+ number  
Increase 
numbers of 
granzyme B+ 
cytotoxic cells 
has significant 
negative 
prognostic effect 
No correlation 
found between 
Treg number 
and prognostic 
outcome 
(231) 
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Endometrial 368  
(FIGO 
stage I-
IV) 
High  FOXP3+ 
cell number  in 
stage I cancers 
compared to 
stage II  
High 
intratumoral 
CD45R0+ 
infiltration linked 
to improved 
overall survival  
High 
intratumoural  
FOXP3+ number 
associated with 
decreased 
survival in type I 
cancers.   
High CD8+/ 
FOXP3+ ratio 
correlates with 
improved 
survival and 
longer disease 
free period 
(232) 
Liver 123 
(stage I, n 
= 32; 
stage II, n 
= 29;  
stage III, 
n = 62)  
High 
intratumoural 
and circulating 
CD4+CD25+ 
FOXP3+ T cell 
number 
compared to 
normal tissue 
Low CD8+ T cell 
tumour infiltrate. 
 Low tumoural 
Perforin, 
Granzyme A/B 
expression on 
tumoural CD8+ 
T cells 
Increased 
intratumoural 
and circulating  
CD4+CD25+ 
FOXP3+ T cell 
number lead to 
increased 
mortality and 
reduction in 
disease free 
survival  
(233) 
302 
(stage I, n 
= 50;  
stage II, n 
= 105;  
stage III, 
n = 100;  
stage IV, 
n = 47) 
Higher  FOXP3+ 
cell number in 
peritumoural 
regions 
compared to 
intratumoural 
Intratumoural 
Treg associated 
with tumour 
invasiveness 
High CD8+/Treg 
ratio correlates 
with improved 
disease free 
survival and 
overall survival 
(234) 
Follicular 
Lymphoma 
97(stage 
I, n = 24;  
stage II, n 
= 57,  
stage III, 
n = 16) 
Reduced 
FOXP3+ number 
in diffuse 
tumours 
compared to 
follicular 
FOXP3+ number 
decreases with 
disease severity 
High  FOXP3+ 
correlated to 
overall improved 
survival 
(235) 
Classical 
Hodgkins 
Lymphoma 
98 No significant 
increase in  
FOXP3+ cell 
number around 
Hodgkin/ReedSt
ernberg cells 
 
High 
GranzymeB/ 
FOXP3+ ratio 
linked to 
improved overall 
survival 
High FOXP3+ 
number 
associated with 
improved 
prognosis 
(236) 
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Gastric 110  
(stage II, 
n = 46; 
stage III, 
n = 64) 
High  FOXP3+ 
number in 
tumour 
compared to 
normal gastric 
tissue 
Increased 
FOXP3+ number 
linked to 
increased 
vascular 
invasion 
High  FOXP3+ 
number 
associated with 
decreased 
relapse free 
survival and 
overall survival 
 
(237) 
133 
(stage I, n 
= 38; 
stage II, n 
= 28; 
stage III, 
n = 59; 
stage Iv, 
n = 8) 
  
Higher  FOXP3+
 
intratumoural 
versus 
peritumoural 
sites 
CD4+ and CD8+ 
tumour 
infiltrating 
lymphocytes not 
associated with 
overall survival 
Low 
intratumoural  
FOXP3 + cell 
number linked to 
improved 
disease free 
survival. High 
CD8+/ FOXP3+ 
ratio linked to 
improved 
disease free 
survival  
(172) 
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1.6.1 Mechanisms of Treg-mediated Immune Suppression 
Treg can influence the activity of diverse effector cell populations including, 
CD8+ T lymphocytes, DC, NK, natural killer T (NKT) cells, and B lymphocytes 
(238). Several mechanisms of Treg-mediated immune suppression have 
been identified and can be categorised into cell contact-dependent and 
contact±independent suppression respectively. 
It is currently unclear whether Treg primarily suppress through cell-cell 
contact or through expression/secretion of paracrine factors. Strong in vitro 
evidence suggests that Treg fail to suppress when cell-cell contact is 
prevented i.e in a transwell system (239,240). Work by Rudensky et al. (241) 
in IL-10-/- mice, demonstrated that IL-10 produced by Treg is not required for 
limiting systemic autoimmunity but is necessary for restraining immunological 
hyperactivity at environmental interfaces. In contrast, CTLA-4 ablation in Treg 
cells resulted in systemic lymphoproliferative syndrome and severe 
pancreatic lesions, whereas the colon and skin remained largely unaffected 
(242). These results strongly suggest that Treg utilise multiple non redundant 
or partially redundant mechanisms to limit the immune response with 
individual suppressor mechanisms potentially operating in a particular tissue 
RULQÀDPPDWRU\VHWWLQJ)LJXUH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1.6.1.1 Cell Contact-dependent Suppression  
Cytotoxic T lymphocyte-antigen 4 (CTLA-4) is constitutively expressed by 
Treg under the direct control of FOXP3 (203,243). Antagonism of CTLA-4 has 
been shown to abrogate Treg-mediated suppression (244,245) indicating an 
important role in the regulatory capacity of Treg. CTLA-4 has a much higher 
binding affinity for CD28 than that of either of the co-stimulatory molecules 
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CD80 and CD86 (246,247). In addition CTLA-4 can also bind CD80 and 
CD86 adding further competition against their successful interaction with the 
co-stimulatory molecule CD28 (248). Interaction of CTLA-4 with professional 
antigen-presenting cells (APC) leads to down regulation of the co-stimulatory 
molecules CD80 and CD86 (249); crucial for activation of naïve and memory 
T lymphocytes (250). Interaction of CTLA-4 with CD80/86 has also been 
shown to induce DC expression of IDO, the rate limiting enzyme in the 
catabolism of tryptophan; essential for the proliferation/survival of activated T 
cells (251,252). 
Membrane bound TGF-ȕ on Treg has been shown in vitro to mediate cell-
contact dependent immunosuppression. Nakamura et al. (253)demonstrated 
that high membrane expression of TGF-ȕZDVUHVSRQVLEOHIRUVXSSUHVVLRQE\
Treg. In this system, soluble TGF-ȕ was found to be low; however treatment 
with a depleting anti±TGF-ȕ DQWLERG\ EORFNHG 7UHJ-mediated suppression 
(253). Following TCR stimulation, TGF-beta receptor II expression on effector 
T cells is induced. Experiments utilising a double negative TGF-beta receptor 
II B6 mouse model of type I diabetes demonstrated that antigen activated 
CD8+ T cells could not be suppressed by adoptive transfer of membrane 
bound TGF-beta positive Treg, suggesting that this axis is important in 
regulating immune responses (254).       
Treg can transfer cAMP through gap junctions, formed with responder cells 
(255) inhibiting key proliferative pathways; notably STAT5 which is 
responsible for IL-2 receptor transduction (256). Further, over-expression of 
cAMP-induced ICER (inducible cAMP early repressor), has been identified in 
both murine and human Treg (257,258). ICER can bind NFAT/AP1 sites 
within the IL-2 promoter suppressing transcription (259). Interestingly, this 
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inhibitory complex is also up-regulated in CD4+ T cells upon contact with Treg 
(255,258). 
CD8+ T cells and NK use perforin and granzyme B to mediate cytotoxicity 
against target cells. Similarly, activated Treg cells express granzyme A and 
perforin, permitting lysis of effector T cells and APCs (260).  Additionally, 
experiments using Granzyme B and perforin deficient mice demonstrate that 
Treg can mediate immune suppression through a granzyme B dependent but 
perforin independent mechanism (261). 
 
1.6.1.2 Cell Contact-independent Suppression 
Elevated levels of a plethora of immune-modulators including, vascular 
endothelial growth factor (129), PGE2 (262), IL-10 (155,263) and TGF-ȕ(264) 
have been characterised in human cancers. This tumour-associated milieu, in 
addition to supporting tumour cell survival and proliferation is potently immune 
suppressive (265-267). Treg, through the production of IL-10 (268), TGF-ȕ
(269), IL-35 (270) and adenosine (84) contribute to this immune suppressive 
microenvironment. Activation of DC in the presence of Treg has been shown 
to induce a suppressive phenotype characterised by high IL-10 expression 
(271) and expression of B7-H4; a negative regulator of effector T cell function 
(166). 
Due to their elevated expression of CD25, Tregs consume local IL-2, 
depriving actively dividing effector T cells of the IL-2 required for their survival 
and expansion (272,273). However, Zambricki et al. (274) suggested that the 
in vitro relevance of IL-2 sequestration on T cell functionality is unclear with 
IL-15 able to compensate for the loss of IL-2. Further, T cells persist in IL-2-/- 
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mice suggesting alternative survival factors (275). Yates et al. (276) showed 
that IL-4, IL-7 and IL-15 were able to maintain the suppressive potency of 
human Treg in vitro.  In addition to this, in vitro studies monitoring IL-2 and 
IFN-Ȗ JHQH H[SUHVVLRQ DQG SURGXFWLRQ LQ KXPDQ SHULSKHUDO EORRG
lymphocytes demonstrated that Treg-induced suppression occurred 
independent of IL-2 consumption (258).  
Mounting evidence suggests that regulatory T cells play a major role both in 
the development of malignancy and in the response to anti-cancer therapies 
by mediating tumour-immune escape. Successful management of Treg 
through inhibition of the function, restriction of tumour trafficking or 
enhancement of cytotoxic T cell activity can influence the local immunological 
milieu which in turn may determine the outcome of local and systemic 
immune responses.  
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Figure 1.5 ± Proposed Mechanisms of Treg Suppression. A ± Inhibitory cytokines include IL-10, IL-35 and TGF -ȕB - Cytolysis includes granzyme-A- 
and granzyme-B-dependent and perforin-dependent killing mechanisms. C - Metabolic disruption includes high-affinity CD25 (also known as IL-2 receptor  )-
dependent cytokine-deprivation-mediated apoptosis, cyclic AMP (cAMP)-mediated inhibition, and CD39- and/or CD73-generated, adenosine receptor 2A 
(A2AR)-mediated immunosuppression. D - Targeting dendritic cells (DCs) includes mechanisms that modulate DC maturation and/or function such as 
lymphocyte-activation gene 3 ±MHC-class-II-mediated suppression of DC maturation, and CTLA4±CD80/CD86-mediated induction of indoleamine 2,3-
dioxygenase (IDO), which is an immunosuppressive molecule made by DCs. Adapted from (268).  Reprinted with permission (License number 
2812720344296), Nature Publishing Group Ltd 
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Chapter 2 
Project Aims 
The evolution of surgical techniques and chemotherapy regimens over the 
past three decades has resulted in improvements in ovarian cancer treatment 
(1,2). Debulking surgery remains key in ovarian cancer treatment while 
adjuvant chemotherapy improves both overall and progression-free survival in 
all patient subgroups. Evidence from several randomised controlled clinical 
trials has now established that the platinum±paclitaxel combination regimen 
as first-line treatment for advanced ovarian cancer, yielding response rates of 
over 80% and 40±60% complete responses (1,3-7). However, these patients 
will eventually relapse with a median progression-free survival of 18 months 
(8).  
However, the response rates to treatment decrease with each subsequent 
relapse following the development of drug resistance. To overcome the poor 
prognosis of ovarian cancer, immunotherapeutic strategies have been 
devised such as the use of an anti-CTLA-4 antibody in melanoma. 
Although various immunotherapeutic approaches have been examined for the 
treatment of ovarian cancer, it remains true that no such therapy has entered 
into the clinical arena. This is due to several challenges that need to be 
overcome. When patients are diagnosed with cancer, by definition, the 
WXPRXU KDV ³HVFDSHG´ WKH LPPXQH V\VWHP KDYLQJ SDVVHG WKH SKDVHV RI
³HOLPLQDWLRQ´ DQG ³HTXLOLEULXP´ $OWKRXJK WKere is no shortage of ovarian 
cancer antigens due to genomic instability and accumulation of mutated 
genes at this point, the generation of immune responses against these 
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antigens is likely to be unproductive in the later stages of disease, due to 
multiple immune tolerance mechanisms as described in Chapter 1.  
At the outset of this work, careful consideration was needed to select tumour 
immune suppressive mechanisms that could be targeted with existing 
compounds. This thesis explores, in principle, a strategy to propagate an anti-
ovarian cancer immune response by targeting three different facets of ovarian 
cancer immunity; Regulatory T cell (Treg) migration, poor release of the 
tumour-associated antigen, MUC1 and reduced cytotoxic T cell (CTL) 
proliferation (Figure 2.1). 
As mentioned above tumours develop an environment which is conducive to 
their survival. In addition, this tumour-associated milieu supports a network of 
immunosuppressive adaptations favouring the  accumulation of Treg; potent 
suppressors of CD8+ T cell-mediated cytotoxicity (9).  An increase in tumour 
infiltrating Treg through the CCR4-CCL17/CCL22 chemokine axis has been 
well documented in progressive ovarian cancer (10,11).  Courtesy of 
AstraZeneca, a CCR4 antagonist, AZ1, designed for use as an adjuvant in 
Asthma, blocks receptor internalisation and thus downstream activation of the 
cell. Inhibiting CCR4 activation on Treg could provide a method by which to 
restrict Treg accumulation at the tumour site.  
However, it is important to assume that inhibition of Treg migration would not 
be sufficient in inducing an anti-tumour immune response. Therefore, other 
targets must be employed to fully enhance any anti-tumour activity. The 
availability of antigen is the basis for a T cell response (12). As tumours 
develop, less antigen is presented for immune detection. Current evidence 
suggests that tumour cell death could be immunogenic, with a release of 
tumour antigen being observed (13). It would, therefore, be logical to use 
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chemotherapy, in combination with immunotherapeutic adjuvants to reduce 
tumour burden. However, current chemotherapeutic agents, such as 
Camptothecin, are well-known for possessing severe lymphopaenic adverse 
effects. This would be counter-productive when attempting to enhance the 
anti-tumour immune response.  To overcome this, targeted delivery of 
chemotherapeutic agents is required. This can be achieved through 
encapsulation of the drug in polymeric miFHOOHVZKLFKFDQµGLUHFW¶WKHGUXJWR
WKHVLWHRIDFWLRQZKLOVWµVKLHOGLQJ¶LWIURPRII-target effects. In doing so, tumour 
cell death and tumour-associated antigen release would increase while the 
tumour immune infiltrate and peripheral immune population would remain 
intact.  
In order to take advantage of the increase in tumour-associated antigen and 
the debulking of the tumour mass, it is critical to induce an effective and 
prolonged enhancement of CTL proliferation.  Toll-like receptors are well 
known for initiating immune responses. Of particular interest in this thesis is 
the distribution of toll-like receptor 7 (TLR7). TLR7 is expressed on CTLs and 
on plasmacytoid DC (pDC), a type of dendritic cell which accumulates in 
ovarian cancer (14). Crucially, Treg are described as also possessing this 
receptor. The TLR7 agonist Imiquimod has been used to treat basal cell 
carcinoma and malignant melanoma and has been shown to enhance not 
only CTL (15) and pDC (16) activity but reduce Treg suppressive activity (17).    
In order to develop and validate this strategy, Treg needed to be purified from 
whole blood and demonstrate their suppressive properties (Chapter 3). 
Proportionally, Treg represent a small fraction of the total PBMC population 
and as such their use in downstream experimentation is hampered by lack of 
numbers.  Treg expansion has been a burgeoning field of interest due to its 
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potential in auto-immune disease (18). Thus a Treg expansion protocol was 
conceptualised.  Isolated and expanded Treg demonstrated their suppressive 
activity against CD8+ and CD4+CD25- T effector cells (key mediators of any 
anti-tumour immune response (19)).  
Chapter 4 shows the development of a suitable cell migration assay to 
reproduce the infiltrating capacity of Treg via the CCR4-CCL17/CCL22 axis. 
The demonstration of CCR4 expression on a variety of immune cells and 
tumour cells was critical in determining the specificity of this target. 
Conversely, cancer cells needed to show the capacity to produce 
CCL17/CCL22. Once chemokine-dependent Treg migration had been 
demonstrated the effects of the CCR4 antagonist, AZ1, were investigated. 
In Chapter 5, the effect of Camptothecin on the release of the tumour-
associated antigen MUC1 from ovarian cancer cells and its lymphopaenic 
adverse effects were assessed. This was then compared to the effects of 
Camptothecin incorporated into polymeric micelles to determine whether 
µWDUJHWHG GHOLYHU\¶ RI FKHPRWKHUDSHXWLFV ZRXOG EH D VXFFHVVIXO ZD\ RI
enhancing antigen release while retaining immune cell function.  
Finally, in Chapter 6 the effect of the TLR7 agonist, Imiquimod, on CTL and 
pDC stimulation as well as Treg suppressive activity was assessed. Activation 
with Imiquimod produced a pro-inflammatory cytokine milieu as well as induce 
pDC to cross-present antigen (20). Using the evidence of enhanced pDC 
activation, an attempt was made to generate MUC1-specifc cytotoxic T cells.  
In summary, this thesis explores, in principle, the potential of polypharmacy to 
treat ovarian cancer using existing compounds. The treatment stratagem 
suggested herewith, aims to demonstrate a reduction in the immune 
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suppressive and chemotactic behaviour of Treg as well as a reduction in 
tumour cell migration. It is intimated that the combination of chemo- and 
immunotherapy aides tumour debulking, releases the tumour-associated 
antigen MUC1 and improves the subsequent presentation and generation of 
antigen specific-cytotoxic T cells (Figure 2.1). The stratagem highlights the 
potential benefit of carefully selecting immune suppressive mechanisms that 
can be taken advantage of using readily available compounds rather than 
developing costly new drugs. The efficacy of existing drugs can be enhanced 
when used synergistically and therefore provides a unique perspective on 
cancer immunotherapy. 
 
 
76 
 
 
Figure 2.1 ± The Suggested Effect of JPM137, Imiquimod and AZ1 on Tumour Immunity. A ± JPM137 will localise at the tumour site and cause 
cytolysis. B- Tumour cell death will lead to the release of tumour associated antigen. C ± Imiquimod activates dendritic cells at tumour draining- and 
peripheral- lymph nodes causing antigen uptake, improved antigen presentation and generation of antigen specific cytotoxic T cells. D ± Imiquimod induces 
the proliferation of CD8+ T cells and improves the production of pro-inflammatory cytokines (E). F ± Imiquimod reduces the suppressive effects of Treg while 
AZ1 blocks their migration to the tumour site (denoted by red crosses).   The net result would be a reduction in tumour burden and a durable anti-tumour 
immune response. 
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Chapter 3 
Isolation, Expansion and Functionality of 
Regulatory T cells 
 
3.1 Introduction 
Several subsets of T regulatory cells have been described in humans. The CD4 
derived major Treg populations include natural T regulatory cells (Treg) which 
originate in the thymus (1-5), induced Treg (iTreg) derived from naive CD4+ T 
cells in the periphery (6,7), Tr1 cells which secrete predominantly IL-10 (8,9) and 
Th3 cells which secrete predominantly TGF-ȕ (10). Other cell populations such 
as NKT cells and CD8 T suppressor cells can also mediate immune regulation. 
As discussed previously, natural Treg play a key role in inducing and maintaining 
immunological tolerance, immune homeostasis and tumour immunity (1-3,5,11). 
These cells have been implicated in the suppression of anti-tumour immunity and 
have been repeatedly identified in several clinical settings to correlate with 
negative outcome (Table 1.2).  Natural Treg constitute a minor population in 
peripheral blood with a frequency of 1±2% of total circulating CD4+ T cells (12). 
In order to progress the work in this thesis, Treg needed to be isolated from 
human blood and, due to their small number, expanded to a suitable population 
size for experimentation.  
 
Expanded CD4+ T cells should ideally have the characteristics of Treg i.e.  a 
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stable phenotype of CD25hiFOXP3+ expression and a retention of their functional 
ability to suppress immune reactive T cells. To accomplish the goal of expanding 
Treg ex-vivo for experimental purposes, it is critical to begin with the appropriate 
starting cell population and to use culture conditions that selectively favour the 
expansion of Tregs with properties characteristic of a Treg lineage.   
 
3.1.1 The Definition of Treg? 
In humans there is no Treg-VSHFL¿F FHOO VXUIDFH PDUNHU ZKLFK ZRXOG DOORZ IRU
their isolation and no clear understanding of how they function to control immune 
responses In vivo. The majority of CD4+CD25+ Treg are produced by the thymus 
with a repertoire RIDQWLJHQVSHFL¿FLWLHVWKDWDUHDVEURDGDVWKDWRIQDwYH7FHOOV
They are capable of recognising both self and non-self antigens and control 
various immune responses such effector T cell proliferation and DC activation (1-
3) $ VSHFL¿F UROH RI )2;3 LQ WKH GHYHORSPHQW DQG IXQFWLRQ RI QDWXUDO
CD4+CD25+ Treg has been described (13-15). Mutations of the human gene 
FOXP3, similar to the gene mutated in scurfy mice (Foxp3) were found to be the 
cause of IPEX syndrome which has X linked inheritance and is characterised by 
polyendocrinopathy, entropathy and immune dysregulation (16,17). However, 
H[SUHVVLRQ RI )2;3 LV QRW VXI¿FLHQW WR GHVLJQDWH FHOOV DV 7UHJ DQG
FOXP3+CD4+ cells may in fact be composed of a mixture of Treg derived from 
the thymus, iTreg generated in the periphery from CD4+ naive cells and activated 
non-regulatory CD4+ cells which may not have suppressor activity. Therefore the 
functional characteristics that differentiate true Treg from other subsets are 
FULWLFDOIRUGH¿QLQJ7UHJWKDWDUHXVHGLQVXEVHTXHQWDVVD\VGXULQJWKLVSURMHFW 
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For the magnetic isolation of Treg, peripheral CD4+ cells with a high expression 
of CD25 were utilised as the main markers. The choice of markers on which to 
isolate human Tregs for expansion has been controversial. As FOXP3 is an 
intracellular protein it cannot be used to isolate viable cells. CD25 represents the 
ĮFKDLQRIWKH,/-2 receptor that is essential for the generation and maintenance 
of Treg. The high expression of CD25 is frequently taken advantage of in 
protocols for isolating as well as targeting peripheral Treg. However, CD25 is 
also upregulated upon cellular activation, thus recently activated effector CD4+ T 
cells may be confused with Treg and iTreg. Nevertheless there are differences 
between CD4+CD25+ Treg and activated T cells with respect to the 
characteristics of CD25 expression. Human and mouse CD4+ cells with potent 
regulatory properties express high and sustained levels of CD25, whereas 
recently activated T cells express transient and low levels of CD25 (11,12). Thus 
a stable and high expression of CD25 is an essential characteristic of Treg. 
Throughout the course of this thesis, the expanded Treg population were derived 
from the CD4+CD25+ cell fraction which maintained a stable, high expression of 
CD25. 
Other markers, such as latency-associated peptide (LAP) and IL-1 receptor type I 
& II (CD121a/CD121b) have also been used for Treg. These markers are not 
expressed on resting FOXP3+Treg, but are rapidly induced and expressed for a 
short time period after TCR-mediated activation (18). Thus these markers can 
only isolate TCR activated FOXP3+ Treg but not resting, peripheral FOXP3+ 
Treg. Other markers have been ascribed to natural Treg, e.g. CTLA-4 and GITR 
but, currently, the most reliable marker for natural Treg is FOXP3 when applied in 
conjunction with the other properties of Treg. 
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A feature that is increasingly used for isolating Treg from blood is the absence of 
CD127, the IL-7 receptor alpha subunit, which is abundantly expressed on naïve 
cells.  There are several reasons to suggest that CD127 negativity should not be 
used to select the initial starting population for Treg expansion. Firstly, there is 
the potential to eliminate thymic derived resting precursors of Treg which may 
express CD127. Recent data of Treg expansion using umbilical cord blood which 
is enriched in naïve cells support this. Umbilical cord blood Treg isolated by 
positive selection using either AutoMACS or CliniMACS based on CD4+CD25+ 
expression and not on the absence of CD127 expression, were cultured with 
anti-CD3/CD28 mAb coated Dynabeads with IL2 and Rapamycin (19,20) and 
showed approximately 100-fold (19) to 199-fold (20) expansion. Foxp3 
expression was 72.6% in one report (20) and they exhibited potent suppressor 
activity of ~95% (18) and 58 +/- 11% (20) respectively in allogeneic mixed 
lymphocyte reaction. In freshly isolated CD4+CD25+ populations, the expression 
RI &' ZDV DSSUR[LPDWHO\  DQG WKH ¿QDO H[SDQGHG SRSXODWLRQ ZDV
negative for CD127. 
This suggests that CD127 negativity may be more useful for characterising 
functional expanded Treg rather than for initial selection of the population to be 
expanded. Another reason against using the absence of CD127 expression for 
selecting the initial population is that CD127 negativity as a biomarker cannot 
discriminate between Treg and T effector cells (9,21). Upon cellular activation 
CD127 is down-regulated in CD4+ cells including CD4+CD25+ Treg. Thus when 
CD127 low/- expression is used in combination with CD25+ expression for 
isolating Treg, it can concentrate a heterogeneous subpopulation of cells 
consisting of Treg, iTreg and activated CD4+CD25+ non-Treg which can 
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transiently express FOXP3. Thus, the CD4+CD25+CD127ORZí population may 
have greater potential for differentiating into cytokine secreting effector cells. A 
previous study that has used FACS sorting for isolating CD4+Treg based on 
CD25 expression and CD127 negativity and subsequent expansion resulted in 
contamination with eIIHFWRU FHOOV EDVHG RQ WKHLU F\WRNLQH SUR¿OH (22). In that 
report, the expanded cells, despite showing FOXP3 expression of ~95%, 
manifested substantial cytokine producing cells. This is an important criterion 
because the mechanism of natural Treg function is by cell-to-cell interaction and 
not via secretion of cytokines IL-10 and TGF-ȕ ZKLFK DUH UDUHO\ IRXQG LQ WKH
supernatants of in vitro Treg assays and that the use of anti-IL-10 or anti-TGF-ȕ
antibodies fails to abrogate suppression (3). Another distinct subset of regulatory 
T cells (Tr1) suppresses immune responses via cell-to-cell interactions and/or the 
production of IL-10 and TGF-ȕ (8,9) for a variety of antigens (9). IL-10 is also 
secreted by other cells like Th2 cells (23,24), macrophages (25,26), monocytes 
(27) and dendritic cells (28). 
 
3.1.2 Expansion of Treg 
The expansion of Treg both in vivo and in vitro provides useful information 
pertaining to their ontogeny and existence within the tumour microenvironment. 
3.1.2.1 In vivo 
As Treg are present in the immune system as a functionally distinct and mature 
population with a diverse TCR repertoire, mere clonal expansion of Treg through 
appropriate pathways of antigenic stimulation leads to induction of antigen-
VSHFL¿F LPPXQHVXSSUHVVLRQ)RUH[DPSOH7UHJVSHFL¿FIRU LVOHWDQWLJHQZHUH
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shown to be more potent in suppressing diabetes in NOD mice than polyclonally 
activated Treg (29,30). 
Allergen-VSHFL¿FLPPXQRWKHUDS\6,7ZKLFKFRQVLVWVRIUHSHDWHGVXEFXWDQHRXV
or sublingual administration of allergen, has been widely used and proved 
effective for the management of allergies (31). The mechanism of the therapeutic 
effect of SIT is not completely understood (32) but might involve the activation 
and expansion of  Treg (33,34) along with the induction of adaptive Treg, such as 
IL-10±secreting Tr1 cells (35,36). Regarding the mechanism of SIT, it is of note 
that Treg can be activated to exert suppression at a much lower concentration of 
antigen than required for activation of naive T cells (37). 
As mentioned above, Treg bear a T-cell receptor (TCR) repertoire that is as 
broad and diverse as that of naive T cells yet is more self-reactive than the latter. 
7KLVPHDQVWKDWWKH7&5VRI7UHJEHDUDKLJKHUDI¿QLW\WKDQRWKHU7FHOOVIRUWKH
class II MHC/self-peptide ligands, positively selecting them in the thymus (2). 
They also express a higher level of accessory molecules, including adhesion 
molecules, such as lymphocyte function associated 1 (LFA-1) and intercellular 
adhesion molecule 1 (ICAM-1) (38). 
These unique immunological features of Treg make them well suited for 
controlling self-reactive T cells efficiently and swiftly during episodes when self-
antigens are aberrantly or excessively presented in the immune system. 
By exploiting the immunologic characteristics that differentiate Treg from other T 
cells, the expansion of antigen-VSHFL¿F 7UHJ FHOOV FDQ EH DFKLHYHG E\ D
controlled exposure to antigen, and alteration of the cytokine milieu while 
suppressing the activation and expansion of effector T cells. The immune 
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privileged site of the tumour microenvironment could provide the basis for the 
generation of tumour antigen specific Treg (39).  It is suggested that before the 
development of systemic metastasis, antigenic cancer cells (i.e. those that 
express tumour antigen) are embedded in the solid tumour. The stroma of the 
tumour prevents the efficient release of TAAs (40) which are ignored in 
conventional sites of antigen priming and presentation ² the draining lymph 
nodes (41,42). 
Initially, tumour antigen is thought to be efficiently released, which propagates 
anti-tumour responses. However, several tolerogenic mechanisms, as discussed 
before, would already be upregulated in the surrounding microenvironment. This 
would cause the abrogation of the functions of APCs and other effector 
populations (43). This in turn allows tumour development to occur unchecked, 
leading to stroma development. The generation of dysfunctional APCs can not 
only induce T cell tolerance through soluble factors and tryptophan depletion but 
can also generate antigen specific Treg (39,44).     
3.1.2.2 Polyclonal Expansion of Treg In vivo 
In addition to the antigen- or TCR-based approaches to Treg expansion 
discussed above, control of Treg and effector populations via soluble factors or 
pharmacological agents can be conducive to establishing Treg cell±mediated 
dominant tolerance. This would occur either by expanding Treg, reducing effector 
T cells, or both. 
As mentioned previously the immune suppressive milieu which is associated with 
malignancy can lead to enrichment in the Treg fraction of tumour-immune 
infiltrates. Naïve CD4+CD25- FHOOVFDQEHµFRQYHUWHG¶WRDQDOPRVWLGHQWLFDO7UHJ
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phenotype through a combination of cytokines such as IL-10 and TGF-ȕ(45), a 
lack of IL-2 (46) and induced anergy via tryptophan depletion (47) and increased 
extracellular adenosine (48).  
Several pharmacological treatments can lead to increased numbers of Treg. 
Administration of IL-2, a key cytokine for the development and, in particular, the 
maintenance of Treg might facilitate the expansion of antigen-stimulated Treg 
FHOOVLQWKHSHULSKHU\RUDWWKHVLWHRILQÀDPPDWLRQ,/-2 is pleiotropic in function; 
in addition to maintaining Treg, it induces activation-induced cell death in 
activated T cells, maintains CD8+ cytotoxic T cells, and inhibits Th17 cell 
differentiation (49). Drugs that facilitate immune suppression such as the cancer 
chemotherapeutics, Cyclosporine and Rapamycin lead to a deletion in 
proliferating effector populations thus leaving a proportionally greater Treg 
fraction (50).  
 
3.1.2.3 In vitro Expansion of Treg 
Approaches to activate and expand Treg  ex-vivo are now well established. Most 
involve the use of anti-CD3 plus anti-CD28 mAb co-stimulation together with IL-2. 
More recently Rapamycin, a macrocyclic lactone commonly used in organ 
transplantation to prevent acute rejection (51) has been used as an adjuvant in 
Treg expansion. The enrichment of Treg by Rapamycin treatment can be 
attributed to their relative resistance to apoptosis/necrosis because of different 
modes of activation in the phosphoinositide 3-kinase/Akt/mammalian target of the 
Rapamycin (mTOR)-signaling pathway in Treg cells and effector T cells (52).  
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Retinoic acid, a derivative of vitamin A, plays an important role in T cell function 
and trafficking and has been postulated as an alternative to Rapamycin to 
promote the expansion of Treg. All-Trans Retinoic Acid (ATRA) produced by DC 
facilitates de-novo generation of FOXP3+ T regulatory cells from CD25í T cell 
populations in mice (53,54). Two non-mutually exclusive mechanisms have been 
proposed to account for the ATRA-promoted induction of suppressive T cells. 
One set of data indicates that ATRA augments TGF-ȕ PHGLDWHG VLJQDOLQJ
(55,56), while other investigators report that ATRA suppresses the ability of 
memory T cells to block the induction of FOXP3 expressing Treg (57). Many 
studies have tried to mimic the in vivo conversion of  CD4+CD25- T effector cells 
to Treg by ATRA in vitro as a means to rapidly generate suppressive T cells (58-
60). Two studies have reported that human CD4+CD25í T cells derived from 
adult peripheral and cord blood were converted to suppressive cells in the 
presence of TGF-ȕ DQG $75$ (61,62). One of these groups also performed a 
series of experiments examining how ATRA affected the expansion and function 
of natural Treg and concluded that ATRA augmented their suppressive activity 
and should therefore be considered for use in Treg-based therapy (62). 
Studies have also indicated that Treg can be generated from CD4+CD25í T cells 
through Foxp3 induction in response to a variety of stimuli in vitro (63-65). One 
group has described the generation of antigen-specific Treg from human 
CD4+CD25í T cells. This group had previously shown that anti-CD3 activation of 
human CD4+CD25í cells in the presence of APC lead to the induction of FOXP3 
and suppressive activity in a population of cells that remained CD25high (66).  
Further work went on to show that stimulation of human CD4+CD25í cells with 
APC and HA peptide resulted in the generation of a population of HA-specific 
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CD25high cells that expressed Foxp3 (67). Antigen-specific cells were then 
isolated using HLA class II tetramers presenting the HA peptide. These cells 
required cognate antigen to activate suppressive function but once activated 
were capable of bystander suppression in vitro. 
 
3.1.3 Functionality of Treg 
With both isolated and expanded populations it is important to ascertain the 
suppressive activity of Treg against effector populations. Reports of standard 
assays for Treg suppression look at their impact on the proliferation of 
CD4+CD25- effector T cells (68). This is a good starting point in the first instance 
as it enables optimisation of the assay conditions as well as providing useful data 
on the potency of Treg against other T helper cells.  However, with regards to 
tumour immunity and the project as a whole, a large proportion of clinical data 
looks at CD8+/FOXP3+ ratio as a prognostic indicator for many cancers including 
ovarian malignancies (69). Therefore, assessing Treg function against CD8 T 
cells is also important.  
The cytokine profile of Treg suppression assays can not only corroborate the 
observations seen during proliferation but also provide insight into the molecular 
basis of Treg activation when different stimuli are used. Critically, these assays 
lay the foundation for probing Treg function and gaining an understanding of the 
potential mechanism by which they operate. 
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3.1.4 Experimental Objectives described in Chapter 3 
x Isolation of Treg from whole blood 
x Demonstration of Treg suppressive activity against both CD4+CD25- and 
CD8+ T cells 
x Development of a viable and cost effective Treg expansion protocol 
x Demonstration of expanded Treg functionality 
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3.2 Methodology 
3.2.1 Isolation of Regulatory T cells via Magnetic Selection (Dynal) 
A maximum volume of 100 ml of peripheral blood was obtained from healthy 
donors in accordance with local ethical committee approval (EC# BT/04/2005).  
Peripheral blood mononuclear cells (PBMC) were separated via a density-
gradient centrifugation over Histopaque-1077 (Sigma) twice, firstly to isolate 
PBMCs with the second density gradient used for the removal of platelets.  The 
resultant cells were then washed and resuspended at 5 x 107 cells per 500 µl 
isolation buffer containing phosphate buffered saline (PBS) + 1% w/v bovine 
serum albumin (BSA) (Sigma) + 1 mM EDTA (Sigma) before viability counting via 
Trypan Blue exclusion (Fluka). 200 µl of CD4 Human Antibody Mix (Invitrogen) 
and 100% v/v foetal calf serum (Sigma) (FCS) were incubated with PBMC for 20 
minutes.  This was followed by the addition of 1 ml Depletion MyOne Dynabeads 
(Invitrogen) before magnetic removal of bead-bound non-CD4+ cells, leaving 
CD4+ cells in solution.   
CD4+CD25+ T cells were isolated by positive selection using 200 µl CD25 
Dynabeads per 1.5 x 107 cells.  The CD4+CD25+ Treg population was liberated 
from the CD25 Dynabeads using Detach-a-bead solution (Invitrogen) and were 
then used in downstream applications.  The remaining CD4+CD25- effector T 
cells were either used in T cell suppression assays or placed in RPMI-1640 
(Sigma) + 10% v/v FCS (Sigma) + 5 mM L-*OXWDPLQH 6LJPD ,8ȝJPO
Pencillin/Streptomycin (Sigma) and 10% v/v DMSO (Sigma) before undergoing 
controlled freezing at ± ÛC  with prolonged storage in liquid nitrogen.  
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A small volume of cells (10 µl) was taken at each isolation step for analysis via 
flow cytometry. 
 
3.2.2 Isolation of Regulatory T cells via Magnetic Selection (MACS) 
Peripheral blood mononuclear cells (PBMC) were separated via a density-
gradient centrifugation as described previously.  The resultant cells were then 
washed and resuspended at 1 x 107 cells per 90 µl of isolation buffer containing 
phosphate buffered saline (PBS) + 1% w/v bovine serum albumin (BSA) (Sigma) 
+ 1 mM EDTA (Sigma) before viability counting via Trypan Blue exclusion 
(Fluka). PBMC were then labeled with 10 µl anti-biotin cocktail followed by 20 µl 
anti-biotin Microbeads. The cell/bead mixture was applied to a priPHG µ/'¶
magnetic column which was subsequently washed several times before the 
enriched, bead-free CD4+ T cell population was eluted. 
CD4+CD25+ T cells were selected via addition of CD25 Microbeads. The labeled 
cell suspension was then applied to a primed µ06¶ PDJQHWLF FROXPQ 7KH
unlabeled CD4+CD25- T cells were collected were either used in T cell 
suppression assays or placed in RPMI-1640 (Sigma) + 10% FCS (Sigma) + 5 
mM L-*OXWDPLQH 6LJPD   ,8ȝJPO 3HQFLOOLQ6WUHSWRP\FLQ 6LJPD DQG
10% DMSO (Sigma) before undergoing controlled freezing at ±  Û& with 
prolonged storage in liquid nitrogen.  The bead bound CD4+CD25+ T cells were 
eluted from the column for downstream applications. A small volume (10 µl) of 
cells was taken at each isolation step for analysis via flow cytometry. 
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3.2.3 Isolation of CD8+ T cells via Magnetic Selection 
Peripheral blood mononuclear cells (PBMC) were separated via density-gradient 
centrifugation as described previously.  The resultant cells were then washed 
and resuspended at 1 x 107 cells per 80 µl of isolation buffer containing 
phosphate buffered saline (PBS) + 1% w/v bovine serum albumin (BSA) (Sigma) 
+ 1 mM EDTA (Sigma) before viability counting via Trypan Blue exclusion 
(Fluka). Cells were labeled with 20 µl CD8 Microbeads (Miltenyi Biotec) per 1 x 
107 cells for 15 minutes before washing in isolation buffer. The cell/bead mixture 
was appOLHGWRDSULPHGµ/'¶PDJQHWLFFROXPQZKLFKZDVVXEVHTXHQWO\ZDVKHG
several times before the enriched, bead-free CD8+ T cell population was eluted. 
A small volume (10 µl) of cells was taken for counting and phenotypic analysis 
via flow cytometry. 
 
3.2.4 Flow Cytometry Analysis 
Cells were stained with cell surface markers CD4-ECD (1.25 µl) (clone 
SFCI12T4D11 - Beckman Coulter), 2.5 µl CD8-FITC (Clone HIT8a ± BioLegend) 
CD25-PE (7.5 µl) (Clone BC96 - BioLegend), CCR4-PerCP/Cy5.5 (2.5 µl) (Clone 
TG6 - BioLegend).  Cells were incubated with flourochrome-conjugated 
antibodies for 15 minutes before fixation with 3% v/v formaldehyde (Sigma).  
Cells were then permabilised using FOXP3 Perm Buffer (BioLegend) before 
incubation with Foxp3-AlexaFluor488 (Clone 259D ± BioLegend) for 30 min.  
Cells were then resuspended in FACS wash buffer (BioLegend) and read via a 
Beckman Coulter FC 500 flow cytometer. Analysis involved gating on lymphocyte 
populations from forward/side-scatter plots before selecting regions of interest. 
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3.2.5 Suppression Assays 
T cell proliferation assays were set-up in triplicates in 96-well, round-bottomed 
plates with stimulated and non-stimulated divisions for comparison where 
possible.  Briefly, CD4+CD25- or CD8+ effector T cells were either resuscitated 
from frozen stocks or freshly isolated from whole blood. These were plated out at 
5 x 104 cells/well in X-vivo-15 + 5% v/v Human AB serum.  Treg were then added 
to each well to provide Teff:Treg ratios of 1:5, 1:10, 1:20, 1:40  to bring volume 
per well to 100 µl.  Cells were stimulated with 10 µg/ml anti-CD3 (Clone-OKT, 
Biolegend) and 5 µg/ml anti-CD28 (Clone ± 28.2, Biolegend) or 10 µg/ml of PHA 
(Sigma).  The final volume was adjusted to 200 µl using X-vivo-15 + 5% Human 
AB serum. After 72 hours, 100 µl of cell supernatant was taken and stored at ± 
 Û& WKHSODWHZDV WKHQSXOVHGZLWK&LRI >3H]-labelled thymidine per well 
(TRA120, Amersham).  The plate was left to incubate for a further 18 hours 
before being harvested onto a microscintillation plate (Perkin-Elmer).  After 
repeated washes with de-ionised water, the plate was allowed to dry for an hour.  
20 µl of scintillation fluid (Microsint 0, Perkin-Elmer) was added per well before 
the plate was covered with optical tape (Perkin Elmer).  Thymidine incorporation 
was quantified using a Packard TopCount NXT Microplate Scintillation counter. 
 
3.2.6 Expansion of CD4+CD25+ T Cells 
Isolated CD4+CD25+ T cells were divided into three experimental groups and 
placed into culture using X-Vivo-15 + 5% Human AB Serum (Lonza). The final 
cell concentration was maintained at 1 x 106cells/ml. The first experimental group 
was supplemented with 1000 IU/ml recombinant IL-2 (Novartis) and stimulated 
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with 10 µl/PO Į&' VXSHUDJRQLVW $QFHOO  The second group was 
supplemented with 1000 IU/ml recombinant IL-2 and stimulated with plate bound 
1 µg/ml Į&' DQG VROXEOH 1 µg/ml Į&' DQWLERGLHV %LROHJHQG  7KH WKLUG
group was as a negative control with no media supplementation or stimulation. 
After days 3, 10 and 17, those cells being expanded were supplemented with 
500 IU/ml recombinant IL-2.  At days 7, 14 and 21, cells were collated and 
counted via Trypan Blue (Fluka).  A sample was taken for analysis via flow 
cytometry.  The cells were then re-suspended in culture media and re-stimulated 
as described previously.   
3.2.7 Enzyme linked-immunosorbant Assay (ELISA) 
Cytokine production was measured by ELISA. The cytokines of interest were 
IFN-ȖDQG ,/-10. Polystyrene 96-well plates (MaxSorp, Nunc) were coated with 
the relevant capture antibody (2 µg/ml IFN-Ȗ&ORQH0'-1 ± BioLegend, 2 µg/ml 
IL-10; Clone JES3-12G8, BioLegend) overnight.  The plate was then blocked 
with 5% w/v skimmed milk powder in PBS (pH 7.2) + 0.05% v/v Tween 
(PBS/Tween) to prevent non-specific binding. The plate was washed in 
PBS/Tween using an automated plate washer and tapped dry. The relevant 
recombinant cytokine (PeproTech) and samples were added to the plate.  After 2 
hours, the plate was washed in PBS/Tween before the appropriate biotinylated 
detection antibody (1 µg/ml IFN-Ȗ  JPO ,/-10; BioLegend) was diluted in 
PBS, 1% w/v BSA, and 0.1% v/v Tween 20 and incubated for 2 h at room 
WHPSHUDWXUH EHIRUH EHLQJ ZDVKHG  ȝO RI  JPO VWUHSWDYLGLQ-horseradish 
peroxidase (BD-Pharmaginen) was added each well. After 30 minutes incubation 
at room temperature, the plate was washed and bound horseradish peroxidase 
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was visualised with 0.1 mg/ml tetramethylbenzidine (Sigma) and 2 ul of 30% v/v 
hydrogen peroxide (Sigma) diluted in 3 M sodium acetate buffer (Sigma). The 
colour reaction was stopped with addition of 2 M sulphuric acid (Sigma), and 
absorbance was measured at 450 nm using a MRX spectrophotometer (Dynex 
Technologies). The concentrations of samples were calculated from standard 
curves of each recombinant cytokine. ELISA detection limits were determined as 
follows (IFN-Ȗ± 10 pg/ml, IL-10 ± 2 pg/ml). 
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3.3 Results and Discussion 
3.3.1 Magnetic Isolation of Treg from PBMC 
Key to the outcome of this project was the successful isolation of Treg from 
healthy volunteers. Although several methods for the isolation of Treg were 
available, it was decided that magnetic isolation would be the most cost-effective 
approach. Magnetic isolation involves the selective labeling of target cell 
populations using antibody-bead complexes. Using magnetic fields, these cells 
can be separated from PBMC populations relatively easily with a generally high 
level of purity. Isolation systems from two companies, Invitrogen (Dynal) and 
Miltenyi Biotec (MACS) were assessed for their ease of use, cell purity and cost 
effectiveness. 
In order for Treg to be isolated by this method, sequential magnetic separations 
are required. Due to Treg being an inherently small population (1 ± 2% of total 
PBMC) (70), an enriched CD4+ T cell population is required. This can be 
achieved by either positive or negative selection of CD4+ cells. A further positive 
selection step is required to isolate those CD4+ cells which also highly express 
CD25. Figure 3.1 demonstrates the purification process of Treg from PBMC in a 
step-wise manner.  Treg were strictly analysed as those cells which were 
CD4+CD25hiFOXP3+. By maintaining such a strict analysis, it appears that the 
cells isolated are of a low purity. However, this ensures improved accuracy when 
attempting to quantify those Treg which have been expanded (Figure 3.9).  
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Figure 3.1 - Flow Cytometry Analysis of Cells Isolated using Magnetic Selection. Cells were stained for CD4, CD25, FOXP3 and CCR4 
expression.  Lymphocytes were identified from forward/side scatter plots before populations of interest were gated upon.  Cells gated as 
CD4+CD25hi were analysed for FOXP3 and CCR4 expression respectively. Analysis confirms CD4+CD25hi Treg proportion as approximately 4% 
of total CD4+ T cells which agrees with those percentages found in literature.  
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3.3.2 Assessment of Vendors for Treg Isolation Kits 
As previously mentioned, two vendors Invitrogen (Dynal) and of Miltenyi Biotec 
(MACS) of Treg magnetic selection kits were compared for ease of use, cell 
purity and cost effectiveness. Figure 3.2 represents the Treg purity obtained from 
the same donor using these two different kits. To calculate the purity of Treg the 
percentage of CD4+CD25hi cells was multiplied by percentage of CD4+FOXP3+ 
cells. The purity of Treg (CD4+CD25+FOXP3+) isolated using Dynal was 
calculated to be 68.5% (CD4+CD25hi ± 74.9 x CD4+FOXP3+ - 91.6) compared to 
MACS which provided a purity of 40.7% (CD4+CD25hi ± 85 x CD4+FOXP3+ - 
47.9).  
These results meant that Dynal from Invitrogen was used as the main method for 
isolating Treg. 
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Figure 3.2 - Comparison of Treg Isolated from Dynal© and MACS© Regulatory T cell Magnetic Selection Kits.Cells were taken from the 
same donor and phenotyped as described previously for CD4,CD25 and FOXP3. Differences in the purity of isolated Treg (CD4+CD25+FOXP3+)  
were found with Dynal achieving 68.5 % purity compared to 40.7 % isolated via MACS. On the basis of this result and the respective costs 
involved when using each kit, Dynal were selected as the Treg isolation kit of choice. 
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3.3.3 Isolated Treg Suppress Effector T cell proliferation 
The major characteristic of Treg is their ability to suppress the proliferation of 
multiple effector T cell populations.  This can be demonstrated through the use of 
T cell proliferation assays. Figure 3.3 and Figure 3.5 show that these isolated 
Treg have suppressive activity against CD4+CD25- T cells and CD8+ T cells 
which have been stimulated with PHA or anti-CD3/anti-CD28 respectively. Treg 
demonstrated a dose-dependent effect in suppressing CD4+CD25- T cells which 
was statistically significant up to a 1/10 fraction  (Figure 3.3; Effector vs. 1/10 
(cpm) ± 4086 vs. 1385, n = 6; p < 0.05).  With regards to CD8+ T cells, Treg 
again demonstrated a dose-dependent effect in suppressing proliferation which 
was statistically significant up to a 1/10 fraction (Figure 3.5; CD8 vs. 1/10 (cpm) ± 
19420 vs. 13375, n = 3; p < 0.05). 
Suppression at a 1/20 fraction was not significant for both CD4+CD25- T cells 
(Figure 3.3; Effector vs. 1/20 (cpm) ± 4086 vs. 4007, n = 6; p < 0.05) or CD8+ T 
cells (Figure 3.5; CD8+ vs. 1/20 (cpm) ± 19420 vs. 17224, n = 3; p < 0.05).  This 
suggests that there is a limit to which Treg can suppress effector T cell 
populations. Therefore it can be hypothesised that reducing the numbers of Treg 
within a co-inhabited system e.g. the tumour microenvironment, would allow 
greater effector T cell proliferation.  
The supernatants of the suppression assays were analysed for classical pro-
inflammatory (IFN-Ȗ DQG VXSSUHVVLYH ,/-10) cytokines (Figure 3.4).  Previous 
evidence dictates that effector populations should produce more IFN-ȖDQGOess 
IL-10 as Treg number decreases, and that Treg should not readily produce either 
IFN-ȖRU ,/-10 when stimulated alone. The cytokine profiles seen when effector 
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populations have their TCR engaged with anti-CD3/anti-CD28 appear to 
corroborate with existing evidence. However when these cells are stimulated with 
PHA, there appears to be an increase in IFN-ȖDQGDVXEVHTXHQWGHFUHDVHLQ,/-
10 with increasing Treg number. PHA stimulated Treg demonstrated significantly 
higher IFN-ȖSURGXFWLRQFRPSDUHG WR&'+CD25-  T cells (Figure 3.4; Treg vs. 
Effector (ng/ml) 5.39 vs. 3.01, n = 6; p < 0.05).    
This counter intuitive result could be explained by the existence of different 
molecular activation pathways in Treg compared to effector T cells. Recently, 
there have been several advances in defining how the intracellular signalling 
events in Treg differ from those in effector populations, particularly in regard to 
TCR activation.  It is well defined that in order for T cells to be fully activated, 
proliferate and acquire effector functions, they must receive two activation 
signals. One signal via the TCR and the other via one of several co-stimulatory 
molecules expressed by APCs e.g. CD80/CD86. However, Treg remain 
hyporesponsive to TCR engagement, which is demonstrated by the lack of 
cytokine production seen when stimulated with anti-CD3/anti-CD28 (71,72) 
(Figure 3.7).  This is due to reported differences in the Ras and phosphokinase C 
pathways where FOXP3 restricts the translocation and transcription of NF-ț%
which leads to cytokine production (73) (Figure 3.8). 
Yet, with mitogenic stimulation, such as the use of PHA, there is a bypassing of 
these pathways such that NF-ț%Ls activated (74), thus promoting production of 
cytokines such as IFN-ȖDQG,/-10 which corroborates with the cytokine profile of 
PHA stimulated Treg (Figure 3.7). This suggests that NF-ț% LQGXFWLRQFRXOGEH
advantageous in modulating Treg cytokine output. 
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Figure 3.3 - Treg Suppress the Proliferation of PHA-stimulated CD4+CD25- Effector T cells in a Dose-dependent Manner. Figure represents 
the means of six independent experiments from six different donors. Treg demonstrate suppression of CD4+CD25- T cells where Treg were 
present at a 1/5 and 1/10 fraction of total co-culture. n = 6, *=p<0.05. Statistical significance determined by a one-way ANOVA analysis with 
column comparisons using Tukey's Multiple Comparison Test.   
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Figure 3.4 - Production of IL-10 and IFN-Ȗ IURP 7 FHOO 6XSSUHVVLRQ $VVD\V
Stimulated with PHA. Treg demonstrate an increase in IFN-ȖDQGDGHFUHDVH LQ ,/-10 
when stimulated with PHA.   A - IFN-Ȗ SURGXFWLRQ  B ± IL-10 production. Figures 
represent the means of six independent experiments from six different donors. Error bars 
represent standard deviations. *=p<0.05. Statistical significance determined by a one-
way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. 
Detection limit = 40 pg/ml.  
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Figure 3.5 - Treg Suppress the Proliferation of anti-CD3/anti-CD28-stimulated CD8+ 
T cells in a Dose-dependent Manner. A ± FACS analysis of CD8+ and CD4+CD25+ T 
cell isolations. Purity of CD3/CD8 isolation was calculated to be 93.3 % (92.1 ± 95.7 %; n 
= 3). Purity of CD4+CD25+ T cells calculated to be 78.01 % (77.3 ± 79 %; n = 3). B ± CD8 
T cell proliferation suppressed by Treg. Figure representative of the means of three 
independent experiments from three different donors. Treg demonstrate suppression of 
CD8+ T cells where Treg were present at a 1/5 and 1/10 fraction of total co-culture. n = 3 
*=p<0.05. Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. 
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Figure 3.6 - Production of IL-10 and IFN-Ȗ IURP &'+ T cell Suppression Assays 
Stimulated with anti-CD3/anti-CD28. Treg restrict CD8+ T cell production of IFN-Ȗ1R
significant change in IL-10 production detected. A - IFN-Ȗ SURGXFWLRQ B - IL-10 
production. Figures representative of the means of three independent experiments from 
three different donors. Error bars represent standard deviations. n = 3, *=p<0.05. 
Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. Detection limit = 40 pg/ml.  
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Figure 3.7 - Production of IL-10 and IFN-ȖIURP7UHJVWLPXODWHGZLWK3+$RUDQWL-
CD3/anti-CD28. Treg demonstrate an increase in A - IFN-Ȗ DQG B - IL-10 when 
VWLPXODWHGZLWKJPO3+$FRPSDUHGWRVWLPXODWLRQRI7UHJZLWKJPOĮ&'DQG
JPOĮ&'   Figures representative of the means of three independent experiments 
from the same donor. Error bars represent standard deviations. n = 3, *=p<0.05. 
Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. Detection limit = 40 pg/ml 
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Figure 3.8 - Differences between Effector T cell and Treg Activation. A ± Effector T cells, once TCR engagement occurs, have multiple 
proliferative pathways engaged which causes the activation of NF-ț%DQG $.7 OHDGLQJ WRSURGXFWLRQRI ,)1-ȖDQG RWKHU F\WRkines as well as 
inducing cell proliferation. B ±Treg have several signaling components whose activation/phosphorylation have been demonstrated to be defective, 
thus TCR engagement causes Treg hyporesponsiveness and thus very little IFN-Ȗ and IL-10 as seen in Figure 3.7. C ± Treg stimulated with PHA, 
see a direct innervation by the mitogen on NF-ț%DFWLYDWLRQWKXVOHDGLQJWRSURGXFWLRQRI,)1-ȖDQG,/-10.   
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3.3.4 Expansion of Treg 
Due to the high cost of isolating Treg, their small cell number and ethical 
restriction on the amount of blood that could be taken from healthy donors, it 
became essential to develop a cost effective expansion protocol for these cells. 
This would allow the generation of enough Treg for use in experimentation. The 
expansion protocol is made up of two distinct components. The first is T cell 
stimulation.  
&ODVVLF 7 FHOO H[SDQVLRQ ZRUN VXJJHVWV WKH XVH RI Į&'Į&' VWLPXODWLRQ
either in the form of soluble antibodies or coated expander beads (9,21,68,75). 
This approach, although validated, was not cost effective.  An alternative 
stimulus was found in the fRUP RI DQ Į&' VXSHUDJRQLVW (76). This form of 
stimuli provides durable activation of T cells without the need for further TCR 
engagement. This method proved to be cost effective and thus was incorporated 
into the expansion protocol.  Work by Battaglia et al. (21) and Pahwa et al. (75) 
GHPRQVWUDWHG WKDW 5DSDP\FLQ LQ FRQMXQFWLRQ ZLWK Į&'Į&' VWLPXODWLRQ
selectively expands murine and human CD4+CD25+FOXP3+ in vitro. This is due 
to Rapamycin selectively blocking the expansion and proliferation of CD4+CD25- 
effector T cells thus sparing and promoting growth of Treg.  However, using 
Rapamycin, as suggested, continuously in culture was too expensive. 
The other component of Treg expansion is growth factor supplementation. As 
discussed previously, IL-2 is considered to be one of the key growth factors in 
Treg homeostasis. However, other cytokines can be used as well. Garden et al. 
(68) showed that several other cytokines, namely IL-4, IL-7 and IL-15 can help 
maintain Treg phenotype and function. IL-35, a cytokine reportedly secreted from 
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Treg, also aides their proliferation (77). Due to the high cost of supplementing 
Treg with these growth factors, it was decided that only IL-2 would be used.  
One constant throughout the literature on Treg expansion was the high 
concentration (1000 IU/ml) of IL-2 provided to cells. It has been suggested that 
high concentrations of IL-2 in culture assist in the breaking of Treg anergy and 
that contaminating CD4+CD25- T cells can be peripherally converted to become 
CD25+ (78). The ability to obtain Aldesleukin (recombinant IL-2 used in Renal 
Cell Carcinoma) cheaply meant that supplementing Treg with high 
concentrations of IL-2 was not an issue.  
&RPSDUDWLYH DQDO\VLV RI Į&'Į&' YHUVXV Į&' VXSHUDJRQLVW DV WKH
stimulus in Treg expansion  showed that anti-CD28 superagonism provided a 
significantly faster rDWHRIFHOOJURZWKRYHUGD\VRIFXOWXUH Į&'Į&'YV
Į&'6$J ± 3.3 x 106 vs. 4.6 x 106, n = 3) (Figure 3.9). Figure 3.10 indicates 
WKDW QRW RQO\GLGH[SDQVLRQ ZLWKĮ&'6$JSURYLGHPRUH FHOOV EXW WKDW LW DOVR
produced a population of Treg that was of a significantly higher purity (Figure 
3.10; % CD4+CD25+FOXP3+; Į&'6DJ YV Į&'Į&' 88.5 vs. 82.9 % - 
starting population = 78.04 %, n = 3) and as such was adopted as the stimuli of 
choice in the expansion protocol.  The increase in purity could be due to 
expansion of Treg clones and an increase in CD25+ due to high levels of IL-2. 
However, it must be noted that FOXP3 can be seen on activated T cells and so it 
is a possibility that the increased purity could be due to a greater proportion of T 
cells being activated. 
The reproducibility of Treg expansion with anti-CD28SAg was seen with six 
different donors (Figure 3.11).  Starting populations were 3 x105 (n = 6) which 
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were expanded over 70 days. The rate of expansion appeared to be 
reproducible. This suggests that the protocol was sufficient for the needs of the 
project.      
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Figure 3.9 - Comparison of Treg Expansion Methodologies.   Treg from each donor 
(A ± Donor 4, B ± Donor 5, C ± Donor 6) were separated into three experimental groups. 
First group (red ZHUH H[SDQGHG XVLQJ  ȝJPO Į&' DQG  ȝJPO Į&' P$EV
Second group (blue ZHUH H[SDQGHG XVLQJ  ȝJPO Į&' VXSHU DJRQLVW ,/-2 
concentration remained constant at 1000 IU/ml. Third group (green) acted as the non-
expanded control. Data represents three donors with Treg expanded over 42 days. 
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Figure 3.10 - Comparison of Expanded Treg Purity after Six Weeks.  The expression of CD4, CD25 and FOXP3 were assessed using flow 
cytometry. Treg expanded by anti-CD28 superagonist produced a cell purity of 88.5 % (80.6 ± 97.0 %; n = 3) compared to anti-CD3/anti-CD28 
expanded purity of 82.9 % (82.7 - 83.1 %).  
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Figure 3.11 - Treg Expansion Curve.  7UHJZHUHH[SDQGHGXVLQJȝJPODQWL-CD28 superagonist and 1000 IU/ml IL-2 for 70 days.  
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Expanded Treg demonstrated suppressive behavior, similar to that of natural 
naïve Treg (see Figure 3.12b). Combined with phenotypic analysis of the 
expanded cells (Figure 3.12a) there is sufficient evidence to suggest that these 
FHOOV PDLQWDLQ µ7UHJ-OLNH¶ SURSHUWLHV LH &'+CD25+FOXP3+ and can suppress 
effector cell proliferation). On further analysis of the suppression data in Figure 
3.12b, there is a case for suggesting that the expanded Treg were more 
suppressive than those isolated from whole blood. Suppression with expanded 
Treg was significant at fractions as low as 1/40 (Figure 3.12; Effector vs. 
Expanded Treg vs. Isolated Treg, cpm; 1960 vs. 930 vs. 2132, n = 3, p < 0.05).  
These assays provided a similar cytokine profile to those seen with other PHA-
stimulated proliferation assays (Figure 3.4) and thus do not follow the 
conventional evidence of Treg-mediated suppression. However, as explained 
previously this is could be due to the mechanism by which PHA activates Treg.  
Figure 3.10 highlighted the efficiency of the expansion protocol by showing that 
Treg phenotype is maintained after six weeks. However, Treg could not be 
expanded continuously as seen in Figure 3.13. After prolonged stimulation, Treg 
began to lose their classical phenotype with a decrease in CD25, FOXP3 and 
CCR4. Although still viable, these cells exhibited a loss in suppressive function 
after 56 days which meant that Treg were only expanded for a maximum of 42 
days to avoid loss of function and phenotype.  This loss could be attributed to the 
accumulation of pro-apoptotic factors within the culture environment over time 
during expansion (79). 
The loss of Treg suppressive function combined with a simultaneous loss of 
CD25 and FOXP3 expression is an interesting observation. Although there are 
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documented instances of T cell suppression via cells which are CD25- and 
FOXP3-, the loss of suppressive function suggests that they are important in the 
maintenance of Treg (15). Furthermore, pre-clinical and clinical data of CD25 
antagonism does suggest a potential amelioration Treg number and function 
(80,81). The loss of FOXP3 in man is less well defined and as discussed earlier 
in this chapter does not lend itself to be being an entirely accurate marker for 
phenotyping Treg. 
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Figure 3.12 - Comparison of the Suppressive Function of Isolated and Expanded 
Treg. A - Flow cytometry analysis of CD4, CD25 and FOXP3 expression. One 
representative experiment of three is presented. B - T cell proliferation assay. Figure 
representative of the means of three independent experiments from the same donor. 
Error bars represent standard deviations. n = 3; *=p<0.05. Statistical significance 
determined by a one-way ANOVA analysis with column comparisons using Tukey's 
Multiple Comparison Test. 
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Figure 3.13 - Assessment of Treg Phenotype over Expansion Period. A - Flow 
cytometry analysis of Treg undergoing expansion over 56 days. One representative 
experiment of three is presented. Plots represent analysis at weeks 0, 2, 4, 6 and 8. B - T 
cell proliferation assay. Figure representative of the mean of three independent 
experiments from the same donor. Error bars represent standard deviations. Statistical 
significance determined by a one-way ANOVA analysis with column comparisons using 
Tukey's Multiple Comparison Test. n = 3; *=p<0.05 
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3.4 Conclusions 
The studies conducted above were used to develop a suitable method by which 
to characterise Treg both functionally and phenotypically. Although there is still 
much debate surrounding a truly reliable human Treg phenotype it was decided 
that CD4+CD25+FOXP3+ cells were to be used in all experiments on the basis 
that these were commonly used markers within the literature. Due to the high 
running costs of the project, Treg were isolated via Dynal magnetic beads. This 
was compared to MACS but this was found to be too expensive to use on a 
regular basis.  Critical to the success of the project was the expansion of these 
cells to larger populations than those obtained on isolation from whole blood. 
After comparing the cost/purity benefits of different stimuli used in expansion it 
ZDV GHFLGHG WKDW DQ Į&' VXSHUDJRQLVW ZRXOG EH XVHG DORQJVLGH KLJK
concentrations of IL-2. This allowed breakage of the anergic phenotype of Treg 
and thus provided suitably pure and large populations of cells with which 
downstream experiments could be conducted.  The expansion of Treg is limited 
to 42 days as continued stimulation led to a down-regulation of key Treg markers 
as well as a loss of suppressive activity.  
Treg demonstrated dose dependent suppression of both CD4+CD25- and CD8+ T 
cells. This provides the basis for a functional tool with which to alter the 
suppressive effects of Treg pharmacologically. Interestingly, the cytokine milieu 
generated by Treg suppression can be substantially altered, depending on the 
stimuli added. Mitogenic stimulation leads to the production of IFN-ȖDQG ,/-10 
IURP7UHJZKHUHDV7&5HQJDJHPHQWZLWKĮ&'Į&'GRHVQRW7KLVFRXOGEH
attributed to the altered proliferative pathways that exist within Treg. It also 
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indicates that induction of certain molecular pathways, in particular the NF-ț%
pathway may be of interest in altering Treg function.  
After the establishment of Treg suppression, it became apparent that the less 
Treg present within the environment, the greater the proliferation of the effector 
population. This observation, together with those found in literature suggests that 
strategies to either manipulate Treg function or decrease the number of Treg 
within the tumour microenvironment will be of clinical benefit (82).   The following 
chapters of this thesis will seek to alter the suppressive and migratory capacity of 
Treg as well as enhance the generation of a tumour antigen-specific immune 
response. 
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Chapter 4 
The CCR4-CCL17/CCL22 axis and its 
role in Tumour Immunology 
4.1 Introduction 
It is generally agreed that Treg are involved in generating an 
immunosuppressive milieu within the tumour microenvironment.  As such, 
blocking the mechanism of tumour recruitment of Treg through 
chemokine/chemokine receptor interactions could prove to be of clinical 
importance.  This chapter aims to investigate this. 
 
Chemokines are a group of cytokines with chemotactic properties that have been 
recognised in regulating leukocyte trafficking and positioning in both homeostatic 
and inflammatory conditions.  Currently, more than 40 chemokines have been 
identified. These are classified according to the configuration of cysteine residues 
near the N-WHUPLQXVLQWR&&í&;&í&íDQG&;&FKHPRNLQHV7KH\FDQDOVR
EH FODVVLILHG LQWR µLQIODPPDWRU\LQGXFLEOH¶ DQG µKRPHRVWDWLFO\PSKRLG¶
chemokines based on the site of production and the eliciting stimuli. 
 
A number of studies have examined Treg chemotaxis and receptor expression 
SURILOHV )LJXUH  0XOWLSOH D[LV¶ RI WKLV FKHPRNLQH QHWZRUN UHJXODWH 7UHJ
migration during both normal tissue homeostasis and pathological conditions and 
there is strong evidence for Treg migration into sites of inflammation (1). Solid-
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tumour microenvironments have an altered expression profile of an extensive 
network of chemokine and chemokine receptors (2). Tumour associated 
chemokines are thought to facilitate multiple roles in the biology of primary and 
metastatic disease including; survival and metastatic seeding of tumours, the 
regulation of intra-tumoural trafficking by different immune cell sub-populations - 
which in turn influences the outcome of the immunological response to TAA 
exposure and facilitates the development of an immune suppressive 
microenvironment. This immune suppressive chemokine milieu favours 
angiogenesis (3) and acts as a source of autocrine/paracrine tumour-survival and 
proliferative factors (4,5). 
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Figure 4.1 ± Treg and Chemotaxis. Some of the key markers present on Treg include CD4, CD25, FOXP3, cytotoxic T lymphocyte antigen-4 
(CTLA-4) and glucocorticoid induced tumour necrosis factor receptor (GITR).  Distinct chemokine receptors are implicated in Treg organ/tissue 
migration. Bone marrow±derived CXCL12 mediates Tregs into bone marrow.  CCL22 supports Treg migration into human ovarian cancer and 
mouse cardiac grafts. CCR7 may facilitate lymphoid movement of Treg cells. Certain CC chemokines may mediate Treg migration into 
inflammatory tissues/organs. 
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4.1.1 Direct and Indirect Roles of Chemokines on Tumours 
Recent work has shown a much broader involvement of chemokine function in 
tumour biology. One of the first recognised mechanisms of chemokine function 
different from cell chemotaxis, was their effect on angiogenesis. Chemokines 
have important implications in the regulation of the angiogenic switch in tumours, 
either directly (through receptors expressed on endothelial cells) or indirectly, by 
recruiting leukocytes that provide angiogenic factors (6). Endothelial cells 
express CXCR4 and its triggering by CXCL12 induces endothelial cell migration 
and proliferation; moreover CXCR4 acts synergistically with VEGF to enhance 
neo-angiogenesis in human ovarian cancers (7). CXCL12 also promotes tumour 
angiogenesis by the local recruitment of circulating or bone marrow-derived 
endothelial precursors (8). Both CXCR4 and CXCL12 are targets of the hypoxia 
transcription factor HIF-Į 'XULQJ WXPRXU-induced hypoxia both molecules are 
up-regulated in tumour cells, TAM and vessels. These all participate in the 
building of a vascular network that is essential for tumour progression (9,10). 
In the complexity of the chemokine system, other ligands are characterised as 
inhibitory mediators of angiogenesis. The CXC chemokines (CXCL9, CXCL10 
and CXCL11) inhibit endothelial cell proliferation (11) and suppress tumour 
angiogenesis in several different tumour types (12-14). Therefore, the balance of 
angiogenic vs. angiostatic chemokines produced in the tumour microenvironment 
may determine the rate of angiogenesis within a tumour tissue and thus the 
consequent clinical outcome. 
 
Inflammatory chemokines are also potent activators of matrix-metalloproteases 
(MMPs), enzymes that digest the extracellular matrix. TAMs in the tumour stroma 
132 
 
produce MMPs and other proteolytic enzymes that affect matrix degradation. The 
constant remodelling of the stroma; which is a characteristic of solid tumours has 
two major effects. Firstly, the release of active growth factors and the promotion 
of tumour cell invasion. Chemokines have been shown to induce gene 
expression and functional activation of various MMPs, in particular MMP-9 (15).  
 
4.1.2 Tumour Cell Survival and Proliferation  
Since the discovery that tumour cells express chemokine receptors and may 
functionally respond to ligands, there has been an increased effort to identify the 
direct effect of chemokines on neoplastic cells. Earlier studies highlighted that 
some tumour cell lines were able to migrate in response to CXCL8, and that 
antibodies against CXCR2 inhibited melanoma cell growth in vitro (16). In the last 
decade several studies have provided evidence that tumour cells express a wide 
panel of chemokine receptor (17,18). In general, receptor engagement enhances 
cancer cell resistance to apoptotic stimuli and proliferation through the activation 
of the MAP/Erk and PI3K pathways (17,19). 
 
Most tumours express CXCR4 at levels higher than the normal corresponding 
tissues (17,20); other investigated receptors are for instance: CCR6 and 
CX3CR1 in colorectal and pancreatic cancer (21,22), CXCR6 in prostate cancer 
(23), CXCR2 in melanoma (24), and oesophageal cancer cells (23), CCR7 in 
squamous cell carcinoma of the head and neck (25) and CCR10 in melanoma 
(26). In ovarian cancer cells, the small CXCR4 antagonist CTCE-9908 caused 
cell death via a mechanism that was not apoptotic but involved damage of DNA 
checkpoint proteins and cell cycle arrest (27). 
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4.1.3 Tumour Cell Invasion and Migration to Distant Organs 
There is now ample evidence that chemokines can serve as cues for the 
secondary localisation of tumour cells. The most frequently over-expressed 
chemokine receptor on tumour cells is CXCR4. In general, CXCR4 is associated 
with tumour progression and metastasis (28,29). In a seminal paper, Muller et al. 
(30) demonstrated the expression of CXCR4 and its involvement in metastasis in 
a model of breast cancer. Leukaemic cells expressing CXCR4 migrate to bone 
marrow and localise at sites where stromal cells secrete CXCL12 (19). In 
glioblastoma, several CXC receptors have been reported, with CXCR4 being the 
most frequently described with an associated increase in the aggressiveness of 
the disease as well as poor patient survival  (31-33). 
 
CXCR4 is the principal chemokine receptor identified on cancer stem cells 
(CSC). CXCR4+ CSC have been isolated from glioblastoma (31) and pancreatic 
tumours (34). In the latter case, a distinct subpopulation of CD133+/CXCR4+ CSC 
was identified at the invasive front of the tumour and determined the metastatic 
phenotype of individual tumours (34). Other CXC-receptors have been implicated 
in the malignant dissemination to distant organs. For instance, CXCR1, CXCR2 
and CXCR3 in malignant melanoma (35,36); CXCR3 in B-cell chronic 
lymphocytic leukaemia cells (37); CXCR5 in liver metastasis of colorectal 
carcinoma (38). The CX3CR1 receptor is implicated in the perineural invasion 
frequently occurring in pancreatic adenocarcinoma (22) and in metastasis to 
bone of prostatic tumours (39). 
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Secondary lymphoid organs are a primary site of metastasis; in several tumours 
(e.g. breast, melanoma, gastric, non-small cell lung cancer, head and neck 
tumours, colorectal carcinoma), CCR7 is upregulated and mediates tumour cell 
dissemination to lymph nodes (40-45). In a recent study, brain infiltration by T cell 
leukaemic blasts was mediated by CCR7 (46). Members of the CCR family are 
also used by tumour cells to spread to specific tissues such as the skin, the gut 
and the liver. CCR6 plays a role in organ selective liver metastasis of colorectal 
cancer (47,48). The skin-homing receptors CCR4 and CCR10 were found 
expressed together with CCR3 in cutaneous lymphoma (49-51). CCR9 was 
associated with intestinal melanoma metastasis (52), and CCR10 with spread to 
LN (53). CCR5 is expressed by Hodgkin lymphoma (54), in prostate cancer (55) 
[115] and by mammary tumours (56).  
 
Overall, the above studies have indicated a strong involvement of the chemokine 
system in metastasis dissemination. This was more precisely demonstrated in 
vivo with mouse tumour models where receptor-transduced tumour cells 
metastasised more than parental cells (57,58).  
 
Another important aspect in the generation of a chemical gradient is the 
chemokine production by non-tumoural adjacent cells (e.g. endothelial cells and 
fibroblasts, as well as macrophages). Cancer-associated fibroblasts (CAF) have 
been extensively studied in more recent years and found to be a source of CCL2, 
CCL5 and CXC-FKHPRNLQHV LQGHHG WKHUH LV µFURVVWDON¶ EHWZHHQ WXPRXU FHOOV
and CAF (59,60). A positive correlation has been reported between stromal 
expression of CXCL12 and a high tumour proliferative index (61) and, in another 
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study, with proOLIHUDWLRQRI&'&'íEUHDVWFDQFHUVWHPFHOOV(62). A notable 
example was provided in breast cancer, where tumour cells induced CCL5 
secretion in newly recruited mesenchymal cells; stromal-derived CCL5 then 
interacted with CCR5-positive tumour cells enhancing their growth in vivo and 
metastatic ability (56). 
 
4.1.4 Treg Migration 
Treg cells express a number of chemokine receptors such as CCR2, CCR4, 
CCR5, CCR7, CCR8 and CXCR4 and are able to migrate in response to a 
variety of chemokines such as CCL2, CCL5, CXCL12, CCL17 and CCL22 (63). 
CCL2 is produced by many stromal cells including T cells and monocyte-derived 
cells and also by tumour cells. It is a chemoattractant principally for macrophages 
(64), but also for activated CD8+ and CD4+ T cells (65), and NK cells (66) thereby 
influencing the tumour microenvironment at many levels. CCL2 has also been 
implicated in driving the metastatic seeding of prostate cancer and non-small cell 
lung cancer cells to bone (67-69). In addition to the primary role of the 
CCR2/CCL2 axis in directing monocyte populations it has also been implicated in 
the migration of Treg into human gliomas (70) and prostate cancers (71). 
Interestingly, high expression of CCL2 has been described in patients with breast 
cancer (72) and malignant myeloma (73) and correlates with poor prognosis in 
melanoma (74). Although this data does not directly implicate Treg 
infiltration/activity, further studies are required to delineate the cellular 
consequences of the CCR2/CCL2 signalling axis in cancer.  
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In pancreatic cancer patients, intratumoural Treg cells expressed high-levels of 
CCR5 and respond to CCL5 produced by pancreatic cancer cells (66). 
Interestingly, disruption of CCR5-dependent homing of Treg cells by abolishing 
CCL5 expression in pancreatic tumour cells or antagonism of CCR5 on 
intratumoural Treg cells by CCR5 antagonists inhibits tumour growth in a murine 
model of pancreatic cancer (66). 
In addition to the well documented role of the CXCL12±CXCR4 axis in the 
seeding of tumour cells to metastatic sites (75,76), Treg also express CXCR4 
and can transmigrate along a CXCL12 gradient (77). In a syngeneic murine 
glioma model Grauer et al.(78) were able to show a systematic increase in 
CXCR4+ Treg as the tumour developed.  In a trial of 31 cisplatin resistant ovarian 
cancer patients undergoing IL-2 therapy, CXCR4 expression was found to be 
elevated on Treg with concurrent expression of CXCL12 within tumours (79). 
These data suggest that Treg may be involved in compensatory adaptation of the 
tumour micro-environment during IL-2 therapy thereby limiting effector T cell 
reactivity. This may in part explain the poor response rates of IL-2 therapy in this 
patient population.   
 
As discussed previously it is clear that a Treg response is an integral part of an 
inflammatory process. Human intestinal epithelial cells express CCL22 following 
exposure to TNF-Į DQG ,)1-Ȗ (80). This proclivity has also been observed in 
ovarian cancer cells (81) suggesting that tumours may actively recruit Treg 
during an acute inflammatory response. In a mouse model of ovarian cancer, 
tumour and tumour associated macrophage (TAM) production of CCL22 were 
found to be responsible for selective recruitment of Treg expressing CCR4 (81). 
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Clinical evidence of tumour-associated CCL22 production has been described in 
lung cancer (82,83), Epstein-Barr virus-positive B-cell lymphoproliferative 
disorder (84), oesophageal squamous cell carcinoma (85) and  breast cancer 
(86). In addition, another CCR4 ligand, CCL17 is also implicated in the migration 
of Treg (87,88). In vitro evidence suggests that CCL22 is the dominant 
chemokine in terms of governing Treg migration (89). In a clinical study involving 
163 treatment naïve Hodgkin lymphoma patients 82 % and 57 % demonstrated 
expression of CCL22 and CCL17, respectively, which was associated with 
disease severity (63). Pleural effusions taken from patients with lung cancer 
showed elevated levels of CCL22 and reduced levels of CCL17 compared to 
matched samples taken from serum. To determine the effect of the chemokine 
profile on Treg migration the effusion samples were treated in vitro, with 
neutralising anti-CCL22 or -CCL17 antibodies. Treg migration was partially 
abrogated by anti-CCL22 but not by anti-CCL17 (83). 
In addition to its affinity for CCR4, CCL17 also binds CCR8 (90) which is 
expressed on both human Treg (89) and macrophages (91).  A landmark study 
by Curiel et al. (92) in 2004 detailed the existence of CD4+CD25+FOXP3+ Treg 
cells in 104 individuals affected with ovarian carcinoma. Not only did they 
demonstrate that Treg were associated with a high death hazard and reduced 
survival but that these cells preferentially migrated to and accumulate in tumours 
and ascites, but rarely entered draining lymph nodes in later stages of disease. 
On investigation of the tumour microenvironment they found that CCL22 was 
produced by both tumour cells and tumour-associated macrophages (92).  
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Essentially, tumours could be said to use migratory chemokines as a defence 
mechanism.  Berin et al,(80) looked at inducing the production of CCL22 from 
human intestinal epithelial cells by exposing them to pro-inflammatory 
chemokines such as TNF-ĮDQG ,)1-Ȗ (80).  Their results showed a significant 
increase in CCL22 production upon stimulation.  This was also demonstrated in 
vitro in ovarian cancer cells which suggests that immune assault upon tumours 
may be short-lived as the tumour produce chemokines that actively recruit Treg.  
Tumour-associated macrophages and DC have also been implicated in the 
production of CCL22.  This collective induction of chemotactic pathways leads to 
increased migration of Treg.  Although the CCL22-CCR4 axis is not exclusive to 
Treg, tKLV µVHOHFWLYH¶ UHFUXLWPHQW PLJKW UHSUHVHQW DQRWKHU PHFKDQLVP E\ ZKLFK
tumours may induce immune privilege by affecting the balance between Treg 
and effector T cells.  
 
4.1.5 Chemokine Network Targeting  
Manipulation of the chemokine network to modulate pathological inflammatory 
conditions is an area of active interest both pre-clinically and clinically.   
As described previously the role of CCL2 in the tumour microenvironment is 
diverse and is chiefly implicated in monocyte trafficking. CCR2, the receptor for 
CCL2, is also expressed on Treg (93). Blocking antibodies to CCL2, in 
combination with an anti-CCL12 antibody and either HPV-E7 or Listeria 
mesothelin vaccines were administered in three murine non-small cell lung 
cancer models (TC1, LKR and AE17). In these models a combination of both 
vaccine and anti-CCL2/CCL12 resulted in decreased tumour burden, increased 
intratumoural CD8+ T cell numbers and decreased intratumoural and splenic 
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Treg numbers. However, no change in TAM or splenic MDSC was observed, 
suggesting that the effects on tumour burden were dependent on Treg-tumour 
trafficking and prevention of Treg-mediated immune suppression (94). Several 
CCR2 inhibitors have been trialled in non-cancer indications including MK0812 
(Merck) and INCB-8696 (Pfizer/Incyte) in rheumatoid arthritis and multiple 
sclerosis, BMS-741672 (Bristol Myers Squibb) and CCX140 (Chemocentrix) in 
Type II diabetes and vascular restenosis (95). A neutralising antibody for CCL2, 
ABN912 has also been trialled in rheumatoid arthritis (96). Selective inhibitors of 
the CCL2/CCR2 axis may have clinical utility in the immunotherapy of cancer. 
The CXCR4 antagonist Plerixafor (AMD-3100; Genzyme Corp.) has recently 
been licensed in the United States for use in stem cell transplantation and is 
currently in a phase III trial for malignant myeloma (97). Azab et al. (98) have 
shown that the compound enhanced the sensitivity of myeloma cells to multiple 
therapeutic agents in vitro by disrupting their adhesion to bone marrow stromal 
cells. Although effects on Treg migration were not assessed in this study, 
preclinical data demonstrate that Treg express CXCR4 and are able to migrate 
along a CXCL12 gradient (7).  It is possible that ongoing clinical trials will provide 
clinical evidence that inhibition of the CXCR4/CXCL12 axis affects Treg 
migration. 
 
Bayry et al.(99) have designed a series of CCR4 antagonists which show 
specificity and restrict Treg migration for use as vaccine adjuvants which could 
have applications in an oncology setting. Additionally, Andrews et al. (100) have 
also designed a series of antagonists for both CCR4 and CCR5 for use in 
asthma.  siRNA targeting of CCL17 and CCL22 expression in DCs has been 
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used to reduce Treg and increase CD8+ tumour infiltration in xenograft models of 
human breast cancer (101). Preclinical data using the 4T1 metastatic breast 
cancer model, demonstrated that selective targeting of CCR4 expressing Treg 
with a CCL17-Pseudomonas exotoxin (PE38) fusion protein significantly 
enhanced NK cell activity preventing lung metastasis (102,103). KW-0761 
(Kyowa Hakko Kirin), a humanised defucosylated antibody to CCR4 is currently 
in a phase II trial in CCR4 positive cutaneous T cell lymphoma and acute T-cell 
lymphoblastic leukaemia (104). Preclinical data suggests that efficacy is linked to 
NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) (105). 
Clinical evaluation of the potential of KW-0761 to selectively target CCR4-
expressing Treg in solid tumours is clearly warranted as a selective method for 
Treg depletion.  
 
The lead CCR4 antagonist designed by Andrews et al. was kindly donated by 
AstraZeneca for use in this project. The primary aim was to use this compound 
as a means to abrogate CCR4-mediated Treg migration. In conjunction with this, 
it is important to consider the potential for CCR4-mediated ovarian cancer cell 
migration. If this is observed then the rationale for using a CCR4 antagonist as 
part of an immunotherapeutic regimen would gain further credence.  It is also 
critical to assess the effect of the drug on Treg suppressive activity. This is to 
ensure that CCR4 antagonism does not impinge on peripheral Treg function.  
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4.1.6 Experimental Objectives described in Chapter 4 
x Development of a robust chemotaxis assay 
x Demonstration of CCR4 expression on Treg, CD4+CD25- T cells, CD8+ T 
cells and ovarian cell lines. 
x Confirmation of CCL17 and CCL22 production from ovarian cancer cells 
due to pro-inflammatory stimuli. 
x Use a specific CCR4 antagonist to abrogate the chemotactic effect of 
CCL17 and CCL22 on Treg and ovarian cancer cells. 
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4.2 Methodology 
4.2.1 Isolation of Regulatory T cells via Magnetic Selection (Dynal) 
A maximum volume of 100 ml of peripheral blood was obtained from healthy 
donors in accordance with local ethical committee approval (EC# BT/04/2005).  
Peripheral blood mononuclear cells (PBMC) were separated via a density-
gradient centrifugation over Histopaque-1077 (Sigma) twice as previous, firstly to 
isolate PBMCs with the second density gradient used for the removal of platelets.  
The resultant cells were then washed and resuspended at 5 x 107 cells per 500 
µl isolation buffer containing phosphate buffered saline (PBS) + 1 % w/v bovine 
serum albumin (BSA) (Sigma) + 1 mM EDTA (Sigma) before viability counting via 
Trypan Blue exclusion (Fluka). 200 µl of CD4 Human Antibody Mix (Invitrogen) 
and 100 % v/v foetal calf serum (Sigma) (FCS) were incubated with PBMC for 20 
minutes.  This was followed by the addition of 1 ml Depletion MyOne Dynabeads 
(Invitrogen) before magnetic removal of bead-bound non-CD4+ cells, leaving 
CD4+ cells in solution.   
CD4+CD25+ T cells were isolated by positive selection using 200 µl CD25 
Dynabeads per 1.5 x 107 cells.  The CD4+CD25+ Treg population was liberated 
from the CD25 Dynabeads using Detach-a-bead solution (Invitrogen) and were 
then used in downstream applications.  The remaining CD4+CD25- effector T 
cells (Teff) were either used in T cell suppression assays or placed in RPMI-1640 
(Sigma) + 10 % v/v FCS (Sigma) + 5 mM L-*OXWDPLQH6LJPD,8ȝJPO
Pencillin/Streptomycin (Sigma) and 10 % v/v DMSO (Sigma) before undergoing 
controlled freezing at ± Û&with prolonged storage in liquid nitrogen.  
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A small volume of cells (10 µl) was taken at each isolation step for analysis via 
flow cytometry. 
4.2.2 Expansion of CD4+CD25+ T cells 
Isolated CD4+CD25+ T cells were divided into three experimental groups and 
placed into culture using X-Vivo-15 + 5% Human AB Serum (Lonza). The final 
cell concentration was maintained at 1 x 106 cells/ml. The first experimental group 
was supplemented with 1000 IU/ml recombinant IL-2 (Novartis) and stimulated 
with 10 µl/PO Į&' VXSHUDJRQLVW $QFHOO  The second group was 
supplemented with 1000 IU/ml recombinant IL-2 and stimulated with bound 1 
µg/ml Į&'DQGVROXEOH1 µg/ml Į&'DQWLERGLHV%LROHJHQG7KHWKLUGgroup 
was as a negative control with no media supplementation or stimulation. 
After days 3, 10 and 17, those cells being expanded were supplemented with 
500 IU/ml recombinant IL-2.  At days 7, 14 and 21, cells were collated and 
counted via Trypan Blue (Fluka).  A sample was taken for analysis via flow 
cytometry.  The cells were then re-suspended in culture media and re-stimulated 
as described previously.   
4.2.3 Suppression Assays 
T cell proliferation assays were set-up in triplicates in 96-well, round-bottomed 
plates with stimulated and non-stimulated divisions for comparison where 
possible.  Briefly, CD4+CD25- T cells were either resuscitated from frozen stocks 
or freshly isolated from whole blood. These were plated out at 5 x 104 cells/well in 
X-vivo-15 + 5 % v/v Human AB serum.  Treg were then added to each well to 
provide Teff:Treg ratios of 1:5, 1:10, 1:20, 1:40  to bring volume per well to 100 
µl.  Cells were stimulated with 10 µg/ml of PHA (Sigma).  The final volume was 
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adjusted to 200 µl using X-vivo-15 + 5 % v/v Human AB serum. After 72 hours, 
100 µl of cell supernatant was taken and stored at ± Û& WKHSODWHZDVWKHQ
pulsed with 1 µCi of [3H]-labelled thymidine per well (TRA120, Amersham).  The 
plate was left to incubate for a further 18 hours before being harvested onto a 
microscintillation plate (Perkin-Elmer).  After repeated washes with de-ionised 
water, the plate was allowed to dry for an hour.  20 µl of scintillation fluid 
(Microsint 0, Perkin-Elmer) was added per well before the plate was covered with 
optical tape (Perkin Elmer).  Thymidine incorporation was quantified using a 
Packard TopCount NXT Microplate Scintillation counter. 
4.2.4 MTT Cell Proliferation Assay 
To quantitatively assess the number of cells, 5 mg/mL MTT solution were added 
to each well. The plates were incubated for 4 hours at 37 °C and formazan 
crystals were dissolved by the addition of 100 % v/v DMSO. Absorbance was 
measured at 570 nm. The amount of cells migrated was deduced from a 
standard curve of known cell number. 
4.2.5 CFSE Cell Staining 
To quantitatively assess the chemotaxis of cells, CFSE was used (Sigma).  
Briefly, cells were resuspended in PBS at a concentration of 2 x 107 cells/ml.  An 
equal volume of PBS containing CFSE was added to the cells to provide a final 
CFSE concentration of 2.5 µM.  Cells were washed repeatedly in phenol red-free 
X-Vivo-15 (Lonza) to remove excess stain. 
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4.2.6 T cell Chemotaxis Assay 
Recombinant human CCL22 was made up to various concentrations (0.0 ± 100 
ng/ml) using phenol-red free X-vivo-15.  50 µl of these chemokine solutions were 
plated in triplicate into 96-ZHOO &KHPR7;PLFURSODWHV  Pm pore size, 6 mm 
diameter well; Neuroprobe Inc).  The chamber was sealed with 7.5 x 104 cells 
being placed in the upper chamber in a final volume of 50 µl.  After two hours of 
incubation, the microplate was taken from the chamber.  The suspension from 
the upper chamber was removed before the plate was incubated at room 
temperature with a 5 mM solution of EDTA (Fluka) for 30 minutes to detach cells 
from the filter. The chamber was washed with PBS before the contents of the 
lower chamber were transferred to a black fluorescence plate. Visual checks 
were made on both the filter and the lower chamber to ensure no residual cells.  
The plate was read using a Dynex MFX micropate fluorimeter (excitation 490 nm, 
emission detection 520 nm). The number of migrated cells was calculated from a 
standard curve of labeled cells and compared against a non-chemokine control. 
4.2.7 Flow Cytometry Analysis 
Cells were stained with cell surface markers CD4-ECD (1.25 µl) (clone 
SFCI12T4D11 - Beckman Coulter), CD25-PE (7.5 µl) (Clone BC96 - BioLegend), 
CCR4-PerCP/Cy5.5 (2.5 µl) (Clone TG6 - BioLegend).  Cells were incubated with 
flourochrome-conjugated antibodies for 15 minutes before fixation with 3 % v/v 
formaldehyde (Sigma).  Cells were then permabilised using FOXP3 Perm Buffer 
(BioLegend) before incubation with FOXP3-AlexaFluor488 (Clone 259D ± 
BioLegend) for 30 min.  Cells were then resuspended in FACS wash buffer 
(BioLegend) and read via a Beckman Coulter FC 500 flow cytometer. Analysis 
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involved gating on lymphocyte populations from forward/side-scatter plots before 
selecting regions of interest. 
4.2.8 Induction of CCL22 in A2780 
Cell lines A2780 (EACC) and IGROV-1 (Marco Negri Institute, Milan) were grown 
to confluence in six well plates using phenol red free RPMI-1640 (Sigma) + 10 % 
v/v  FCS, L-Glutamine and 100 IU/ml Penicillin/Streptomycin at 1.5 ml per well.  
Recombinant tumour necrosis factor-alpha (Peprotech) and interferon-gamma 
(Peprotech) were added at various concentrations (5 ng/ml, 10 ng/ml, 20 ng/ml) 
both separately and concurrently.  The cells were then incubated for twenty four 
hours after which, the supernatant was taken off and stored at ± Û&7KHFHlls 
were then prepared for mRNA isolation.  
4.2.9 mRNA isolation 
mRNA was isolated using the Qiagen RNeasy Spin Kit.  Briefly, cells were 
disrupted by adding 600 µl Buffer RLT (Qiagen) to wells.  This was then placed 
into 15 ml centrifuge tubes.  The lysate was homogenised for thirty seconds 
before being mixed with an equal volume of 70 % v/v ethanol. 700 µl of sample 
was transferred to an RNeasy spin column (Qiagen) placed in a 2 ml collection 
tube. The tube was spun for fifteen seconds at full speed after which the flow-
through was discarded.  700 µl of Buffer RW1 (Qiagen) was added to the column 
which was then centrifuged at full speed for fifteen seconds. The flow-through 
was again discarded.  500 µl of Buffer RPE (Qiagen) was then added to the 
column which was centrifuged twice at full speed, once for fifteen seconds and 
then for two minutes.  The RNA was eluted by adding 30 µl RNase-free water 
(Ambion) on the spin column membrane and centrifuging for one minute at full 
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speed.  RNA clean-up was carried out using the Turbo DNA-free kit (Ambion). 3 
µl of 10x Turbo DNA (Ambion) and 1 µl Turbo DNAse (Ambion) were added to 
the RNA mixture and incubated for thirty minutes at 37 °C.  DNase Inactivation 
Reagent (Ambion) was added, with the entire mixture left for two minutes before 
centrifugation at full speed for two minutes.  The resultant supernatant containing 
the RNA was removed and placed in a fresh tube.  Optical density of RNA was 
measured using the Gene Meter UV spectrophotometer (AB).  Ratios of 
absorbance at 260 and 280 nm were taken as an indicator of purity (Ratio 
approximately 2). 
 
4.2.10 cDNA preparation 
1 µg of RNA made to a volume of 10 µl using RNase-free water.  To this, 1 µl 
random hex primers (Roche) was added.  The mixture was heated at 70 °C for 
ten minutes.  During this time, a buffer mix was made using 4 ȝOî)LUVWVWUDQG
buffer (Invitrogen), 2 µl 0.1 M DTT (Invitrogen), 1 µl 10 mM dNTPs (Invitrogen) 
and 1 µl RNAse out (Invitrogen). The buffer mix was added to the RNA mixture 
and incubated at 25 ºC for 10 min.  1 µl of Superscript II (Invitrogen) was added 
to this and incubated at 42 °C for 50 minutes followed by incubation at 70 °C for 
15 min.  Following a quick spin, the resultant cDNA was made up to 100 µl, using 
RNase-free water, to provide a final cDNA concentration of (10 µg/ml). 
4.2.11 qRT-PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) was run on a 
TaqMan System. Inventoried TaqMan probe for CCL22 was purchased from 
Applied Biosystems.  cDNA (5 µl) was incubated with 12.5 µl of TaqMan 
MasterMix (Applied Biosystems) containing the fluorescent dye 6-
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carboxyfluorescein (FAM) and 1.25 µl TaqMan probe. The reaction mixture was 
brought up to a final volume of 25 µl with RNase-free water. GAPDH was used 
as a housekeeping gene. The amplification was carried out and analysed in the 
Bio-Rad iCycler iQ real time polymerase chain reaction detection system. To rule 
out contamination from buffers and tubes, a negative control with water instead 
of the cDNA template was used.  Thermal cycler parameters included two 
minutes at 50 °C followed by ten minutes at 95 °C and 45 cycles of 95 °C for 
fifteen seconds and 60 °C for one minute.  The change in expression was 
calculated by the method of Pfaffl.  
4.2.12 Inhibition of Cell Chemotaxis 
Cells were incubated with AZ1 for 60 min in a humidified incubator at 37 °C 
before addition to the chemotaxis assay as described above. For a measurement 
of background activity, 30 µL of assay buffer in the presence of 0.1 % v/v DMSO 
was added to some of the wells. 
4.2.13 CCR4 Internalisation Assay 
Treg were incubated in fresh medium at a concentration of 1 × 106/ml in the 
presence or absence of 500 ng/ml CCL22  and incubated for 30 min at 37 °C. 
Internalisation was blocked on ice and an aliquot of cells were kept on ice for 30 
min during chemokine stimulation to inhibit receptor internalisation as a positive 
control. AZ1 treatment was conducted as described previously. CCR4 expression 
was then evaluated by staining and FACS. 
4.2.13 ELISA 
Chemokine production was measured by ELISA. The cytokines of interest were 
CCL17 and CCL22. Polystyrene 96-well plates (MaxSorp, Nunc) were coated 
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with the relevant capture antibody (2 µg/ml CCL17; Clone - #54026, 2 µg/ml 
CCL22; Clone - #57226, R&D Systems) overnight.  The plate was then blocked 
with 5 % skimmed milk powder in PBS (pH 7.2) + 0.05 % v/v Tween 
(PBS/Tween) to prevent non-specific binding. The plate was washed in 
PBS/Tween using an automated plate washer and tapped dry. The relevant 
recombinant cytokine (PeproTech) and samples were added to the plate.  After 2 
hours, the plate was washed in PBS/Tween before the appropriate biotinylated 
detection antibody (1 µg/ml CCL17, 125 ng/ml CCL22; R&D systems) was diluted 
in PBS, 1 % w/v BSA, and 0.1 % v/v Tween 20 and incubated for 2 hours at room 
WHPSHUDWXUH EHIRUH EHLQJ ZDVKHG  ȝO RI  JPO VWUHSWDYLGLQ-horseradish 
peroxidase (BD-Pharmaginen) was added each well. After 30 min incubation at 
room temperature, the plate was washed and bound horseradish peroxidase was 
visualised with 0.1 mg/ml tetramethylbenzidine (Sigma) and 2 ul of 30 % v/v 
hydrogen peroxide (Sigma) diluted in 3 M sodium acetate buffer (Sigma). The 
colour reaction was stopped with the addition of 2 M sulphuric acid (Sigma), and 
absorbance was measured at 450 nm using a MRX spectrophotometer (Dynex 
Technologies). The concentrations of samples were calculated from standard 
curves of each recombinant cytokine. ELISA detection limits were determined as 
follows (CCL17 - 100 pg/ml, CCL22 ± 100 pg/ml). 
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4.3 Results and Discussion 
4.3.1 Method Development ± MTT vs CFSE 
An important part of the chemotaxis assay was to identify an economical, reliable 
and sensitive assay for detecting cell migration. Two methods of assessing cell 
number were compared for their reliability and sensitivity.  MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced to purple 
formazan in living cells.  A solubilisation solution (isopropanol) is added to 
dissolve the insoluble purple formazan product into a coloured solution. The 
absorbance of this solution can be quantified by measuring at a certain 
wavelength (usually between 500 and 600 nm) by a spectrophotometer. 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent cell staining dye. 
CFSE was originally developed as a fluorescent dye that could be used to label 
lymphocytes and track their migration within animals.   
Literature on migration suggests that either MTT or CFSE are used when looking 
at cell migration (87,106). It was therefore decided to compare the two methods 
via a curve of known cell number.  Cells were stained and measured according to 
their protocol. Figure 4.2 shows the standard curves generated by both MTT and 
CFSE assays.  
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Figure 4.2 ± Output of Standard Cell Number Curves for CFSE and MTT Assays.  A 
standard cell number curve was set up to determine assay sensitivity (cell number = 0 ± 
100,000). A ± CFSE )OXRUHVFHQFHȜH[ QPȜHP . B ± MTT Ȝ QP. 
Both methods provide a good correlation between cell number and signal. CFSE 
demonstrated a greater sensitivity compared to MTT.     
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Although both methods demonstrated good correlation in cell number (Figure 
4.2; r2; CFSE vs. MTT ± 0.9919 vs. 0.9912), there was a difference regards the 
sensitivity of each assay. The MTT assay was able to detect cell numbers to 
approximately 3000 cells (n = 2; p < 0.05), however in comparison, using CFSE 
enabled the detection of cell numbers to approximately 400 cells (n = 2; p < 
0.05). Any slight changes in cell numbers seen with chemotaxis assays require a 
sensitive detection method. CFSE provides this sensitivity whilst remaining cost 
effective and was thus used in all chemotaxis experiments. 
4.3.2 CCR4 Expression 
The specificity of CCR4 as a target for immunotherapy has been widely debated. 
It is critical to understand which cell populations would be affected, should CCR4 
antagonism be employed. Flow cytometry was used to detect CCR4 on different 
cell populations (Figure 4.3). From Figure 4.3, there is definitive expression of 
CCR4 on Treg (89.1 % (79.2 ± 99.1), n = 6), this indicates that Treg would be 
susceptible to CCR4 antagonism. Other cell populations were assessed for their 
CCR4 expression.  CD8+ T cells (18.2 % (15.3 ± 21.4), n = 6) and CD4+CD25- 
effector T cells (30.4 % (19.7 ± 36.2), n = 6) demonstrated significantly lower 
CCR4 expression compared to Treg. Ovarian tumour cells also demonstrated 
significantly lower CCR4 expression compared to Treg (A2780; 5.5 % (4.3 ± 6.3) 
and IGROV1; 41.9 (39.6 ± 44.2); n = 3). Literature suggests that CCR4 tends to 
EHH[SUHVVHGRQ WKRVHFHOO W\SHVZKLFKSURYLGHD µUHJXODWRU\¶ IXQFWLRQVXFKDV
Treg (107) and M2 macrophages (108). Effector immune populations such as 
CD8 T cells and CD4+CD25- effector T cells are reported to express CCR3 and 
CCR5 at higher degrees (109).      
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Figure 4.3 ± CCR4 Expression on Different Cell Populations. FACS analysis for CCR4 expression. A- Isotype Control, Mouse IgG1-FITC, B ± 
CD8+ T cell, C- CD4+CD25- T cell, D ± Treg, E ± A2780, F ± IGROV1, G ± Percentage CCR4 expression; n = 6.   
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4.3.3 Induction of CCL17/CCL22 
The role the tumour plays in causing this migration needs to be established in 
vitro.  Work conducted by Berin et al. (110) demonstrated the upregulation of 
CCL22 at both the genetic and protein level by human intestinal epithelial cells. 
This upregulation was caused by the addition of the cytotoxic cytokines TNF-Į
and IFN-ȖWRPRQROD\HUVRILQWHVWLQDOHSLWKHOLDOFHOOV 
Work by Curiel et al. (92) has suggested that CCL22 is a driver for Treg migration 
in ovarian tumours, with increased levels found in tumour ascites.  This led to the 
concept of CCL22 acting as a regulatory element to cytotoxic immune attack.  If 
effector T cells recognise tumour associated antigens, they mount an immune 
response towards the target, which in part is the release of cytotoxic cytokines 
like TNF-ĮDQG,)1-Ȗ(111). This in turn could cause the increased production of 
CCL22, which induces Treg migration and thus aids suppression of the cytotoxic 
immune response. 
In order to replicate this effect, the ovarian cancer cell line A2780 was exposed to 
varying concentrations of TNF-ĮDQG ,)1-Ȗ 5HVSRQVHVZHUHPHDVXUHGDW WKH
genetic level using qRT-PCR (Figure 4.4) and at the protein level using ELISA 
(Figure 4.4).           
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Figure 4.4 ± Fold increase in Expression of CCL22 from A2780 on addition of TNF-ĮDQG,)1-ȖCytokines were added at concentrations of 
5, 10 and 20 ng/ml as individual treatments and as a synergic mixture.  CCL22 mRNA expression was assessed by real-time PCR after 
stimulation with the indicated cytokines for 24 h. Fold increase in gene expression compared to non-stimulated samples. GAPDH was used as a 
housekeeping gene. Results shown are mean values of triplicates (n = 3, p < 0.05).  Error bars represent standard deviation. *=p<0.05. TNF - 
tumor necrosis factor-alpha; IFN ± interferon-gamma.  
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From Figure 4.4 there is an increase in CCL22 expression with increasing pro-
inflammatory cytokine concentration (E.g. Figure 4.4, TNF-ĮQJPOIROG
increase, 1.74/2.36/3.26). There is no significant increase in expression with low 
concentrations of IFN-Ȗ Figure 4.4, IFN-ȖQJPOIROGLQFUHDVHn 
= 3, p > 0.05).  However, treatment with a combination of 20 ng/ml IFN-ȖDQG20 
ng/ml TNF-Į OHG WR D 183 (+/- 31) fold increase in gene expression.  This 
expression is translated into increases in actual CCL22 production.  Figure 4.5 
shows a correlation with the gene expression data.  With the addition of pro-
inflammatory cytokines, there is a statistically significant increase in CCL22 
production compared to non-stimulated samples (Figure 4.5; no-stim; ng/ml, 
0.841 +/- 0.188, n = 3).  However, there is no statistical difference between 
treatment regimens (p < 0.05).  This could be due to the lack of translation of the 
upregulated gene to protein or the robustness of the assay.  CCL17 was also 
shown to be upregulated on pro-inflammatory stimulus of cells (Figure 4.5; no-
stim; ng/ml, 0.037 +/- 0.006, n = 3). Although CCL17 is a major consideration for 
CCR4 related migration, only protein expression was assessed. This was due in 
part to cost and work by Mariani et al. (112) who suggested that CCL22 acted as 
the dominant chemokine i.e. more readily produced in an inflammatory 
environment.  
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Figure 4.5 ± Concentration of CCL17 and CCL22 Produced by A2780 on Treatment with Varying Concentrations of TNF-ĮDQG ,)1-Ȗ
A2780 cells were grown to confluence and left unstimulated (control) or were stimulated with TNF-ĮRU,)1-ȖDWDQGQJPOUHVSHFWLYHO\
CCL17 and CCL22 in culture supernatants were determined by ELISA. Error bars represent standard deviation. Values are means of triplicates. (n 
= 3, p < 0.05)  *=p<0.05. TNF - tumor necrosis factor-alpha; IFN ± interferon-gamma.  
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4.3.4 Cell Migration 
The migration of Treg and ovarian cancer cells via CCL17 and CCL22 has been 
studied in vitro by several groups (81,87,102,113). The assay involved the use of 
a transwell-like system made of an upper and lower chamber, separated by a 
filter. In the lower chamber, chemokine solutions were placed whilst CFSE-
labelled cells were then placed in the upper chamber. The system was then 
incubated for two hours at 37 °C before the contents of the lower chamber were 
counted using a fluorescent microplate reader. The number of cells that had 
migrated was extrapolated from a standard curve of CFSE labelled cells. The 
major limitation with this type of assay was the number of cells required to 
provide statistical strength i.e. n = 3 replicates.  The ability to expand Treg 
populations which maintain their phenotype and function, as described in 
Chapter 3, allowed experiments to be carried out more readily.  Figure 4.6 shows 
the migration of Treg to CCL17 and CCL22. 
 
Figure 4.6 demonstrates that both CCL17 and CCL22 are chemotactic factors for 
Treg compared to non-chemokine controls (p < 0.05). This dose response data 
highlighted concentrations at which Treg migration was at its highest (Figure 4.6; 
CCL17, control vs. 1 ng/ml; 9827 +/- 1525 vs. 33933 +/- 2033; CCL22, control 
vs. 10 ng/ml; 9216 +/- 941 vs. 36274 +/- 2620). These concentrations 
corroborated with published literature (87,89) and were used in inhibition studies 
(Figure 4.8).  
 
Figure 4.7 shows that ovarian cancer cells can also migrate under the influence 
of CCL17 and CCL22. This was evaluated due to evidence of breast cancer 
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metastases seeding in the lung via CCR4/CCL17 (103). Therefore, it could be 
possible for ovarian cancer to metastasise via the same mechanism to distant 
sites. However, it was noted that higher concentrations of both chemokines (100 
ng/ml) were required to induce a statistically significant migration (p < 0.05).  The 
lower expression of CCR4 has a significant impact on the degree to which these 
cells migrate. A2780 exhibits a significantly lower degree of migration with both 
chemokines compared to IGROV-1 at 100 ng/ml (Figure 4.7 (CCL17; A2780 
(9230 +/- 191) vs. IGROV-1 (19345 +/- 1199) and CCL22; A2780 (12384 +/- 
1525) vs. IGROV-1 (24136 +/- 2620)). The exhibition of CCR4-mediated 
migration suggests that antagonism of the receptor would be advantageous in 
reducing ovarian cell migration.  
 
Despite demonstrating CCR4 expression, the chemotactic activity of CD8+ and 
CD4+CD25-
 
effector T cells were not assessed as literature suggests that the 
dominant chemokines in their migration to tumours are CCL3  and CCL5, which 
bind to CCR1/CCR3 and CCR5 respectively (114).  
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Figure 4.6 - Chemotaxis of Treg. A ± to CCL22, B ± to CCL17.  Treg demonstrate 
migration to CCL17 and CCL22. Peak Treg migratory chemokine concentrations were 
determined. CCL17; 1 ng/ml and CCL22; 10 ng/ml. Results shown are mean values of 
triplicates (n = 3, p < 0.05). Significance of data compared against 0 ng/ml migration 
XVLQJ 'XQQHWW¶V 0XOWLple comparison test. Error bars represent standard deviation. 
*=p<0.05 
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Figure 4.7 - Chemotaxis of A2780 Ovarian Cancer Cells. A ± to CCL17. B ± to CCL22. 
IGROV-1 ovarian cancer cells migrate via CCL17 and CCL22. Peak cell migratory 
chemokine concentrations were determined. CCL17; 100 ng/ml and CCL22; 100 ng/ml. 
Results shown are mean values of triplicates (n = 3, p < 0.05). Significance of data 
compared agaLQVWQJPOPLJUDWLRQXVLQJ'XQQHWW¶V0XOWLSOHFRPSDULVRQWHVW(UURUEDUV
represent standard deviation. *=p<0.05 
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4.3.5 Chemotactic Antagonism 
Once the migration of Treg was established, AZ1 was employed as a CCR4 
inhibitor to investigate its effects on cell chemotaxis.  Figure 4.8 highlights the 
effect on Treg migration toCCL22 (10 ng/ml; 4.8a). CCL17 (1 ng/ml; 4.8b) and a 
combination of both CCL17 and CCL22 (1 and 10 ng/ml respectively; 4.8c). Cells 
were treated with AZ1 at a concentration of (0 ± 10000 nM).  
AZ1 affected Treg migration in a dose dependent manner to CCL17 (100 ± 
10000 nM, n = 3; p < 0.05) and CCL22 (10 ± 10000 nM, n = 3; p < 0.05).  A 
combination of both chemokines at their optimal migratory concentrations for 
Treg (CCL17 = 1 ng/ml; CCL22 = 10 ng/ml) were also restricted by AZ1 (100 ± 
10000 nM, n = 3; p < 0.05). The increased migration of Treg seen with a 
combination of chemokines could be attributed to the ability of CCL17 to bind to 
CCR8, another chemokine receptor present on Treg (89). However, this was not 
substantiated due to time and cost. 
With regards to ovarian cancer cell line migration (Figure 4.9), AZ1 restricted cell 
migration to 100 ng/ml  CCL22 (Figure 4.9a; 10 ± 10000 nM, n = 3; p < 0.05) and 
100 ng/ml CCL17 (Figure 4.9b; 10 ± 10000 nM, n = 3; p < 0.05) and as well as a 
combination of both (Figure 4.9c; 10 ± 10000 nM, n = 3; p < 0.05) in a dose 
dependent manner. Trypan Blue staining revealed that AZ1 did not affect cell 
viability at any concentration. The results indicate that AZ1 could be effective in 
restricting the recruitment of Treg and ovarian cancer cells via CCR4 
antagonism.  
The concentration range of AZ1 was partially determined by the specificity of the 
compound. Previous work has demonstrated  that there is a region of high 
163 
 
homology between the chemokine receptors CCR4 and CCR5 (100). AZ1 has 
been shown to demonstrate affinity for CCR5 at concentrations above 10000 nM. 
As CCR5 is present on CD8+ and CD4+CD25-  effector T cells (115,116) it would 
be counter intuitive to dose at such high concentrations as this may restrict 
effector cell migration to tumour sites.   
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Figure 4.8 - Chemotaxis of AZ1-treated Treg. A ± against CCL22 (10 ng/ml), B ± 
against CCL17 (1 ng/ml), C ± CCL22 (10 ng/ml) and CCL17 (1 ng/ml).  Results shown 
are mean values of triplicates (n = 3, p < 0.05). Significance of data compared against 0 
ng/ml containing 0.1 % v/v DMSO migration. Control non-chemokine control. Significance 
RI GDWD FRPSDUHG DJDLQVW  QJPO PLJUDWLRQ XVLQJ 'XQQHWW¶V 0XOWLSOH FRPSDULVRQ WHVW
Error bars represent standard deviation. *=p<0.05 
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Figure 4.9 - Chemotaxis of AZ1-treated IGROV-1. A ± to CCL22 (100 ng/ml), B ± to 
CCL17 (100 ng/ml), C ± CCL22 (100 ng/ml) and CCL17 (100 ng/ml).  Results shown are 
mean values of triplicates (n = 3, p < 0.05). Significance of data compared against 0 
ng/ml containing 0.1 % v/v DMSO migration. Control non-chemokine control. Significance 
RI GDWD FRPSDUHG DJDLQVW  QJPO PLJUDWLRQ XVLQJ 'XQQHWW¶V 0XOWLSOH FRPSDULVRQ WHVW
Error bars represent standard deviation. *=p<0.05 
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As described previously, pro-inflammatory stimuli can lead to the production of 
CCL17 and CCL22 from ovarian tumour cells. The supernatant analysed from 
cells stimulated with 20 ng/ml IFN-ȖDQG71)-Į&&/FRQFHQWUDWLRQ - 
0.046 ng/ml; CCL22 concentration = 4.26 +/- 3.01 ng/ml) in Figure 4.5 was used 
in a Treg migration assay (Figure 4.10). Treg migrated under the influence of 
CCL22 derived from stimulated ovarian cancer cells. Using AZ1 in Figure 4.10, 
this effect was abrogated (1 ± 10000 nM, n =3; p < 0.05) which adds further 
evidence for the ability of AZ1 to restrict Treg migration to ovarian tumours.  
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Figure 4.10 - Chemotaxis of AZ1-treated Treg to A2780 cancer cell derived CCL22.  Results shown are mean values of triplicates (n = 3, p < 
0.05). Significance of data compared against 0 ng/ml containing 0.1 % v/v DMSO migration. Control non-chemokine control. Significance of data 
FRPSDUHGDJDLQVWQJPOPLJUDWLRQXVLQJ'XQQHWW¶V0XOWLSOHFRPSDULVRQWHVW(UURUEDUVUHSUHVHQWVWDQdard deviation. *=p<0.05 
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4.3.6 CCR4 Internalisation 
Elegant work by Mariani et al. (112) has demonstrated the functional 
consequences of chemokine-chemokine receptor binding. They describe the rate 
at which the CCR4 receptor is internalised and then recycled after CCL22 
engagement. CCL17 did not demonstrate similar phenomena. As described by 
Andrews et al. (100)  AZ1, a pyrazinyl-sulphonamide, requires access to the 
cytoplasm for its activity, suggesting that the compound acts via an intracellular 
site on CCR4 which is could involve part of the C-terminus. This interaction 
between compound and receptor leads to not only a significant reduction in the 
affinity of chemokine binding but the degree of receptor internalisation and thus a 
reduction in downstream calcium signalling (100).  It was therefore decided that a 
demonstration of the pharmacological activity of AZ1 on CCR4+ Treg would be 
important in highlighting its potential use as a chemokine receptor antagonist and 
subsequent immunotherapeutic adjuvant.  
Figure 4.11 demonstrates the effect of AZ1 on CCR4 internalisation. Treg were 
treated with a range of concentrations of AZ1 prior to incubation with CCL22. A 
high dose of CCL22 (500 ng/ml) was used to promote rapid internalisation as 
described by Mariani et al. (112) the surface expression of CCR4 was then 
assessed using FACS analysis. Ideally, intracellular staining for CCR4 would 
also have been conducted. Unfortunately, the expansion of a suitably large, high 
CCR4 expressing Treg population to cover all experimental groups was 
unachievable.  However, the changes in surface expression of CCR4 on Treg 
provide an insight into the effects of CCR4 antagonism.  
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On addition of CCL22 to Treg, CCR4 surface expression fell  significantly from 
95.73 % (94.2 ± 97.2) to 18 % (15.6 - 20.3); p < 0.05,  which is suggestive of 
receptor binding and internalisation. The pre-treatment of Treg with various 
concentrations of AZ1 showed a significant impairment of this internalisation 
event. At concentrations as low as 1 nM (66.93 % (66.1 ± 68.3) vs. control (18 % 
(15.6 - 20.3); p < 0.05), there is still appreciable retardation of receptor 
internalisation. This adds sufficient strength to the argument of functional CCR4 
expression on Treg, whose activity can be impeded through the use of AZ1. 
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Figure 4.11 ± Internalisation of CCR4 on Treg-treated with CCL22 and AZ1.  FACS Plots represent CCR4 expression on Treg. A ± Incubated 
on ice. B ± Treated with 500 ng/ml and 100 nM AZ1, C ± Treated with 500 ng/ml CCL22, D ± Percentage CCR4 surface expression.  Results 
shown are mean values of triplicates (n = 3, p < 0.05). Significance of data compared against 0 nM antagonist. Significance of data compared 
DJDLQVWQ0PLJUDWLRQXVLQJ'XQQHWW¶V0XOWLSOHFRPSDULVRQWHVW(UURUEDUVUHSUHVHQWVWDQGDUGGHYLDWLRQ *=p<0.05 
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Figure 4.12 ± Treg Suppression of CD4+CD25- Effector T cells in the Presence of 100 nM AZ1 Treg demonstrate suppression of CD4+CD25- 
T cells where Treg were present at a 1/5 and 1/10 fraction of total co-culture. AZ1 has no effect on the suppressive activity of Treg. Figure 
representative of three independent experiments from the same donor. Error bars represent standard deviation. *=p<0.05 
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4.3.7 Effect of AZ1 on Treg Suppressive Function 
An important characteristic of Treg is their ability to suppress multiple arms of the 
immune system. In an immune competent individual, Treg homeostasis is critical 
in regulating auto-immunity (117-119) and so it is important to assess whether 
AZ1 has any detrimental effect on this ability. As stated previously, Treg cells 
remained viable after treatment. Figure 4.12 shows how treatment of Treg with 
100 nM of AZ1 does not alter their suppressive phenotype. A concentration of 
100 nM was used as this is the IC50 of the compound (100). This suggests that 
AZ1 could be used as a therapeutic moiety in ovarian cancer without 
compromising peripheral Treg function. 
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4.4 Conclusions 
As part of the immunotherapeutic strategy which has been conceptualised in this 
thesis, the migration of both Treg and ovarian cancer cells has been studied. The 
clinical significance of increased Treg infiltration in progressively poorly 
prognostic ovarian cancer has been, in part, attributed to the chemokine-
chemokine receptor axis CCL17/CCL22-CCR4. The expression of CCR4 and its 
specific chemokines has also been identified as a means for certain tumour types 
to undergo migration and metastatic seeding at distant sites. This evidence 
VXJJHVWV WKDW WKLV PHWKRG RI FHOO µUHFUXLWPHQW¶ PD\ EH D WDUJHW for therapeutic 
intervention.  
Based on the findings above, CCL17 and CCL22 are both implicated in Treg 
migration. Optimal migratory concentrations of both chemokines (CCL17, 1 
ng/ml; CCL22, 10 ng/ml) were obtained and used in subsequent inhibition 
assays.  The propensity of ovarian cancer cells to produce CCL17 and CCL22 in 
response to pro-inflammatory stimuli was also observed. This suggests that the 
immunological time course of events within the solid tumour microenvironment 
starts with a pro-inflammatory period, i.e. an anti-tumour response, followed by 
an ensuing regulatory, or anti-inflammatory, response. The release of CCL17 and 
CCL22 into the microenvironment could be considered part of that anti-
inflammatory response; inducing the migration of Treg to dampen any local pro-
inflammatory event. It should be noted that tumour cells are not the sole 
contributor to CCL17/CCL22 production within the tumour microenvironment and 
that tumour-associated macrophages have also been shown to produce these 
chemokines.   
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The use of AZ1, a specific CCR4 antagonist has demonstrated efficacy in 
reducing both Treg and ovarian cell migration toboth chemokines. The proposed 
mechanism of action of the compound is through association with the 
cytoplasmic tail of the chemokine receptor, thus rendering it unable to internalise 
and activate downstream pathways to facilitate migration. AZ1 ably demonstrates 
this on Treg as shown above. With no change in cell viability or the suppressive 
function of Treg, AZ1 has the potential to be used as part of an 
immunotherapeutic regimen.  Despite its potential, AZ1 cannot be used as a 
standalone therapeutic. This is due to the therapeutic window under which it 
would be administrated. In general, tumour therapy begins after the 
establishment of a solid tumour. During this time, Treg may have already 
migrated from the peripheral to the tumour site. Evidence suggests that as the 
disease progresses there is an increase in Treg infiltration (1,92). This means 
that abrogating the chemotactic function of CCL17 and CCL22 would reduce 
Treg infiltrate over time as the disease progressed. However, it would not limit 
the immune suppressive effects of Treg that have already migrated and thus, 
embedded themselves in the tumour microenvironment architecture. 
To account for this effect, the next two chapters of this thesis look at restricting 
the suppressive function of Treg as well as simultaneously enhancing the 
generation of an anti-tumour immune response. 
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Chapter 5 
Chemotherapeutic induction of 
Tumour-associated Antigen Release 
5.1 Introduction 
Chemotherapy remains the treatment of choice for most advanced 
cancers. However, for solid tumours in particular, it is rarely curative. 
Immunotherapy is a less conventional form of therapy and is also rarely 
curative. Chemotherapy and immunotherapy have usually been 
regarded as unrelated or, more commonly, opposing forms of therapy. 
This is mainly due to the assumption that a) cell death by 
chemotherapeutic agents is non-immunogenic or aides immune 
tolerance and b) haematological adverse effects such as lymphopaenia 
have been assumed to be antagonistic toward mounting an immune 
response.  However, more recent evidence has suggested the case for a 
combination of both chemo- and immunotherapy (1).  
5.1.1 Current Treatment 
Treatment of ovarian cancer is based on the integration of surgery and 
chemotherapy. Chemotherapy plays a major role both in the adjuvant 
treatment and in the care of patients with advanced disease. Moreover, since 
most of the patients suffer a recurrence after front-line surgical and medical 
therapy, further chemotherapy is required for the treatment of the relapse. 
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Several clinical and prognostic factors are taken into account before starting 
an anti-cancer treatment for ovarian cancer. Histological type, degree of 
GLIIHUHQWLDWLRQ SDWLHQW¶V DJH W\SH RI VXUJHU\ DQG UHVLGXDO GLVHDVH DIWHU
SULPDU\ F\WRUHGXFWLRQ DUH DOO LPSRUWDQW YDULDEOHV WKDW LQÀXHQFH WKHUDSHXWLF
strategy. 
Due to the unavailability of effective screening programmes, ovarian cancer is 
diagnosed at an early stage (I-IIA) in about 20 % of cases. In general, surgery 
is able to cure the disease although recurrences are reported in up to 25 % of 
patients (2). However, according to the results of two studies from the 
International Collaborative Ovarian Neoplasm group and the European 
Organisation for Research and Treatment of Cancer, chemotherapy is able to 
reduce the risk of recurrence in patients with stage I to IIA and prolong overall 
survival (3). 
The standard of care for patients with advanced ovarian cancer is maximal 
surgical cytoreduction followed by systemic platinum-based chemotherapy. 
This treatment schedule is considered to yield a 5-year survival rate of 40 % 
and 20 % for women diagnosed with ovarian cancer at stage III and IV, 
respectively (4).  
Over the years, experts and research groups have experimented with 
different combinations of drugs in order to improve the prognosis of ovarian 
cancer. In the 1970s, the treatment of women with advanced ovarian cancer 
was based on alkylating agents such as Melphalan, Cyclophosphamide, 
Chlorambucil and Thiotepa, all given as single drugs; response rates were 
limited with a complete clinical response documented in approximately 20 % 
of patients, and a median survival of 10±14 months for responding patients 
(5). The platinum-based drug, Cisplatin was introduced in the early 1980s and 
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demonstrated that either alone, or in combination with other 
chemotherapeutic agents, an improvement in overall survival compared to 
those regimens without platinum (6,7). 1990 saw the introduction of 
3DFOLWD[HO DQ DFWLYH FRQVWLWXHQW RI EDUN RI WKH 3DFL¿F <HZ WUHH Taxus 
brevifolia (8,9). Two randomised trials, the GOG 111 and the OV-10, 
compared Cisplatin/Paclitaxel with Cisplatin/Cyclophosphamide and showed 
DGGLWLRQDOFOLQLFDOEHQH¿WZKHQ&\FORSKRVSKDPLGHZDVUHSODFHGE\3DFOLWD[HO
DV¿UVW-line therapy (10,11).   
In the last 20 years studies have been performed in order to improve the 
RXWFRPHRI¿UVWOLQHWKHUDS\VXFKDVWKHSRVVLELOLW\WRGHOLYHUGUXJVLQRYDULDQ
cancer through the intra-peritoneal route. The biology of epithelial ovarian 
cancer, in that it arises from the epithelial surface of the ovary with intra-
abdominal spread to the peritoneal cavity, is a strong rationale for the attempt 
to treat the cancer within the abdominal cavity (12).  
In the late 1970s, Robert Dedrick et al. (13) predicted that for anti-neoplastic 
agents possessing particular biological properties there would be a major 
pharmacokinetic advantage for exposure of the drug to cancer present within 
the peritoneal cavity following regional delivery, compared to systemic 
administration of the same agent. Paclitaxel, Cisplatin, and Carboplatin have 
VKRZQ D VLJQL¿FDQW SKDUPDFRORJLFDO DGYDQWDJH ZKHQ JLYHQ WKURXJK DQ
intraperitoneal route (14).  
Although the majority of countries still administer drugs intravenously this 
highlights the importance of localising chemotherapeutic agents at the site of 
interest while attenuating systemic adverse and pharmacokinetic effects.  
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5.1.2 New Therapies 
The larger expectation for improved prognosis in ovarian cancer is related to 
the use of the new biological agents. Sustained research has led to a greater 
fundamental understanding of some key molecular targets such as growth 
factor receptors, signal transduction pathways, cell cycle regulators and 
angiogenic mechanisms. 
One of the most investigated and promising drugs in ovarian cancer is 
Bevacizumab, a monoclonal antibody directed against VEGF. Several phase 
II studies have shown that Bevacizumab is active in recurrent ovarian cancer 
(15,16). A phase III trial has recently evaluated the role of Bevacizumab in 
¿rst-line chemotherapy as an adjunct to Carboplatin and Paclitaxel. The GOG 
218 trial is a multi-centre, placebo-controlled trial with the primary end point to 
determine whether the addition of Bevacizumab to standard cytotoxic therapy 
is able to prolong progression-free survival after primary cytoreductive 
surgery. Preliminary data has been presented at the American Society of 
Clinical Oncology annual congress 2010 showing that Bevacizumab plus 
chemotherapy followed by Bevacizumab maintenance therapy is able to 
prolong progression-free survival by approximately 4 months (10.7 months 
versus 14.1 months) compared to Carboplatin±Paclitaxel alone. The survival 
data for this trial are not yet available (17,18). 
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase 
inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ĮȕDQG c-kit that blocks 
tumour growth and inhibits angiogenesis. Recently approved for use in renal 
cell carcinoma, it is now thought to be of use in ovarian cancer. A recent 
phase II trial saw 11 out of 36 patients respond to the drug (19). Another 
tyrosine kinase inhibitor, Erlotinib which targets epidermal growth factor 
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receptors is currently indicated for metastatic non-small cell lung cancer and 
advanced pancreatic cancer. Phase II trials of Erlotinib have yielded mixed 
results with inconclusive data suggesting that the drug is of benefit in those 
patients that are platinum sensitive (20,21) but causes unexpected 
gastrointestinal adverse effects (22).   
Abagovomab is a murine monoclonal antibody that functionally imitates the 
tumour-associated antigen, CA-125. It has been shown to be well tolerated 
and to induce a sustained immune response in initial Phase I and II clinical 
trials. A  Phase III trial (MIMOSA) completed its double-blind period in 
December 2010 and will compare Abagovomab maintenance therapy to 
placebo, which will determine its efficacy in patients with ovarian cancer 
(23,24). 
 
5.1.3 Chemotherapy and the Immune System 
As mentioned previously, cytotoxic chemotherapy is an effective and common 
modality for the treatment of ovarian cancer. These drugs exploit the rapid 
proliferation of malignant cells and typically act to disrupt the cell cycle 
(Cyclophosphamide), inflict damage by a range of mechanisms including 
prevention of microtubule function (Paclitaxel), disruption of purine and 
pyrimidine supply (Gemcitabine), and DNA damage (Cisplatin) resulting 
predominantly in apoptotic cell death. While such therapy has shown success 
by directly killing tumour cells, the resulting apoptosis was previously 
considered to be a non-immunological event, and chemotherapy itself is 
considered to have an immune suppressive effect on the host immune 
system. 
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During normal cell turnover, apoptotic bodies are cleared through 
macrophage-mediated phagocytosis and do not induce an immune response, 
due to release of potent anti- inflammatory mediators. However, there is 
increasing evidence that cytotoxic drugs result not only in tumour cell death 
but are able to stimulate the immune system (25-30). It is proposed that 
massive tumour cell apoptosis releases a flood of tumour-associated antigen 
which may be processed by DC for cross-presentation to naïve T cells in 
tumour- and peripheral- draining lymph nodes (29). This increase in antigen 
can also result in the loading of tumour stroma allowing bystander killing of 
local tumour cells by activated tumour-specific CD8+ T cells resulting in 
tumour eradication (31). Interestingly, and somewhat more controversially, 
cytotoxic chemotherapy has been shown to modulate the anti-tumour immune 
response directly by altering the context of dying tumour cells and indirectly, 
by reducing immune suppressive pathways (1,26). The well-known 
haematological adverse effects of cytotoxic drugs can affect the balance of 
pro- and anti-tumour immune cell populations and it is probable that this 
contributes to the therapeutic efficacy of some cytotoxic drugs. 
The importance of the immune system in the anti-tumour effects mediated by 
cytotoxic agents has been studied for many years. In the 1960s, Mihich et al. 
(32) examined the possibility that the curative effects of anti-tumour agents 
resulted from synergy between the drug itself and the immune system of the 
host. Since then, the availability of transgenic animal models bearing defects 
in genes encoding immune functions have been key to showing that the 
clinical efficacy of some cytotoxic drugs relies on an intact immune system. 
The removal of the IFN-ȖUHVSRQVHRUGHSOHWLRQRI&'+ T cells abrogated the 
therapeutic effect of Oxaliplatin against EL4 thymoma and CT26 colon 
carcinoma (33) and abolished the anti-tumour effects of Doxorubicin against 
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CT26 cells, MCA-induced fibrosarcomas or rat PROb colon carcinomas 
(33,34). Gemcitabine has also been shown to require an intact immune 
system for its full anti-tumour function (35). Given this, extensive studies have 
been performed over recent years to identify the ways in which cytotoxic 
drugs utilise the immune system for their clinical effectiveness. 
 
5.1.4 Immunogenic Chemotherapy-induced Tumour Cell Death  
Chemotherapy may interfere with several steps in the induction of anti-tumour 
immunity. The final effect of chemotherapy is thus dependent on the overall 
effect on several steps from initial apoptosis induction to the development of 
immunological memory. Scheffer et al. (36) compared the immune response 
against apoptotic or necrotic tumour cells. This study showed that the cell 
death mechanism is important for the immunogenicity of malignant cells. 
Furthermore, cytotoxic drugs often act by inducing apoptosis in malignant 
cells, and in a recent experimental study Casares et al. (34) described that 
the apoptotic phenotype was important for induction of anti-tumour immunity. 
These authors compared the two DNA-binding and apoptosis-inducing drugs 
Doxorubicin and Mitomycin in an experimental animal model and 
demonstrated that malignant cells could take different pathways to apoptosis. 
Death by Doxorubicin triggered an immune response, whereas the apoptotic 
cells killed by Mitomycin did not. The authors demonstrated that colon-
carcinoma (CT26) cells, killed by Doxorubicin were first endocytosed by 
dendritic cells which led to the subsequent induction of anti-tumour CD8+ T 
cells. Direct injection of Doxorubicin into the tumours caused immune-
dependent regression (34,36). In contrast, neither dendritic cell uptake nor 
tumour regression was observed by using Mitomycin. Therefore it was 
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suggested that the Doxorubicin-induced apoptosis and the development of 
tumour-specific immunity was critical for outcome.  
Some chemotherapeutic agents have been shown to alter the context of 
antigen presentation from the dying tumour cell such that it becomes 
immunogenic (37-39). Obeid et al. (38) performed a systematic screening of 
chemotherapeutic compounds for their ability to induce immunogenic tumour 
cell death by treating CT26 colon carcinoma cells with a panel of cytotoxic 
agents known to induce apoptosis and assessing their capacity to generate a 
productive T cell response in a vaccine setting. While the majority of 
apoptosis-inducing agents failed to induce immunogenic cancer cell death, 
Doxorubicin, induced a potent protective anti-tumour immune response, an 
effect which was also observed in EL4 thymoma and MCA205 sarcoma (38). 
Further study revealed that this effect was mediated by translocation of the 
endoplasmic reticulum resident calreticulin (CRT) and ERp57 to the plasma 
membrane of dying cells (38,40). Importantly, CRT/ERp57 exposure 
DSSHDUHG WR IXQFWLRQ DV DQ µHDW-PH¶ VLJQDO ZKLFK ZDV UHTuired for optimal 
phagocytosis of dying tumour cell material by DC, resulting in a protective 
anti-tumour immune response (37).  
These initial studies led to the discovery of other substances associated with 
cellular damage which provide immunogenic signals. High mobility group box 
protein-1 (HMGB-1) is a nuclear protein released from damaged and necrotic 
cells which triggers an inflammatory response (41). Doxorubicin and 
Oxaliplatin-induced apoptosis of tumour cells has been associated with 
release of HMGB-1 into the extracellular milieu (37,42). Subsequent 
interaction of HMGB-1 with its receptor, TLR-4, on DCs is reported to facilitate 
efficient processing and cross-presentation of tumour-associated antigens.  
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However, despite interactions with DC and the resulting CTL response, 
neither HMGB-1 nor CRT/ERp57 was sufficient to induce maturation of DC. In 
contrast, chemotherapy-mediated damage of tumour cells may also induce 
heat-shock proteins such as HSP-90, which can stimulate the immune system 
by (a) interacting with DC via the scavenger receptor CD91 causing activation 
and (b) chaperoning tumour-specific peptides into antigen presentation 
pathways leading to efficient T cell activation (39). HSP-90 expression on the 
surface of Bortezomib-treated myeloma cells enabled phagocytosis and 
activation of autologous DC (39). Delivery of this activation signal was 
dependent on cell±cell contact between DC and dying tumour cells and was 
mediated by Bortezomib-induced expression of HSP-90. This effect was not 
REVHUYHGZKHQP\HORPDFHOOVZHUHWUHDWHGZLWKȖ-irradiation or steroids (39). 
Thus, the type of stress response induced depends on the cytotoxic drug of 
choice. In addition to TLRs, nucleotide-binding domain, leucine-rich repeats 
containing proteins (NLR) can recognise danger signals associated with 
chemotherapy-induced cell damage. A recent study by Ghiringhelli et al. (33) 
identified the importance of the NLR receptor family purine domain containing 
the NLRP3 inflammasome, in the DC-mediated immune response to dying 
tumour cells.  
The ramifications of these findings for human disease have not been 
extensively studied; however, emerging data suggests that some of these 
pathways play a crucial role in mediating the clinical efficacy of anti-cancer 
chemotherapy. The clinical relevance of the HMGB-1/TLR-4 interaction was 
shown recently in Doxorubicin-treated breast cancer patients, where the loss 
of functional TLR4 due to polymorphism correlated with poor survival 
following chemotherapy or radiotherapy (37). The same polymorphism was 
also seen in patients with metastatic colorectal cancer treated with Oxaliplatin 
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(42). Conversely, patients bearing normal expression showed increased 
progression free survival compared with those bearing the mutant allele. This 
effect was unique to those treated with Oxaliplatin as CRC patients who 
underwent curative surgery with no chemotherapy did not differ in their 
progression-free survival in terms of their TLR4 expression (42). These initial 
studies have shown that selective immune defects in cancer patients can 
compromise the clinical efficacy of some anti-cancer drug regimens and thus 
provide proof of principal that an intact immune system helps mediate the 
chemotherapeutic response to some drugs. 
5.1.5 Chemotherapeutic-induced Immune Modulation 
While cytotoxic drugs exploit the increased proliferative activity of cancerous 
cells relative to other cells, they have a narrow therapeutic index, and toxicity 
to more rapidly proliferating normal cells, in particular, haematopoietic cells, 
produces potentially unwanted side effects including neutropaenia, 
lymphopaenia, thrombocytopaenia, and anaemia. This was traditionally 
thought to be detrimental to the immune system as such conditions rendered 
cancer patients more susceptible to infection. However, recent opinion has 
changed, indicating that chemotherapy may actually prime anti-tumour T cell 
responses and thus it is now less clear how this depletion of immune cells 
may affect tumour-specific CD8+ T cells. Transient lymphopaenia following 
treatment of solid tumours is rarely sufficient to cause infective complications 
and may, in fact, lead to elimination of cells that suppress anti-tumour T cell 
responses and activate homeostatic proliferation of tumour-specific CD8+ T 
cells due to the increased availability of IL-7, IL-15, and IL-21 (43). Turtle et 
al. (44) showed that some memory CD8+ T cells survive chemotherapy and 
replenish the memory T cell pool during lymphocyte recovery. In addition, 
lymphodepletion may enhance T cell homing to the tumour site and intra-
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tumoural proliferation of effector cells. However, the clinical relevance of 
these effects is not clear, especially in terms of their requirement for the 
therapeutic efficacy of chemotherapy.  
While most cytotoxic compounds are associated with non-discriminatory 
lymphodepletion, some drugs, when used at certain doses, are able to 
selectively eradicate suppressive cell populations, most notably Treg.  
As discussed previously, Treg depletion or abrogation of Treg function leads 
to an improved clinical outcome in a variety of cancers (45) and has become 
an therapeutic strategy of great potential.  
Cyclophosphamide, can impair the proliferation and effector function of Treg 
in both humans and mice (27,46,47). It also induces a robust type I IFN 
response that can modulate the activation of DC and T cells enhancing the 
generation of effector T cell immunity (48). In animal studies, these effects 
translate into protection against developing tumours and regression of 
established tumours (27).  
Several mechanisms have been suggested for this Cyclophosphamide-
induced impairment of Treg functionality including the downregulation of the 
suppressive molecules FOXP3, GITR and CTLA-4 (49) and inhibition of 
inducible nitric oxide synthase (50). More recently, their sensitivity has been 
attributed to low levels of intracellular ATP (51). Given the widespread use, 
availability, and known toxicity of drugs like Cyclophosphamide, Treg 
depletion through these means is a distinct possibility.  
Several small studies have been conducted in man to assess the capacity of 
Cyclophosphamide to impair Treg function and augment effector T cell 
responses. Low-dose cyclophosphamide has been shown to decrease the 
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proportion of Treg (46,52), augment delayed type hypersensitivity reactions, 
and enhance vaccine protocols (52). In a study by Ghiringhelli et al. (46), low-
dose oral Cyclophosphamide administered to 9 patients with advanced 
disease led to a selective reduction in the proportion, number, and 
suppressive function of peripheral blood Treg. This correlated with an 
enhanced cytotoxic capacity of peripheral blood NK cells and T cells following 
treatment. More recently, the immune-modulatory effects of low-dose 
Cyclophosphamide was studied in 13 patients with advanced hepatocellular 
carcinoma which yielded valuable information about the dose-dependent 
effect of cyclophosphamide-mediated Treg depletion (53). Patients were 
enrolled consecutively in three cohorts of four patients with a dose escalation 
of Cyclophosphamide (150, 250, 350 mg/m2). The authors observed a 
reduction in the number, frequency, and suppressive activity of peripheral 
blood Treg in patients receiving 150 and 250 mg/m2 but not at the higher 
dose of 350 mg/m2.  
Paclitaxel, has also recently been investigated for its capacity to augment the 
function and number of Treg. Paclitaxel treatment of the renal cell carcinoma, 
RENCA, and an EG7 thymoma led to delayed tumour growth which was 
partially abrogated following depletion of CD8+ T cells and enhanced the anti-
tumour effect of the TLR9 agonist, CpG (54). To substantiate this evidence, 
paclitaxel-based chemotherapy was shown to reduce the proportion of 
peripheral blood Treg in a cohort of patients with stage III and IV non-small 
cell lung cancer (55). 
The above observations, in conjunction with data suggesting that sub-
cytotoxic doses of Paclitaxel, Doxorubicin, Mitomycin C, Methotrexate, 
Vincristine, and Vinblastine were found to increase expression of maturation 
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and co-stimulation markers on DC (CD40, CD80, CD83 and CD86) and 
increase antigen presentation to specific T cells (56,57), suggests that 
classical chemotherapeutic approaches indirectly boost anti-tumour immunity 
(Figure 5.1).  However, there is still doubt as to whether chemotherapy-driven 
lymphopaenia allows for generation of a robust anti-tumour response. 
Interestingly, Muller et al. (58) noted that the Treg fraction increased on 
lymphodepletion in mice, while Winstead et al. (59) highlighted changes in the 
constituents of the T cell pool on immune reconstitution. Future work in this 
area needs to understand the kinetics of immune repopulation especially in 
the context of the immune suppressive milieu created by solid tumours (60).       
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Figure 5.1 ± The Direct and Indirect Effects of Chemotherapy. Mechanisms by which chemotherapy may enhance the anti-tumour CD8+ T cell response. 
A Cytotoxic chemotherapy acts directly on tumour cells to (1) reduce the physical burden of disease making it a smaller target for immune attack, (2) increase 
the range of available tumour antigen, and (3) cause immunogenic cell death. B - Some cytotoxic drugs stimulate the immune system by causing 
lymphopenia followed by homeostatic proliferation of immune effectors, activation of DC, or the selective elimination of suppressive subsets, such as Treg. 
Adapted from (127). Reprinted with permission (License number 2813871408369), Springer Ltd 
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5.1.6 Release of Tumour-associated Antigens 
The rate limiting step in the development of an anti-tumour immune response 
is the detection and processing of tumour associated antigens (61). The 
development of approaches for analysing humoral (62) and cellular (63) 
immune reactivity to cancer in the context of the autologous host has led to 
the molecular characterisation of tumour antigens recognised by autologous 
CD8+ T cells (64) and/or antibodies (65). Some of these approaches include 
serological analysis of recombinant cDNA expression libraries (SEREX) (66), 
differential gene expression analysis, T-cell epitope cloning (TEPIC) (67,68) 
and bio-informatics (69,70). As a consequence of these advances, human 
tumour antigens defined to date can be classified into one or more of the 
following categories: (i) differentiation antigens (that are restricted to very 
defined tissues), e.g. tyrosinase (71) Melan-A/MART-1 (72) and gp-100 (73) 
(ii) mutational antigens (that are altered forms of proteins), e.g. CDK4 (74)ȕ-
catenin (75), caspase-8 (76), and p53 (77), (iii) amplification antigens, e.g. 
Her2/neu (78) and p53 (77), (iv) splice variant antigens, e.g. NY-CO-»3'=-
45 (79) and ING-1 (80), (v) glycolipid antigens, MUC1 (81)  (vi) viral antigens, 
e.g. HPV, (82) EBV (83) and (vii) cancer-testis (CT) antigens (that are not are 
restricted in expression to the germ line and tumours) e.g. MAGE (67), NY-
ESO-1 (66) and LAGE-1 (84). 
 
5.1.7 MUC1 
An interesting tumour-associated antigen is Mucin1 (MUC1), because it is 
overexpressed in most adenocarcinomas (85-87). MUC1 is a protein 
expressed on the apical surface of most simple, secretory epithelia and on a 
variety of haematopoietic cells (88). MUC1 is a transmembrane mucin with an 
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extracellular domain made up largely of 20 amino acid tandem repeats. After 
translation, the MUC1 protein becomes modified by extensive O-
glycosylation. Within each tandem repeat, two serines and three threonines 
represent five potential O-glycosylation sites. The extent of glycosylation 
depends mainly on the expression of tissue-specific glycosyltransferases 
(86). Importantly, it has been demonstrated that in most cancer types, 
including ovarian cancer, MUC1 is aberrantly glycosylated, has lost its apical 
expression and is secreted into the circulation (89).  
Mucins have numerous functions in the glycocalyx. Their high degree of 
glycosylation provides lubrication, prevents dehydration, and offers protection 
from proteolysis. Microbial challenge is frequent in most mucous membranes, 
and mucins protect against attack by inhibiting microbial access to the cell 
surface through steric hindrance. Bacterial adhesins bind mucin 
carbohydrates at the cell surface (90,91), a process that normally protects 
against infection. In addition to this, MUC1 and MUC4, modulate cell-cell and 
cell-extracellular matrix interactions (92,93). 
7KH08&F\WRSODVPLFWDLOKDVEHHQVKRZQWRDVVRFLDWHZLWKȕ-catenin (94), 
as well as with other signalling molecules, e.g. Grb2/Sos  (95), suggesting a 
potential role for MUC1 in cell signalling (86). In the mammary gland, MUC1 
expression increases markedly during lactation along with increased 
MUC1:erbB1 interactions (96). Tyrosine phosphorylation of the MUC1 
cytoplasmic tail occurs in both intact MUC1 and chimeric molecules 
consisting of CD8 ecto-domains and the MUC1 cytoplasmic tail (97,98). It is 
not clear if MUC1 phosphorylation or interactions with signal transducing 
proteins change in response to physiological stimuli. Activation of erbB1 with 
EGF induces tyrosine phosphorylation of the MUC1 cytoplasmic tail (96,99) 
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and activation of ERK 1/2 [13]. Moreover, EGF mediated activation of ERK 
1/2 is drastically enhanced in the presence of high levels of MUC1 in the 
mouse mammary gland [13]. Thus, potential stimuli, including growth factors 
or cytokines may affect MUC1 stability, localisation at the cell surface, or 
phosphorylation state. Direct interactions with the MUC1 ecto-domain, e.g. by 
microbes or selectins, also could conceivably trigger signalling events. In this 
regard, increased tyrosine phosphorylation of the MUC1 cytoplasmic tail is 
associated with cell-substratum adhesion (97). Thus, MUC1, and perhaps 
other mucins, have the potential to function as receptors either alone or in 
cooperation with known signal transducing proteins. 
Studies in tumour cells indicate that the amount and type of MUC1 expressed 
modulate immune responses to these cells. MUC1 is differentially 
glycosylated in many cancerous cells, exposing tumour-specific epitopes that 
may trigger an immune response (100,101); however, MUC1 also has been 
shown to protect cancer cells from immune cell attack (102,103), indicating 
both immune stimulatory and immune suppressive functions. Several reports 
demonstrated that MUC1-specific CD8+ T cells could be generated from a 
variety of tumour settings (104-106). This, in conjunction with evidence that 
MUC1 could be found in the systemic circulation (107-109) suggests that this 
could be an antigen of interest in attempting to generate an immune response 
against ovarian tumours. 
From the previous work in this thesis and the evidence described above, it 
became obvious that restricting the migration of Treg to the ovarian tumour 
microenvironment, as seen in Chapter 4, would be not be sufficient to induce 
an anti-tumour immune response. Therefore, a more complex, multi-faceted 
treatment modality would need to be implemented which would account for 
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the potentiation of anti-tumour immune responses. To achieve this, the use of 
the classical chemotherapeutic, the topoisomerase I inhibitor, Camptothecin, 
and an immune stimulatory adjuvant, the TLR7 agonist Imiquimod would be 
used as an additional two-step procedure. First, Camptothecin would cause a 
significant degree of tumour cell death, leading to the release of the antigen, 
MUC1. This would be followed by the use of Imiquimod which would be used 
to stimulate dendritic cells to endocytose and cross-present antigen as well 
increase CD8+ T cell proliferation while reducing the suppressive effects of 
Treg (see Chapter 6). 
However, for this strategy to be successful, the lymphopaenic effect of 
Camptothecin therapy would need to be accounted for. Despite the evidence 
above regarding the unheralded ability for chemotherapeutic agents to 
eliminate Treg and potentiate CD8+ T cell activity, there remains a question 
mark over the durability of this effect. Therefore, any approach which modified 
the potential lymphopaenia caused by Camptothecin would be advantageous 
in this setting. 
In collaboration with Dr. Johannes Magnusson and Prof. Cameron Alexander 
of the Division of Drug Delivery and Tissue Engineering, School of Pharmacy, 
University of Nottingham, Camptothecin was conjugated via disulphide bonds 
to a hydrophilic polymer, poly(ethylene glycol methacrylate), (PEGMA). The 
hydrophobic nature of the drug, in combination with the hydrophilic polymer 
meant that on contact with water, the polymer-drug conjugate self-assembled 
to form a micelle with drug encapsulated within the structure. This self-
assembling phenomena was taken advantage of with the addition of a 
leuteinzing-hormone like peptide, conjugated to the polymer which was 
presented on the surface on micellisation of the construct (Figure 5.2). 
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Leuteinizing hormone releasing hormone receptors (LHRHR) are over-
expressed in ovarian cancer compared to other tissues (110,111), thus the 
application of a ligand to the drug-polymer construct provided a degree of 
tumour localisation, which as described earlier, is of clinical benefit in the 
ovarian setting (14). The utilisation of disulphide bonds to conjugate the drug 
to the polymer also means that on internalisation of the construct into the cell, 
the drug would be released, under the reductive conditions of the endosome.   
This chapter aims to demonstrate, in vitro, that treating ovarian cancer cells 
with Camptothecin yields the tumour associated antigen MUC1. However, it 
can also be shown the Camptothecin causes significant lymphodepletion 
which reduces the number of CD8+ T cells, key mediators in anti-tumour 
immunity. Using the novel delivery system described above, the encapsulated 
drug should yield a reduced adverse immune effect profile while 
demonstrating preferentially toxicity for ovarian cancer cells and release of 
MUC1 antigen. 
 
5.1.8 Experimental Objectives described in Chapter 5 
x Modification of Camptothecin to target ovarian tissue 
x Demonstration of cytotoxicity of modified versus native drug  
x Demonstration of MUC1 antigen release on ovarian cancer cell death 
x Investigation  of the potential for immune toxicity with cytotoxics 
x Determination of cytotoxics to alter CD8+ T cell and Treg fractions in 
PBMC 
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Figure 5.2 ± Development of JPM137.  Camptothecin was conjugated to the polymer poly(ethylene glycol) methyl ether methacrylate via disulphide 
bonds. The leuteinizing hormone-releasing hormone (LHRH) was grafted onto the construct. On solubilisation in water, JPM137 self assembles, creating 
polymeric micelles which have a Camptothecin core, thus enhancing drug solubility. 
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5.2 Methodology 
5.2.1 LHRHR Detection  
To detect the expression of LHRHR on the cell surface of IGROV-1, A2780, 
CACO-2 and CALU-3, indirect immunofluorescence staining was performed. 
Cells were incubated with Rabbit Polyclonal LHRHR (Abcam) (500 ng/mL) or 
a Rabbit polyclonal IgG isotype control (Sigma) (500 ng/mL) for 20 minutes. 
After washing, cells were incubated with a goat anti-rabbit-FITC IgG (Sigma) 
for 30 minutes in the dark. The cells were washed again and re-suspended in 
for analysis via flow cytometry. 
5.2.2 Cytotoxicity Assay 
The cell lines A2780, IGROV-1, CALU-3 and CACO-2 were seeded on 96-
well plates at 1 x 104/well. Cells were then treated with a concentration range 
(0 ± 100 µM) of Camptothecin or JPM137, with JPM135 used a non-targeting 
control (i.e. no LHRH peptide present). The equivalent amounts of DMSO or 
PBS were used as vehicle controls.  Treatment durations were 24, 48 or 72 
hours.   After treatment of cells 10 µl of 5 mg/mL MTT solution (Sigma) was 
added to each well. The plates were incubated for 4 hours at 37 °C and 
formazan crystals were dissolved by the addition of isopropanol. Absorbance 
was measured at 570 nm. The percentage of cell viability was calculated 
using untreated cells as a maximal proliferation and repeatedly freeze-thawed 
cells as minimal proliferation. 
5.2.3 Competitive Inhibition of JPM137 by LHRH 
Cells were seeded as described above. A2780 and IGROV-1 cells were 
incubated simultaneously with 10 µM LHRH peptide (GenScript) and a 
concentration range of JPM137 (equivalent to 0 ± 100 µM Camptothecin). 
Assays ran for 24, 48 and 72 hours. Cell viability was measured by MTT 
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assay as described above  percentage of cell viability was calculated using 
untreated cells as a maximal proliferation and repeatedly freeze-thawed cells 
as minimal proliferation. 
5.2.4 ELISA 
Antigen release was measured by ELISA. The antigens of interest were 
MUC1 and CA-125. Polystyrene 96-well plates (MaxSorp, Nunc) were coated 
with the relevant capture antibody (MUC1; Clone - #ME97, Abcam,  CA-125; 
Clone - #57226, Fitzgerald) overnight.  The plate was then blocked with 5 % 
w/v skimmed milk powder in PBS (pH 7.2) + 0.05 % v/v Tween (PBS/Tween) 
to prevent non-specific binding. The plate was washed in PBS/Tween using 
an automated plate washer and tapped dry. The relevant purified antigen 
(Obtained from Fitzgerald) and samples were added to the plate.  After 2 
hours, the plate was washed in PBS/Tween before the appropriate 
horseradish-peroxidase detection antibody (MUC1; Clone - #M3A106, 
Abcam,  CA-125; Clone - #M77161, Fitzgerald) was diluted in PBS, 1 % w/v 
BSA, and 0.1 % v/v Tween 20 and incubated for a further 2 hours. After 
incubation at room temperature, the plate was washed and bound 
horseradish peroxidase was visualised with 0.1 mg/ml tetramethylbenzidine 
(Sigma) and 2 ul of 30 % v/v hydrogen peroxide (Sigma) diluted in 3 M 
sodium acetate buffer (Sigma). The colour reaction was stopped with the 
addition of 2 M sulphuric acid (Sigma), and absorbance was measured at 450 
nm using a MRX spectrophotometer (Dynex Technologies). The 
concentrations of samples were calculated from standard curves of each 
recombinant cytokine. ELISA detection limits were determined as follows 
(MUC1 - 2 IU/ml, CA-125 ± 4 IU/ml). 
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5.2.5 PBMC Toxicity Assay 
Peripheral blood was obtained from healthy donors in accordance with local 
ethical committee approval (EC# BT/04/2005).  Peripheral blood mononuclear 
cells (PBMC) were separated via a density-gradient centrifugation over 
Histopaque-1077 (Sigma) twice as before, firstly to isolate PBMCs with the 
second density gradient used for the removal of platelets.  The resultant cells 
were then washed in isolation buffer containing phosphate buffered saline 
(PBS) + 1 % w/v bovine serum albumin (BSA) (Sigma) + 1 mM EDTA (Sigma) 
before viability counting via Trypan Blue exclusion (Fluka). 1 x 105/well PBMC 
cells were stimulated with 10 µg/ml PHA (Sigma).  The final volume was 
adjusted to 200 µl using cell media. After 72 hours, 100 µl of cell supernatant 
was taken and stored at ± Û&&HOOVZHUH WKHQHLWKHUVWDLQHGIRUYLDELOLW\
using Propidium Iodide (Sigma) or pulsed with 1 µCi of [3H]-labelled thymidine 
per well (TRA120, Amersham).  The plate was left to incubate for a further 18 
hours before being harvested onto a microscintillation plate (Perkin-Elmer).  
After repeated washes with de-ionised water, the plate was allowed to dry for 
an hour.  20 µl of scintillation fluid (Microscint 0, Perkin-Elmer) was added per 
well before the plate was covered with optical tape (Perkin Elmer).  Thymidine 
incorporation was quantified using a Packard TopCount NXT Microplate 
Scintillation counter. 
5.2.6 PI Live/Dead Sorting 
Treated PBMC were washed in PBS + 0.1 % w/v BSA before being incubated 
with 2 µg/ml Propidium Iodide for 5 minutes. Cells were then washed and 
sorted by the MoFlo flow cytometer. Cells that were negative for Propidium 
Iodide were sorted into tubes for Treg and CD8 staining.  
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5.2.7 Flow Cytometry Analysis 
Cells were stained with cell surface markers CD4-ECD (1.25 µl) (clone 
SFCI12T4D11 - Beckman Coulter), 2.5 µl CD8-FITC (Clone HIT8a ± 
BioLegend) CD25-PE (7.5 µl) (Clone BC96 - BioLegend), CCR4-PerCP/Cy5.5 
(2.5 µl) (Clone TG6 - BioLegend).  Cells were incubated with flourochrome-
conjugated antibodies for 15 minutes before fixation with 3 % v/v 
formaldehyde (Sigma).  Cells were then permabilised using FOXP3 Perm 
Buffer (BioLegend) before incubation with FOXP3-AlexaFluor488 (Clone 
259D ± BioLegend) for 30 min.  Cells were then resuspended in FACS wash 
buffer (BioLegend) and read via a Beckman Coulter FC 500 flow cytometer. 
Analysis involved gating on lymphocyte populations from forward/side-scatter 
plots before selecting regions of interest. 
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5.3 Results and Discussion 
5.3.1 Expression of LHRHR 
LHRHRs are overexpressed in several types of human cancer cells including 
ovarian, breast, and prostate cancers (112-116). Figure 5.3 demonstrates the 
expression profile of LHRHR on ovarian (A2780 and IGROV-1), lung (CALU-
3) and colon (CACO-2) cancer cell lines. These cell lines were used as they 
were readily available. The expression of LHRHR is evident on A2780, 
IGROV-1 and CALU-3 with no detectable expression seen with CACO-2. The 
expression seen on these cells correlates with existing evidence in both 
ovarian (115) and lung (117).  However, LHRHR is expressed at significantly 
higher levels compared to other organ groups (116). This differential 
expression allows for the use of the LHRH peptide and LHRHR as a targeting 
moiety and target, respectively, to direct Camptothecin specifically to cancer 
cells. These results demonstrate that the choice of LHRH peptide as a 
targeting moiety permitted the selective targeting of the tumour and, 
therefore, prevent damage to normal tissues.  
5.3.2 Cytotoxicity of JPM137 
Once expression of LHRHR had been confirmed it was important to assess 
the cytotoxicity of the Camptothecin/PEGMA/LHRH construct (JPM137) 
against a variety of cell lines in order to ascertain whether this type of delivery 
system would be useful as part of the treatment stratagem suggested in this 
thesis.  
Figures 5.4, 5.5, 5.6 and 5.7 illustrate the cytotoxicity of Camptothecin, 
JPM137 and JPM135 (Camptothecin/PEGMA) against the cell lines A2780, 
CACO-2, CALU-3 and IGROV-1 respectively. These cell lines provide 
different tissue types which allow for a more accurate assessment of site-
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specific targeting.   The first observation that can be made is that in those cell 
lines that express LHRHR (A2780, CALU-3 and IGROV-1) the IC50 values of 
JPM137 decreased over time. However, treatment of CACO-2 demonstrated 
an inverse trend with an increase in the IC50. 
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Figure 5.3 ± Expression of LHRHR on Different Cell Lines. LHRHR expression measured by flow cytometry. Black represents unstained cells. Red 
represents Rabbit polyclonal IgG with a goat anti-rabbit IgG-FITC as isotype control. Blue represents Rabbit polyclonal LHRHR Rabbit polyclonal IgG with a 
goat anti-rabbit IgG-FITC IgG. Figure represents one experiment of three. 
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This suggests that JPM137 demonstrates greater selectivity for cells which 
express LHRHR (e.g. A2780 vs. CACO-2 (72 hours) ± Figure 5.4C vs. Figure 
5.5C; IC50 (M) 8.18 x 10-8 vs 6.78 x 10-4, n = 3; p < 0.05). Confirmation of this 
observation comes from comparing JPM135 (Camptothecin/PEGMA) with 
JPM137 (Camptothecin/PEGMA/LHRH). The lack of targeting ligand reduces 
the efficacy of the construct (IGROV-1 (72 hours) ± Figure 5.7C, JPM135 vs. 
JPM137; IC50 (M) 9.40 x 10-8 vs. 1.24 x 10-8, n = 3; p < 0.05).  There is also a 
notable difference in cytotoxicity between those cells that express LHRHR at 
different levels.  As mentioned previously, A2780 ovarian cells express 
LHRHR at a significantly higher degree compared to CALU-3 (112,116). This 
difference in expression is highlighted in the IC50 of JPM137 (A2780 vs. 
IGROV-1 vs. CALU-3 (72 hours), Figure 5.4C vs. Figure 5.7C vs. Figure 
5.6C; IC50 (M) (8.18 x 10-8 vs. 1.24 x 10-8 vs. 6.78 x 10-4, n = 3; p < 0.05). The 
change in potency adds further evidence to the suggestion that JPM137 is 
site-specific.         
Interestingly, the potency of Camptothecin decreases over time (e.g. A2780, 
Figure 5.4; 24 hours vs. 72 hours; IC50 (M) 7.21 x 10-9 vs. 5.69 x 10-8, n = 3; p 
< 0.05). This decrease in potency could be attributed to the ease with which 
Camptothecin can hydrolyse, becoming a sodium salt which displays up to 90 
% reduction in activity compared to the parent drug (118).   
By focusing on the ovarian cell lines only (Figures 5.4 and 5.7), it becomes 
clear that JPM137 acts in a controlled release manner. The IC50 of JPM137 
decreases over time (A2780 ± Figure 5.4; 24 vs. 48 vs. 72; IC50 (M) (8.49 x 
10-7 vs. 1.01 x 10-7 vs. 8.18 x 10-8, n = 3; p < 0.05). Ideally, a longer time 
course would be run to observe whether this effect continued, however the 
effects of cell death through cell media depletion would make it harder to 
215 
 
assess such a phenomena accurately.  The likely rationale for such an effect 
could be attributed to a two causes. The first is the degree to which LHRH is 
presented on JPM137. The results suggest that binding and internalisation of 
the construct does not occur as often, or as quickly, as first hoped. However, 
characterisation of JPM137 shows that more than 50 % of the micelle surface 
is LHRH. Higher percentages of ligand presentation could lead to steric 
hinderance and therefore decreased efficacy, although this needs to be 
LQYHVWLJDWHG7KHVHFRQGUHDVRQ LVWKHGHYHORSPHQWRI µUHGXFLQJFRQGLWLRQV¶
within the culture environment inducing release of drug. It is generally 
considered that the extracellular environment is an oxidising milieu whereas 
the intracellular environment is a reducing milieu (119). However, as cells 
proliferate there is cysteine uptake, leading to increase glutathione synthesis, 
export and finally, degradation to cystenine outside the cell. T cells are key 
contributors to this effect (120). The increased concentrations of cysteine and 
glutathione reduce the oxidising potential of the extracellular fluid leading to 
the development of reducing conditions.  
As mentioned above, drug release occurs under reducing conditions. Thus, 
as cell proliferation occurs and the culture media is utilised, it is possible that 
the media became a more reductive environment which implies that 
extracellular drug release could occur over time. However, data below in 
Figure 5.8 indicates that this second reason is less likely. Nonetheless, it is 
important to account for such a phenomena as this could lead to a secondary 
complication in the generation of Camptothecin resistant cells. Metronomic 
treatment of tumours is known to confer cellular resistance (121), therefore a 
slow and steady extracellular release of drug could lead to resistance 
developing. A repetitive dose regimen would be needed to determine whether 
this would be possible.   
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Crucially, JPM137 does not demonstrate superior potency compared to 
Camptothecin over time (Figure 5.4; A2780 (72 hours) ± Figure 5.2C, CPT vs. 
JPM137; IC50 (M) 5.69 x 10-8 vs. 8.18 x 10-8, n = 3; p > 0.05;  Figure 5.7; 
IGROV-1 (72 hours) ± Figure 5.5C, CPT vs. JPM137; IC50 (M) 1.02 x 10-8 vs. 
1.24 x 10-8, n = 3; p > 0.05).  The performance of JPM137 is comparable to 
Camptothecin and could be improved upon by increasing the prescence of 
LHRH on the construct, thus increasing the opportunity for LHRHR binding 
and internalisation.    
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Figure 5.4 ± Cytotoxicity of Compounds against A2780 Ovarian Cancer Cell 
Line. Cytotoxicity of JPM135 (green), JPM137 (red) and Camptothecin (blue) at A ± 
24 hours, B ± 48 hours and C ± 72 hours. IC50 values are also presented. Figure 
represents the mean of three independent experiments. Error bars represent 
standard deviation. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. 
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Figure 5.5 ± Cytotoxicity of Compounds against CACO2 Colon Cancer Cell 
Line. Cytotoxicity of JPM135 (green), JPM137 (red) and Camptothecin (blue) at A ± 
24 hours, B ± 48 hours and C ± 72 hours. IC50 values are also presented. Figure 
represents the mean of three independent experiments. Error bars represent 
standard deviation. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. 
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Figure 5.6 ± Cytotoxicity of Compounds against CALU-3 Lung Cancer Cell Line. 
Cytotoxicity of JPM135 (green), JPM137 (red) and Camptothecin (blue) at A ± 24 
hours, B ± 48 hours and C ± 72 hours. IC50 values are also presented. Figure 
represents the mean of three independent experiments. Error bars represent 
standard deviation. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. 
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Figure 5.7 ± Cytotoxicity of Compounds against IGROV-1 Ovarian Cancer Cell 
Line. Cytotoxicity of JPM135 (green), JPM137 (red) and Camptothecin (blue) at A ± 
24 hours, B ± 48 hours and C ± 72 hours. IC50 values are also presented. Figure 
represents the mean of three independent experiments. Error bars represent 
standard deviation. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. 
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5.3.3 Competitive Binding Assay 
In order to further substantiate the claim that JPM137 does bind to LHRHR on 
ovarian cancer cells, A2780 cells were treated with a combination of 10 µM 
LHRH and a concentration range (0 ± 100 µM) of JPM137 before measuring 
cytotoxicity over a period of time. The most accurate method for assessing 
the competitive binding of ligands to a receptor would be through using a 
radiolabelled ligand. This would allow quantitative analysis of the radio-ligand 
binding to the receptor (122,123). However, due to cost restrictions an 
alternative assay needed to be sought. Early work by Dharap and Minko used 
cell cytotoxicity as a way to measure whether their peptide-mediated 
construct would compete with for its target receptor (113). Given the access 
to such an assay, cell cytotoxicity was used as the end point in this set of 
experiments.  
Figure 5.8 illustrates the effect LHRH treatment has on inhibiting the 
cytotoxicity of JPM137. At 24, 48 and 72 hours, LHRH treatment significantly 
restricts JPM137-mediated cytotoxicity (24 hours ± Figure 5.8A, JPM137 + 
LHRH vs. JPM137; IC50 (M) 6.38 x 10-5  vs. 8.36 x 10-7, n = 3; p < 0.05; 48 
hours ± Figure 5.8B, JPM137 + LHRH vs. JPM137; IC50 (M) 1.21 x 10-5  vs. 
1.21 x 10-7, n = 3; p < 0.05; 72 hours ± Figure 5.8C, JPM137 + LHRH vs. 
JPM137; IC50 (M) 0.71 x 10-5  vs. 8.3 x 10-8, n = 3; p < 0.05).  
As expected JPM137 failed to outcompete 10 µM LHRH. This is an 
exceptionally high concentration of ligand used compared to competitive 
assays of a similar nature (124). The rationale for this high concentration was 
to demonstrate that LHRHR antagonism led to decreased cytotoxic activity. It 
also demonstrated that the cytotoxic effect of JPM137 is primarily mediated 
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by receptor internalisation, rather than via a controllHGUHOHDVHµOHHFKLQJ¶LQWR
the extracellular environment as discussed above.  
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Figure 5.8 ± Competitive Inhibition of JPM137 Activity using LHRH. Cytotoxicity 
of JPM137 (red) was compared to JPM137 incubated with 10 µM LHRH (blue) at A ± 
24 hours, B ± 48 hours and C ± 72 hours. IC50 values are also presented. Figure 
represents the mean of three independent experiments. Error bars represent 
standard deviation. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. 
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5.3.4 Release of Tumour-associated Antigen MUC1 
In order for the treatment strategy proposed in this thesis to be successful, 
chemotherapy-induced cell death needs to be followed by subsequent 
tumour-associated antigen release. Much has been made of the potential for 
chemotherapy to induce immunogenic-cell death (1,125-127) and thus it is 
important to determine whether treatment of ovarian cancer cell lines with 
Camptothecin, and more crucially JPM137, leads to an increase in tumour-
associated antigen.   
As previously mentioned, this thesis will focus on the generation of anti-MUC1 
immune responses. To achieve this, MUC1 needs to be released into the 
extracellular milieu where it will either be processed by antigen presenting 
cells such as dendritic cells and macrophages or be recognised by MUC1 
specific T cells embedded in the tumour stroma (31,128). The supernatant of 
A2780 and IGROV-1 cells, after treatment with a concentration range (0 ± 
100 µM) of Camptothecin or JPM137 for 72 hours, was analysed for MUC1 
and CA-125. CA-125 is a tumour marker widely used to diagnose, monitor, 
and follow-up women with epithelial ovarian cancer (129). A2780 is a CA-125-
negative cell line (130) but both have been shown to both express MUC1 
(131).  
Figure 5.9 illustrates the release of MUC1 in both A2780 and IGROV-1 as the 
concentration of drug increases (0.01 ± 100 µM, n = 3; p < 0.05). Correlating 
the cell death observed in Figure 5.4C (A2780) and Figure 5.7C (IGROV-1)  
with the data in Figure 5.7 indicates that increased cytotoxicity leads to an 
increase in MUC-1 release (A2780, Spearmans Rank Co-HIILFLHQWȡ - 0.93, 
p < 0.05, IGROV-1, Spearmans Rank Co-HIILFLHQWȡ - 0.94, p < 0.05). This 
suggests that treatment of tumours with chemotherapy leads to a significant 
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release in MUC1. The extra, available antigen means that there is an 
increased prospect of inducing a MUC1-specific anti-tumour immune 
response through the mechanisms mentioned above. 
Figure 5.10 indicates the release of the tumour marker CA-125 from treated 
cells. IGROV-1 shows an increase in CA-125 release (0 ± 100 µM, n = 3; p < 
0.05). Although clinically, an increase in CA-125 is considered as a marker for 
progressive disease (129), there is evidence of a sharp increase of CA-125 
on initial treatment with chemotherapy (132). The data in Figure 5.8 mimics 
this increase and thus can be considered as an indicator of tumour cell death.    
Interestingly in both Figures 5.9 and 5.10, there is a significant increase in the 
amount of antigen released when cells were treated with dimethyl sulphoxide 
(DMSO) as a vehicle control. When correlated with the cytotoxicity data, there 
is a dose-dependent increase in antigen release with DMSO (Spearmans 
Rank Co-HIILFLHQWȡ - 0.98, p < 0.05). The high percentage of DMSO (10 % 
v/v) is required due to the poor solubility of Camptothecin (133) in aqueous 
solutions and could thus be a contributing factor to the cytotoxic effect of 
Camptothecin (134). In comparison, JPM137 is soluble in phosphate buffered 
saline and as such demonstrates a far greater solubility profile.  
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Figure 5.9 ± Detection of MUC1 from Ovarian Cancer Cell Lines on Cytotoxic 
Treatment. Detection of antigen via ELISA from A- A2780 and B- IGROV1. Cells 
treated with Camptothecin (blue), JPM137 (green), and DMSO (red) as a vehicle 
control (blue) 72 hours. Figure representative of three independent experiments. 
Error bars represent standard deviation. *=p<0.05, n = 3. Detection limit = 2 IU/ml. 
Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. 
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Figure 5.10 ± Detection of CA-125 from Ovarian Cancer Cell Lines on Cytotoxic 
Treatment. Detection of antigen via ELISA from A- A2780 and B - IGROV1. Cells 
treated with Camptothecin (blue), JPM137 (green), and DMSO (red) as a vehicle 
control (blue) 72 hours. Figure representative of three independent experiments. 
Error bars represent standard deviation. *=p<0.05, n = 3. Detection limit = 4 IU/ml. 
Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. 
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5.3.5 Effect of Cytotoxics on Immune Cells 
With the increase in free MUC1, it is critical to have a fully functional immune 
system to process, present and proliferate and thus induce a response 
against the antigen. However, the lymphopaenia associated with several 
F\WRWR[LF DJHQWV LQFOXGLQJ &DPSWRWKHFLQ FRXOG UHQGHU WKLV µOLEHUDWLRQ¶ RI
antigen inappropriate. As mentioned previously, cytotoxic agents can 
conceivably alter the T cell pool in either an anti-tumour or pro-tumour 
manner. In order to assess the effect of Camptothecin and JPM137 on the 
immune population, PBMC were divided into stimulated and non-stimulated 
groups (stimulation with the T cell mitogen, PHA) and treated with JPM137 or 
Camptothecin over a concentration range (0 ± 100 µM) for 72 hours. The 
duration of this assay was selected as at this time point the IC50 of both 
JPM137 and Camptothecin were similar in ovarian cell cultures (Figure 5.4 
and Figure 5.7). The proliferation of these cells was then measured.  
Figure 5.11 highlights the change in proliferation seen on addition of each 
compound. From Figure 5.11A it is clear that Camptothecin almost completely 
abrogated stimulated PBMC proliferation (0.01 ± 100 µM, n = 3; p < 0.05). In 
comparison, JPM137 demonstrated a dose-dependent effect with doses of 1 
µM and higher causing a significant decrease in cell proliferation (1 ± 100 µM,  
n = 3; p < 0.05). In Figure 5.11B, a similar trend follows, whereby 
Camptothecin shows a reduction in cell proliferation, albeit to a lesser extent 
compared to when incubated with stimulated cells (Camptothecin 
stimulated - Figure 5.11A vs. non-stimulated ± Figure 5.11B (% cell 
proliferation) 0.01/0.1/1/10/100   ± 0.20 vs. 74.53, 0.37 vs. 79.73, 1.63 vs. 
86.10, 2.64 vs. 91.2, 4.90 vs. 96.67, n = 3; p < 0.05).   The marked reduction 
in proliferation is due the selectivity of Camptothecin to proliferating cells 
(135). T cell proliferation has also been documented to generate a reductive 
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environment (120) which could induce the release of Camptothecin from 
JPM137 thus explaining the effect it has on PBMC proliferation.    
To quantify these observations further, cytotoxic-treated PBMC were stained 
with Propidium Iodide to identify those cells that had died. Live cells were 
collected and then phenotyped for CD8+ T cell and Treg populations. Figure 
5.12 illustrates the percentage of PBMC that had died after treatment. There 
was a significant difference in the percentage of cells that died, in both 
stimulated and non-stimulated groups, when treated with Camptothecin in 
comparison to JPM137  (Non-stimulated - Figure 5.12B, Camptothecin vs. 
JPM137 (% dead cells)  0.01/0.1/1/10/100   ± 20.94  vs. 15.53, 25.09 vs. 
17.47, 41.91 vs. 15.83, 67.59 vs. 12.54, 81.01 vs. 50.67, n = 3; p < 0.05), 
(Stimulated - Figure 5.12C, Camptothecin vs. JPM137 (% dead cells)  
0.01/0.1/1/10/100   ± 84.95  vs. 15.53, 88.36 vs. 16.30, 94.10 vs. 56.90, 93.75 
vs. 80.01, 84.70 vs. 93.96, n = 3; p < 0.05).   
The high percentage of cell death seen in both treatment groups correlates 
with the inhibition in proliferation seen in Figure 5.11. This, together with the 
proliferation data, is a critical result as it indicates that Camptothecin impairs 
PBMC competency through immune cell death. This effect would be seen 
peripherally as well as at the tumour microenvironment level and is a major 
contributing factor to the adverse effects seen when using these drugs.   
Many pieces of literature describe how chemotherapy-induced 
lymphodepletion is of benefit in cancer due to the phenomena of proliferating 
cells during immune re-capitulation (1,25,28,136). However, it could be 
argued that as long as tumour cells exist they are capable of inducing several 
immune suppressive mechanisms as described previously. This could give 
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rise to a tolerogenic environment which leads to tumour progression and 
subsequent disease relapse. 
A key factor in the recapitulation of the immune system is the phenotype of 
those cells which remain after cytotoxic treatment. In order to assess this, 
those cells that were Propidium Iodide-negative were collected and stained 
for CD3+CD8+ T cells and Treg. Figure 5.13 depicts the proportion of these T 
cell subsets within the remaining viable PBMC population. The first 
observation to be made is from Figure 5.13A where the percentage of Treg 
(CD4+CD25+FOXP3+) in stimulated PBMC is very high compared to non-
stimulated cells (% Treg, Figure 5.13A, stimulated vs. non-stimulated, 0.01 
µM Camptothecin (%)  40 vs. 4, n = 3; p < 0.05).  This can be attributed to the 
markers used to phenotype Treg.  
As mentioned in Chapter 3, FOXP3 is not an accurate marker for Treg in 
human and can be transiently expressed in non-suppressive cells, especially 
upon stimulation (137-139). Therefore, it becomes difficult to accurately 
phenotype Treg in proliferating PBMC. CD8+ T cells are easily phenotyped 
due to their co-expression of the T cell specific marker CD3. In Figure 5.13C, 
the proportion of CD8+ T cells is significantly decreased in stimulated PBMC 
that are treated with Camptothecin (Figure 5.13C, Camptothecin 
(%CD3+CD8+) 0 vs. 0.01/0.1/1/10/100 µM ± 34.53 vs. 
36.24/11.81/6.40/6.57/2.22, n = 3; p < 0.05). Treatment with JPM137 did not 
alter the percentage of CD8+ T cells at doses below 1 µM (Figure 5.13C, 
JPM137 (%CD3+CD8+) 0 vs. 0.01/0.1/1/10/100 µM ± 34.86 vs. 
36.24/36.24/36.14/34.53/7.17/0.80, n = 3; p < 0.05).  
Non-stimulated PBMC yielded two key observations. Firstly, low doses of 
Camptothecin and JPM137 caused a statistically significant reduction in the 
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fraction of Treg within the viable PBMC population (Figure 5.13B, 
Camptothecin (% Treg) 0 vs. 0.01/0.1/1/10/100 µM ± 4.14 vs. 
3.64/1.64/0.87/2.79/4.02, n = 3; p < 0.05), (Figure 5.13B, JPM137 (%Treg) 0 
vs. 0.01/0.1/1/10/100 µM ± 4.05 vs. 4.12/3.74/3.15/3.65/4.27, n = 3; p < 0.05). 
This effect is well documented (53,140-143) and highlights the link between 
chemo- and immunotherapy. The Treg-depleting effect of JPM137 could be 
DWWULEXWHG WR WKH µOHHFKLQJ¶ RI &DPSWRWKHFLQ DV GHVFULEHG HDUOLHU LQ WKH
chapter.  The second observation is that JPM137 does not reduce the 
proportion of CD8+ T cells whereas there is a statistically significant reduction 
when treated with Camptothecin (Non-stimulated - Figure 5.13D, 
Camptothecin vs. JPM137 (%CD3+CD8+) 0.01/0.1/1/10/100 ± 31.75 vs. 
32.56, 30.07 vs. 34.11, 27.39 vs. 34.74, 26.62 vs. 35.64, 27.85 vs. 29.80, n = 
3; p < 0.05).  These results indicate that JPM137 is less toxic to immune cells. 
7KLV µLPPXQH-SURWHFWLYH¶ SURSHUW\ RI -30 PHDQV WKDW WKH SURSRUWLRQ RI
CD8+ T cells within PBMC remains intact while causing a reduction in Treg. 
This would be of benefit within the ovarian tumour microenvironment as a 
reduction in tumour burden, combined with an increase in CD8+:FOXP3+  
ratio (a prognostic indicator in malignancy (144-147)) would lead to greater 
tumour clearance.  
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Figure 5.11 ± PBMC Proliferation on Treatment with Cytotoxics. 3H-Thymidine 
incorporation used to assess the proliferation of PBMC when treated with cytotoxics. 
Cells were treated with a concentration range (0 ± 100 µM) of Camptothecin (red) or 
JPM137 (blue) with A - PBMC were stimulated with 10 µg/ml PHA or B - PBMC were 
non-stimulated. Cultures were treated for 72 hours before being pulsed with 3H-
Thymidine.   Figure representative of three independent experiments from three 
different donors. Error bars represent standard deviation. *=p<0.05, n = 3. Statistical 
significance determined by a one-way ANOVA analysis with column comparisons 
using Tukey's Multiple Comparison Test. 
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Figure 5.12 ± Percentage of Dead PBMC after Treatment with Cytotoxics. 
Propidium Iodide used to differentiate between live and dead cells. Cells were treated 
with a concentration range (0 ± 100 µM) of Camptothecin (red) or JPM137 (blue) with 
A - PBMC stimulated with 10 µg/ml PHA or B - PBMC non-stimulated. Cultures were 
treated for 72 hours before being stained with propidium iodide. Remaining viable 
cells (PI negative) were collected for phenotypic analysis.   Figure representative of 
three independent experiments from three different donors. Error bars represent 
standard deviation. *=p<0.05, n = 3. Statistical significance determined by a one-way 
ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. 
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Figure 5.13 ± Fraction of CD8+ T cells and Treg after Treatment with JPM137 or Camptothecin. Percentage populations calculated by flow cytometry. 
Cells  were treated a concentration range (0 ± 100 µM) of Camptothecin (red) or JPM137 (blue) with A ± Fraction of Treg after treatment and stimulation with 
10 µg/ml PHA. B ± Fraction of Treg after treatment without stimulation with PHA. C - Fraction of CD8+ T cells after treatment and stimulation with 10 µg/ml 
PHA. D ± Fraction of CD8+ T cells after treatment without stimulation. Cultures were treated for 72 hours before being staining for flow cytometry.  Figure 
representative of three independent experiments from the same donor. Error bars represent standard deviation. *=p<0.05, n = 3. Statistical significance 
determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. 
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5.4 Conclusions 
This chapter has sought to highlight the immunological importance of 
chemotherapy. Immune populations can be affected by treatment with 
cytotoxics and although there is a growing opinion that lymphodepletion is 
clinically beneficial it is still a controversial area.  In order to improve tumour 
targeting and thus reduce peripheral lymphodepletion, JPM137 was created. 
This novel drug delivery system, encapsulated the drug within a hydrophilic 
polymer to improve solubility and its pharmacokinetic profile. The addition of 
the Leuteinizing-hormone releasing hormone ligand (LHRH) gave the 
construct tumour specific targeting properties.   
Before the use of JPM137, several cell lines were assessed for their 
expression of LHRHR. Higher expression was noted in ovarian cell lines 
compared to lung and colon as per previous findings. The cytotoxic activity of 
JPM137 was then compared against Camptothecin in these cell lines. 
Importantly, the construct demonstrated site-specific cytotoxicity, with greater 
toxicity seen in ovarian cell lines compared to colon and lung. However, 
JPM137 had similar, rather than superior, cytotoxic activity to Camptothecin 
although this could be attributed to an inefficient level of LHRHR ligand on the 
surface of the construct.  
On cell death, there was a significant increase in the tumour-associated 
antigen MUC1. This antigen has been shown to be highly expressed in 
ovarian cancer and thus its release into the extracellular environment could 
be advantageous in attempting to generate an anti-ovarian tumour immune 
response.  Clinically, despite a cytoreduction in tumour burden and the 
increase in MUC1 availability, the lymphodepletive effect of Camptothecin  
would mean that generating a potent anti-tumour immune response would be 
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difficult.  This was highlighted by the significant lack in PBMC proliferation but 
also in terms of a reduction in CD8+ T cells. Interestingly, and in concordance 
with current literature, low doses of Camptothecin reduced the number of 
Treg from PBMC. JPM137, however, demonstrated a reduction in these 
effects with improved PBMC proliferation, cell viability and maintenance of the 
CD8+ T cell population whilst also causing a reduction in Treg.  
The data above indicates that JPM137 could localise at ovarian tumour sites, 
retain similar cytotoxic performance compared to Camptothecin while 
maintaining a more viable immune cell population. Critically, JPM137 would 
have an effect at the tumour site, depleting Treg while maintaining CD8+ T 
cells whereas Camptothecin would cause peripheral, as well as localised 
immune suppression which would not be as advantageous or clinically 
beneficial.  
The release of the tumour associated antigen MUC1 means that there is a 
significant opportunity to induce an antigen specific anti-tumour immune 
response. The final experimental chapter, Chapter 6, attempts to take 
advantage of this antigen release by potentiating an immune response 
through the use of toll-like receptors.   
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Chapter 6 
Enhancement of immune responses 
against tumour-associated antigens 
6.1 Introduction 
As discussed previously a fundamental tenet of tumour immunology is 
that cancer cells express antigens that differentiate them from their non-
transformed counterparts. However, it is the inability of the immune 
system to detect, process, present and use these antigens as a means 
to illicit an anti-tumour immune response. In order to improve tumour 
antigen presentation, it is important to understand why there is a failure 
to generate a significant population of antigen specific cytotoxic T cells.  
 
6.1.1 Issues with Adequate Antigen Presentation 
Models of infection have provided useful information about the process of 
antigen-specific T cell generation. Recent studies indicate that antigens are 
presented in the draining lymph nodes a few hours after the subcutaneous 
injection of a pathogen (1,2). The activation of naive CD8+ T cells is a 
relatively rapid process, with as little as 2.5 hours of antigen exposure 
required to induce clonal expansion and differentiation of CD8+ T cells in vitro 
(3,4). Further work by Wong et al. (5) has suggested that 24 hours of 
pathogen presence is sufficient for the induction of protective CD8+ T-cell 
responses in vivo, albeit in mice. 
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Therefore it can be said that CD8+ T cell priming takes place at a very early 
stage of infection ² the acute infection phase. This rapid process seems to 
be crucial for effective expansion of antigen-specific T-cells, followed by the 
development of a memory T cell population.  However, the same cannot be 
said of T cell priming in the context of TAA-specific T cell immunity. The 
development of tumours is fundamentally a slow process that, like chronic 
infection, might occur over several years. An acute infection may effectively 
activate the immune system at multiple levels. E.g. acute infection might be 
crucial for systemic antigen distribution and efficient induction of an innate 
immune response such as that from NK. It is well known that activated NK 
stimulate the maturation of DC and facilitate adaptive anti-tumour immunity 
(6).  
Immune surveillance in tumours is impacted upon due to the lack of 
detectable antigen.  It is suggested that before the development of systemic 
metastasis (including lymphoid metastasis), antigenic cancer cells 
(expressing TAA) are embedded in the solid tumour. The stroma of the 
tumour prevents the efficient release of TAA (7,8) which are ignored in the 
conventional central priming sites ² the draining lymph nodes (9,10). 
In the later stages of tumour development, TAA are thought to be efficiently 
released, which induces the protective immune system to mount an effective 
response (11,12). However, with tumour growth comes the development of 
tolerising mechanisms within the microenvironment, which limit the normal 
functions of APCs and effector T cells. These mechanisms include down-
regulation of MHC expression (13,14), dysregulation of antigen processing 
machinery (15,16), secretion of immunosuppressive paracrine and endocrine 
factors such as transforming growth factor-ȕ7*)-ȕ(17), interleukin-10 (IL-
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10) (18), prostaglandin E2 (PGE2) (19) and tumour expression of inhibitory 
receptors such as B7H1 (20), B7DC (21) and CTLA-4 (22). 
To support this notion, studies have shown that CD8+ T cell responses to 
common melanoma epitopes are generally weak, localised, and occur mostly 
in patients with advanced metastatic disease (11,12). This suggests that the 
quality of the tumour immune response is not only due to efficient T cell 
priming but also due to the kinetics and temporal release of tumour 
associated antigen. Chapter 5 has demonstrated that increased tumour cell 
death using  chemotherapeutics, like Camptothecin, can facilitate the release 
of antigen and thus should improve the possibility for effective antigen 
presentation occurring.   
In addition to peripheral TAA priming, antigen presentation within the tumour 
microenvironment may also occur to some degree. Indeed, intra-tumoural 
TAA specific priming has been reported (23,24). However, there is a 
FRQVHQVXVWKDWWKH WXPRXU LVD µIDOVH¶ O\PSKRLGRUJDQDQG7FHOOSULPLQJ LQ
the tumour microenvironment has at least two basic defects.  Firstly, intra-
tumoural antigen presenting cells are either dysfunctional or induce T cell 
tolerance. Secondly, the infrastructure of tumours is different from that of 
lymph nodes. Tumour tissues show increased interstitial fluid pressure and 
contain defective blood vessels. There is fibrosis and contraction of the 
interstitial matrix. Many tumours lack lymph vessels. These structural and 
haemodynamic defects would potentially contribute to poor or dysfunctional T 
cell priming within the tumour microenvironment. This would lend credence to 
the argument discussed in Chapter 5 regarding the targeting of tumours to 
reduce the potential immune suppressive effect exerted by a tumour mass.  
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6.1.2 Antigen Presenting Cells  
APCs include DC, monocytes/macrophages and B lymphocytes. DC are a 
heterogeneous group of APCs that display differences in anatomic 
localisation, cell-surface phenotype, and function (25,26). Human DC are 
traditionally divided into two main populations: Myeloid (mDC) and 
Plasmacytoid (pDC) (25,27,28). 
Vermi et al. (29) were one of the first to identify immature mDC and pDC 
LQ¿OWUDWLQJVROLGWXPRXUVS'&VLQSDUWLFXODUDSSHDUWRODFNWKHDELOLW\WRSULPH
and induce tumour antigen specific cytotoxic T cells (29). Interestingly, they 
still present tumour antigens and induce IL-10-producing CD4+CD25+ Treg 
that contribute to the inhibition in anti-tumour immunity (30,31). Recently 
published work has added weight to their immune suppressive contribution in 
ovarian cancer (32). pDC from 44 patients were isolated and found to have 
their capacity for pro-inflammatory cytokine production reduced, as well as 
increased production of IL-10.  Nevertheless, work in mice, using an anti-IL-
10 mAb and CpG oligodeoxynucleotides, demonstrated that it is possible to 
induce a robust anti-tumour T cell response and tumour rejection in vivo 
(33,34). Functional plasmacytoid DC are found in the local tumour 
environment of patients with ovarian cancer (32,35), melanoma (36) and head 
and neck squamous-cell carcinoma (37). Tumour cells produce the 
chemokine ligand CXCL12 and plasmacytoid DC express CXCR4, the 
receptor for CXCL12 (also expressed on Treg). Tumour-derived CXCL12 
mediates trafficking of plasmacytoid DC into the tumour (35,38).  Their use in 
this project is justified due to work by Zou et al. (35) who identified that a large 
amount of pDC, but not functional mature mDC, accumulate in the tumour 
microenvironment. 
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It has been reported that pDCs pulsed with tumour antigens in vitro can prime 
,)1Ȗ-secreting melanoma-VSHFL¿F &7/V (36). The synergy among DC 
subsets has not been fully explored in the development of anti-tumour 
immunity. An interesting study has shown that immunisations with a mixture 
of matured pDC plus mDC resulted in increased levels of antigen-VSHFL¿F
CD8+ T cells and an enhanced anti-tumour response compared with 
immunisation with either dendritic cell subset alone (39). This is possibly due 
to the type I IFN secreting, particularly IFN-ĮFDSDFLW\RIS'&(40). IFN-ĮQRW
only triggers innate immunity, such as activating NK cells, but also promotes 
adaptive Th1-type T-cell responses.  Altogether, these studies suggest that it 
is possible to re-establish and/or maximise an anti-tumour immune response 
when pDC are targeted (41,42). 
6.1.3 Antigen Presentation Capacity of pDC 
The antigen presenting ability of pDC has been widely debated in literature for 
many years. The category of antigens that pDC seem to present poorly is 
exogenous²antigens that have to be captured from the extracellular 
environment.  Recently, murine pDCs have been described to have the ability 
to elicit In vivo, in naive mice, an antigen-VSHFL¿F &'+ T cell response 
against endogenous antigens, as well as exogenous peptides, but not against 
exogenous antigens, and were capable of protecting mice from tumour 
challenge (43).  
These are the antigens that mDC present with a higher efficiency than any 
other APCs. There are three features that make mDC particularly efficient at 
exogenous antigen presentation: 1) high endocytic activity, 2) ability to retain 
on their surface long-lived MHCII-peptide complexes, and 3) the capacity to 
cross-present. Although all three characteristics are important, the role of 
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pDC in tumours hinges primarily on their endocytic activity and their ability to 
cross-present antigen. mDC can internalise extracellular material by 
macropinocytosis, phagocytosis, and receptor-mediated endocytosis, the 
latter two facilitated by the expression of multiple types of receptors  (44). 
7KLVPDNHVP'&V µµPXOWL-SXUSRVH¶¶$3&VFDSDEOHRIcapturing virtually any 
extracellular material (e.g., soluble proteins, glycosylated compounds, 
immunocomplexes, artificial particles, cells, bacteria, nucleic acids, etc). 
Overall, pDC do not appear as endocytic as mDC, but this is still a matter of 
contention. Several mouse and human studies concluded that pDC cannot 
phagocytose dead cells, or artificial particles (45-48).  
The ability of mDC to cross-present antigen is well documented (44). The 
phenomena of cross-presentation can be described by looking at the classical 
model of MHC I antigen presentation. CD8+ T cells recognise peptide-class I 
MHC complexes. These complexes are generally generated after direct 
presentation as a result of endogenous production of the antigens in the 
cytosol. Exogenous antigens are internalised by dendritic cells and generally 
presented as MHC II.  Cross-presentation is the exception to this rule 
whereby exogenous antigen is internalised and then processed and 
presented as MHC I.  This allows presentation of antigens from 
microorganisms that do not infect DC, from autologous and importantly, in the 
context of this project, from tumour cells (49). 
Whether pDC are able to cross-present is a controversial and unresolved 
matter. Several studies have shown that mouse pDC do not possess the 
capacity to cross-present (43,50) or that their capacity is negligible when 
compared to mDC (51). This is consistent with a number of reports that 
showed that cross-priming of CD8+ T cells in vivo against viruses or 
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intracellular bacteria is exerted by mDC, with no detectable involvement of 
pDC (44,52). The cross-presenting capacity of human pDC had only been 
assessed in vitro. The tumour antigen NY-ESO-1 in soluble form, associated 
to immunoglobulins or formulated with an adjuvant, was not cross-presented 
by human pDC, although there was MHC II presentation (53). In contrast, two 
studies have reported cross-presentation of lipo-peptides, cell-associated 
antigens, and viral particles by human pDC (54,55).  At present it is difficult to 
give an explanation for the contrasting results of the different mouse and 
human studies.  
Yamahira et al. (56) have a leukemic pDC line. By stimulation with LPS, this 
cell line showed enhancement in expression of antigen presentation-
associated surface molecules and production of cytokines (IL-12p70 and TNF-
Į7KHDQWLJHQSUHVHQWLQJDELOLW\ZDVDOVRPDUNHGO\ increased. Co-culture of 
CD8+ T cells with LPS-stimulated and the WT1/CMVpp65 peptide-pulsed cell 
line led to the efficient generation of WT1/CMVpp65 tetramer+ cytotoxic T 
lymphocytes (56). There has been debate as to whether pDC only cross-
present antigens captured via some specific receptors or if stimulated in a 
particular way. Interestingly, work by Mouries et al. (57) has demonstrated 
that pDC can cross-present antigen in vivo using the TLR 7 agonist 
Imiquimod as an adjuvant. They found that efficiency of antigen presentation 
was not compromised in presence of Treg, suggesting that their suppressive 
effects had been circumvented (57). This raised an interesting observation 
regarding the role of TLR agonists and their potential effects on the 
suppressive activity of Treg. 
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6.1.4 Toll-like Receptors 
TLR are a family of 11 pattern recognition receptors (PRRs) which mediate 
the recognition of many pathogens through the detection of distinct pathogen-
associated molecular patterns (PAMPs) (58). pDC and mDC each have a 
different  TLR expression profile. In humans, mDC can express TLR-1, -2, -3, 
-4,-5, -7, and -8, while pDC express mainly TLR7 and -9 (59,60). 
7UDQVFULSWLRQDO UHJXODWLRQ RI ,)1ȕ DQG ,)1Į JHQHV RQ S'&V LV FRQWUROOHG
mainly by the factors IRF-3 and IRF-5/7. IRF-3 can be activated by TLR3 and 
TLR4, but there is no evidence of this pathway on pDC. Instead, IRF-7 has a 
constitutively high expression in pDC and it is recruited by myeloid 
differentiation  primary response gene 88 (MyD88) through the adaptor 
molecule TRAF6 when TLR-7 or -9 is triggered (61).  
Many studies have shown that exposure to synthetic TLR7 (Imiquimod and R-
848 (also acts on TLR8)) or -9 (Cpg ODN) agonists induces pDC to secrete 
IFN-ĮDQGRWKHUSUR-inflammatory cytokines  such as IL-6 and TNF-ĮDVZHOO
causing pDC maturation which heighten their T cell stimulatory capacity 
(40,59,62).  
However, T-cell priming not only depends on the activation status of DC but 
also by the activity of Treg. Although the presence of TLR on mDC and pDC 
has been reported, their existence and function on T cells, and Treg in 
particular, remains a topic of debate.  
 
6.1.5 TLR Prevalence 
Caramalho et al. (63) were the first to compare the TLR expression profiles of 
murine Treg and effector T cell subsets. Both Treg and effector T cells 
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expressed TLR1, TLR2 and TLR6 in equal measure. However, Treg 
expressed significantly more TLR4, TLR5, TLR7 and TLR8 (63). This study 
also showed that LPS, acting on TLR4, induced Treg activation and 
proliferation, resulting in an increased suppressive activity. Similar 
observations were made with the triggering of TLR5 with flagellin on human 
Treg with an increase in FOXP3 expression also seen (64). These data imply 
that Treg increase their suppressive capacity following TLR4 and TLR5 
triggering.  
Interestingly, a synthetic bacterial lipoprotein, Pam3Cys-SK4, a ligand for 
TLR2, induced proliferation in effector T cells and Treg, yet abrogated the 
suppressive activity of Treg (65). In addition to this, Foxp3 expression, a key 
regulator of Treg-cell function, was decreased following TLR2 stimulation of 
the Treg cells, thus providing a further insight into the mechanism by which 
TLR2 controls Treg-cell function (65).  
It is not known exactly how the TLR triggering of Treg modulates their 
suppressive effects, and whether the triggering of different TLR occurs 
through the same pathway or has the same effect on Treg function. One 
explanation could be the upregulation or downregulation of Foxp3 expression 
following the different TLR stimulations (64,66), but how TLR-signaling affects 
Foxp3 expression is still unclear. 
A key study by, Peng et al. (67) showed that human Treg cells express high 
levels of TLR8, and that the TLR8 triggering of Treg cells also prevents their 
suppressive phenotype. The results from their co-culture suppression assay 
demonstrated that suppression is abrogated by TLR8 triggering directly on 
Treg, and not effector T cells. It seemed that the TLR8 stimulation of human 
Treg did not induce proliferation. However, recent work by Forward et al. has 
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(68) suggested that TLR7 engagement on murine Treg lead to an increase in 
the suppressive activity. TLR7 and TLR8 share similar signalling pathways, 
and as such there are suggestions that the effects of TLR engagement on 
Treg differ on a species-by-species basis.  
The most convincing clinical evidence thus far of using TLR7/TLR 8 agonists 
was a study by Huang et al.(69) who investigated the effect of Imiquimod on 
squamous cell carcinoma (SCC). SCC treated with Imiquimod prior to 
excision contained dense T cell infiltrates associated with tumour cell 
apoptosis and histologic evidence of tumour regression. Effector T cells from 
treated SCC produced more IFN-ȖJUDQ]yme and perforin and less IL-10 and 
TGF-ȕWKDQ7FHOOVIURPXQWUHDWHGWXPRXUV$NH\REVHUYDWLRQKRZHYHUZDV
that Imiquimod acted on Treg to reduce their suppressive activity. Treatment 
also led to an increased production of IL-6, which is known for rendering 
effector T cells resistant to Treg suppression (70,71).  
Tumour immune vaccination has for a long time been focused on fostering T 
cell central priming in draining lymph nodes. As peripheral TAA-specific T cell 
priming is possible, although technically challenging, it could be postulated 
that another alternative would be to restructure the tumour into a real 
IXQFWLRQDO µO\PSKRLG RUJDQ¶ DQG WR HQJLQHHU µTXDOLW\¶ SHULSKHUDO 7$$-specific 
priming (for example, T cell priming within the tumour microenvironment), 
which would overcome the potential TAA ignorance in the draining lymph 
nodes of a tumour. 
In the previous chapter of this thesis, targeted treatment of ovarian cancer 
cells with Camptothecin caused a release of MUC1 antigen while causing 
limited immune toxicity. In vivo, treatment with cytotoxics should alter the 
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structure of solid tumours, thus reducing their suppressive effect upon the 
surrounding milieu as well as providing an increase in TAA (72).   
The above evidence, suggests that using TLR7/TLR8 agonists as an 
immunotherapeutic adjuvant would be highly beneficial on several fronts. 
TLR7 engagement would not only affect Treg but also pDC as well. The 
suppressive capacity of Treg would be restricted while there would be an 
increased potential for TAA presentation (via the cross presentation 
mechanisms mentioned above), CD8+ T cell priming and a generation of a 
pro-inflammatory cytokine milieu. 
 
This final experimental chapter seeks to take advantage of the antigen 
release described previously by enhancing antigen presentation and cytotoxic 
T cell generation while reducing the suppressive effect of Treg. 
6.1.6 Experimental Objectives described in Chapter 6 
x Determination of TLR 7 expression on Treg, CD4+CD25- T cells, CD8+ T 
cells, pDC and ovarian cancer cell lines. 
x Demonstration of Imiquimod activity on Treg suppressive function. 
x Demonstration of Imiqiuimod activity on pDC maturation. 
x Determination of the effect of Imiquimod on MUC1+ Cytotoxic T cell 
generation 
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6.2 Methodology 
6.2.1 Isolation of Regulatory T cells via Magnetic Selection (Dynal) 
A maximum volume of 100 ml of peripheral blood was obtained from healthy 
donors in accordance with local ethical committee approval (EC# 
BT/04/2005).  Peripheral blood mononuclear cells (PBMC) were separated 
via a density-gradient centrifugation over Histopaque-1077 (Sigma) twice, as 
previous, firstly to isolate PBMCs with the second density gradient used for 
the removal of platelets.  The resultant cells were then washed and 
resuspended at 5 x 107 cells per 500 µl isolation buffer containing phosphate 
buffered saline (PBS) + 1 % w/v bovine serum albumin (BSA) (Sigma) + 1 
mM EDTA (Sigma) before viability counting via Trypan Blue exclusion (Fluka). 
200 µl of CD4 Human Antibody Mix (Invitrogen) and 100 % v/v foetal calf 
serum (Sigma) (FCS) were incubated with PBMC for 20 minutes.  This was 
followed by the addition of 1 ml Depletion MyOne Dynabeads (Invitrogen) 
before magnetic removal of bead-bound non-CD4+ cells, leaving CD4+ cells in 
solution.   
CD4+CD25+ T cells were isolated by positive selection using 200 µl CD25 
Dynabeads per 1.5 x 107 cells.  The CD4+CD25+ Treg population was 
liberated from the CD25 Dynabeads using Detach-a-bead solution 
(Invitrogen) and were then used in downstream applications.  The remaining 
CD4+CD25- effector T cells were either used in T cell suppression assays or 
placed in RPMI-1640 (Sigma) + 10 % v/v FCS (Sigma) + 5 mM L-Glutamine 
6LJPD,8ȝJPO3HQFLOOLQ6WUHSWRP\FLQ6LJPDDQGYY'062
(Sigma) before undergoing controlled freezing at ±80 Û& ZLWK SURORQJHG
storage in liquid nitrogen. A small volume of cells (10 µl) was taken at each 
isolation step for analysis via flow cytometry. 
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6.2.2 Isolation of CD8+ T cells via Magnetic Selection 
Peripheral blood mononuclear cells (PBMC) were separated via density-
gradient centrifugation as described previously.  The resultant cells were then 
washed and resuspended at 1 x 107 cells per 80 µl of isolation buffer 
containing phosphate buffered saline (PBS) + 1% w/v bovine serum albumin 
(BSA) (Sigma) + 1 mM EDTA (Sigma) before viability counting via Trypan 
Blue exclusion (Fluka). Cells were labelled with 20 µl CD8 Microbeads 
(Miltenyi Biotec) per 1 x 107 cells for 15 minutes before washing in isolation 
buffer. The cell/bead mixture was applied WRDSULPHG µ/'¶PDJQHWLFFROXPQ
which was subsequently washed several times before the enriched, bead-free 
CD8+ T cell population was eluted. A small volume (10 µl) of cells was taken 
for counting and phenotypic analysis via flow cytometry. 
 
6.2.3 Isolation of Plasmacytoid Dendritic Cells 
Peripheral blood mononuclear cells (PBMC) were separated via a density-
gradient centrifugation as described previously.  The resultant cells were then 
washed in isolation buffer containing phosphate buffered saline (PBS) + 1% 
w/v bovine serum albumin (BSA) (Sigma) + 1 mM EDTA (Sigma) before 
viability counting via Trypan Blue exclusion (Fluka). Cells were incubated with 
100 µl of FcR Blocking Reagent and 100 µl of CD304 MicroBeads per 108 
cells (Miltenyi Biotec) for 15 minutes before washing in isolation buffer. The 
FHOOEHDGPL[WXUHZDVDSSOLHG WRDSULPHG µ/'¶PDJQHWLFFROXPQZKLFKZDV
subsequently washed several times before the enriched, bead-free pDC 
population was eluted into another column. Elution was repeated to enhance 
cell purity.  A small volume (10 µl) of cells was taken for counting and 
phenotypic analysis via flow cytometry. 
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6.2.4 Flow Cytometry Analysis 
Cells were stained with cell surface markers 2.5 µl CD3-ECD (clone UCHT1-
Beckman Coulter), 1.25 µl CD4-ECD (clone SFCI12T4D11 - Beckman 
Coulter), 2.5 µl  CD8-FITC (Clone HIT8a ± BioLegend), 7.5 µl  CD25-PE 
(Clone BC96 - BioLegend), 2.5 µl CCR4-PerCP/Cy5.5 (Clone TG6 - 
BioLegend), 2.5 µl CD69-PE/Cy5 (Clone FN50 ± BioLegend), 2.5 µl CD80-
FITC (Clone 2D10, BioLegened), 2.5 µl CD83-PE (Clone HB15e, BioLegend), 
2.5 µl CD86-PE/Cy5 (Clone IT2.2, BioLegend), 2.5 µl CD123 (Clone 6H6 ± 
BioLegend), 2.5 µl CD303-PE (Clone 446921 ± R & D Systems), 10 µl HLA-
A2-FITC (Clone BB7.2 ± Abcam). Cells were incubated with stains for 15 
minutes before fixation with 2 % v/v formaldehyde (Sigma).   Cells, if required, 
were then permabilised using FOXP3 Perm Buffer (BioLegend) before 
incubation with FOXP3-AlexaFluor488 (Clone 259D ± BioLegend) or TLR7-
FITC (Abcam) or TLR8-PE (Abcam) for 30 min.  Cells were then resuspended 
in FACS wash buffer (BioLegend) and read via a Beckman Coulter FC 500 
flow cytometer. Analysis involved gating on lymphocyte populations from 
forward/side-scatter plots before selecting regions of interest.  
 
6.2.5 Imiquimod-treated T cell Suppression Assays 
T cell proliferation assays were set-up as described in chapter 3. Treg were 
incubated with Imiquimod at various concentrations (0 ± 30 µM) for one hour. 
Control samples were incubated with equivalent concentrations of DMSO. 
The cells were then washed and added to the assay as per normal protocol.  
6.2.6 CD8+ T Cell Proliferation Assay 
5 x 104/well CD8+ T cells were stimulated with 10 µg/ml anti-CD3 (Clone-OKT, 
Biolegend) and 5 µg/ml anti-CD28 (Clone ± 28.2, Biolegend) or 10 µg/ml of 
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PHA (Sigma).  The final volume was adjusted to 200 µl using X-vivo-15 + 5% 
Human AB serum. After 18 hours, 100 µl of cell supernatant was taken and 
stored at ±  Û& &HOOV ZHUH WKHQ HLWKHU VWDLQHG IRU IORZ F\WRPHWU\ XVLQJ
CD69-PE/Cy5 (Clone ± FN50, Biolegend) as a activation marker or pulsed 
with 1 µCi of [3H]-labelled thymidine per well (TRA120, Amersham). The 
pulsed plate was left to incubate for a further 18 hours before being harvested 
onto a microscintillation plate (Perkin-Elmer).  After repeated washes with de-
ionised water, the plate was allowed to dry for an hour.  20 µl of scintillation 
fluid (Microsint 0, Perkin-Elmer) was added per well before the plate was 
covered with optical tape (Perkin Elmer).  Thymidine incorporation was 
quantified using a Packard TopCount NXT Microplate Scintillation counter. 
 
6.2.7 pDC Stimulation Assay 
1 x 104/well pDC were treated alone or in combination with either Imiquimod 
(0-30 µM), DMSO (0 ± 10 % v/v) or MUC1 peptide (LLLLTVLTV ± 0 -100 
µg/ml). The final volume was adjusted to 200 µl using X-vivo-15 + 5 % v/v 
Human AB serum. After 18 hours, 100 µl of cell supernatant was taken and 
stored at ± 40 °C for analysis at a later date. Activation of pDC was 
determined by flow cytometry using CD80, CD83 and CD86 as activation 
markers. Donors from which cells were isolated were screened for being 
HLA-A2+.  
 
6.2.8 ELISA 
Cytokine production was measured by ELISA. The cytokines of interest were 
IFN-Į ,)1-Ȗ ,/-6, IL-10 and TNF-Į 3RO\VW\UHQH -well plates (MaxSorp, 
Nunc) were coated with the relevant capture antibody (1 µg/ml IFN-Į&ORQH
EBI-10 ± eBioscience, 2 µg/ml IFN-Ȗ&ORQH0'-1 ± BioLegend, 1 µg/ml IL-6; 
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Clone MQ2-39C3, BioLegend, 2 µg/ml IL-10; Clone JES3-12G8, BioLegend, 
2 µg/ml  TNF-Į &ORQH 0$E %LR/HJHQG RYHUQLJKW  7KH SODWH ZDV WKHQ
blocked with 5 % w/v skimmed milk powder in PBS (pH 7.2) + 0.05 % v/v 
Tween (PBS/Tween) to prevent non-specific binding. The plate was washed 
in PBS/Tween using an automated plate washer and tapped dry. The relevant 
recombinant cytokine (PeproTech) and samples were added to the plate.  
After 2 hours, the plate was washed in PBS/Tween before the appropriate 
biotinylated detection antibody (2 µg/ml IFN-ĮH%LRVFLHQFHJPO,)1-Ȗ
µg/ml IL-6, 2 µg/ml IL-10, 1 µg/ml TNF-Į%LR/HJHQGZDVGLOXWHGLQ3%6
w/v BSA, and 0.1 % v/v Tween 20 and incubated for 2 hours at room 
temperDWXUHEHIRUHEHLQJZDVKHGȝORIJPOVWUHSWDYLGLQ-horseradish 
peroxidase (BD-Pharmaginen) was added each well. After 30 minutes 
incubation at room temperature, the plate was washed and bound 
horseradish peroxidase was visualised with 0.1 mg/ml tetramethylbenzidine 
(Sigma) and 2 µl of 30 % v/v hydrogen peroxide (Sigma) diluted in 3 M 
sodium acetate buffer (Sigma). The colour reaction was stopped by addition 
of 2 M sulphuric acid (Sigma), and absorbance was measured at 450 nm 
using a MRX spectrophotometer (Dynex Technologies). The concentrations 
of samples were calculated from standard curves of each recombinant 
cytokine. ELISA detection limit were determined as follows (IFN-Į- 40 pg/ml, 
IFN-Ȗ± 10 pg/ml, IL-6 ± 8 pg/ml, IL-10 ± 2 pg/ml, TNF-Į± 4 pg/ml). 
 
6.2.9 Cytotoxic T cell Generation 
5 x 104/ml pDC were cultured and pulsed with 40 µg/ml MUC1 peptide (amino 
acids 12 ± 20, LLLLTVLTV, ProImmune) for 2 hours. 1 x 106/ml CD8+ T cells 
were added to the co-culture with or without 2 x 105/ml Treg or 3 µM 
Imiquimod for seven days in the presence of 50 IU/ml IL-2. Fifty percent of the 
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medium was replaced on days 3 and 5 with fresh medium containing 25 IU/ml 
IL-2. The co-culture was harvested and analysed by flow cytometry for 
CD8+MUC1+ cells using an R-PE labelled Pro5 MHC Pentamer (A*02:01; 
ProImmune).  
 
6.2.10 Cytotoxic T cell Expansion 
Purified CD8+MUC1+ T cells were placed in culture using X-Vivo-15 + 5% 
Human AB Serum (Lonza).  The culture was supplemented with 1000 IU/ml 
recombinant IL-2 (Novartis) and VWLPXODWHGZLWKJPOĮ&'DQGVROXEOH
JPO Į&' %LROHJHQG $IWHU GD\V   DQG  FHOOV ZHUH VXSSOHPHQWHG
with 1000 IU/ml recombinant IL-2. The cells were then re-suspended in 
culture media and re-stimulated on day 10 as described previously. Viability 
and cell number were assessed using Trypan Blue Staining.   
 
6.2.11 Intracellular Cytokine Staining 
Analysis of intracellular cytokines by flow cytometry was performed. Cytokine 
secretion was blocked with the addition of 10 µg/ml brefeldin A (BioLegend) 
for the last 6 hours of culture. Permabilisation was carried out as described 
previously and cells stained with IFN-Ȗ-FITC (Clone - 4S.B3, Biolegend). 
Cells were then resuspended in FACS wash buffer (BioLegend) and read via 
a Beckman Coulter FC 500 flow cytometer. Analysis involved gating on 
lymphocyte populations from forward/side-scatter plots before selecting 
regions of interest.    
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6.3 Results and Discussion 
6.3.1 TLR Expression Profiles 
Clarification was sought on the expression of TLR7 using flow cytometry.  
Figure 6.1 shows the expression of TLR7 on CD8+ T cells, pDCs, CD4+CD25- 
T cells, Treg and the ovarian cancer cell line A2780. As mentioned previously, 
the expression of TLR7 on various cell populations, and in particular Treg, 
has been debated for some time (73).  
As expected, pDC demonstrated the most prominent expression of TLR7. 
Interestingly, CD8+, CD4+CD25- and Treg also expressed TLR7. Therefore, 
the use of TLR7 agonists, like Imiquimod, will have an effect on several 
different immune populations. The existence of toll-like receptors on effector 
populations (CD8+ and CD4+CD25- T cells) has been widely discussed, 
though focus in this area has tended to be on TLR1, -2,-3 and -5 (74,75). The 
expression of TLR7 on Treg is of great interest as earlier literature suggested 
that TLR7 was not present on human Treg (76). A widely cited paper in this 
area by Peng et al. (67) suggested that TLR7 was not expressed in with 
CD4+CD25- T cells or Treg. However, Figure 6.1 and recent evidence has 
suggested otherwise (77,78).   
Of all the cell populations tested, only the ovarian cancer cell line A2780 was 
negative for TLR7 expression. TLR expression on both normal and malignant  
ovarian tissue has been investigated (79) which indicates the expression of 
several other TLR (-2,-3,-4,-5). Cremer et al. (80) have demonstrated that 
primary human lung tumours and human lung cancer cell lines express TLR7. 
Interestingly, they also show that engagement of TLR7 lead to an increase in 
cancer cell proliferation as well as increased chemoresistance to poly-
chemotherapy (Doxorubicin, Navelbine, Cycloheximide and Cisplatin).  
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Figure 6.1 ± Expression of TLR7 on Various Cell Populations ± TLR7 expression 
measured by flow cytometry. Black represents unstained cells. Red represents Rabbit 
polyclonal FITC IgG as isotype control. Blue represents Rabbit polyclonal TLR7 IgG. 
Figure representative of three independent experiments. 
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6.3.2 Effect of Imiquimod on Treg Activity  
The key question to now answer is the effect of TLR7 activation on Treg and 
other immune populations. Activation of TLR7 on CD8+ T cells (69,81,82) and  
pDC (57,83,84) has been described in detail. However, the effect of TLR7 
activation on Treg is a matter of contention. Huang et al. (69) have suggested 
that TLR7 agonism leads to a decrease in FOXP3+ cells in squamous cell 
carcinoma patients. These cells, on isolation, were poorly suppressive and 
allowed the proliferation of IFN-Ȗ VHFUHWLQJ cytotoxic T cells. Despite their 
claim that Treg do not possess TLR7, Peng et al. (67) have shown that 
Imiquimod can significantly reduce Treg mediated CD4+CD25- T cell 
suppression. Their rationale for this effect is the potential agonism of TLR8 by 
Imiquimod. However, key papers suggest that Imiquimod is more selective for 
TLR7 (40,85).  As mentioned previously, Forward et al. (77) have described 
how TLR7 agonism leads to an increase in the suppressive behaviour of 
murine Treg. It was therefore essential to assess the effect of TLR7 agonism 
on Treg function. 
Imiquimod was selected as the TLR7 agonist of choice. Although,  its 
chemical progeny, Resiquimod, is reportedly up to 50 times more potent for 
TLR7 binding (40), Imiquimod was used as it was significantly cheaper to 
obtain.  
Figure 6.2 shows the effect of 3 µM Imiquimod on Treg mediated suppression 
of both CD4+CD25- T cells and CD8+ T cells. The concentration of Imiquimod 
was selected on the basis of literature in the field (67,69). Treatment with 
Imiquimod caused a partial abrogation of Treg mediated suppression on 
CD4+CD25- T cells (Figure 6.2A). There was a significant increase in 
CD4+CD25- T cell proliferation at the 1/5 fraction (Figure 6.2A; 1/5; Control vs. 
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Treated (cpm) ± 452 vs. 1387, n = 3; p < 0.05) and the 1/10 fraction (Figure 
6.2A; 1/10; Control vs. Treated (cpm) ± 1502 vs. 2447, n = 3; p < 0.05). 
There was no change in either Treg (Treg; Control vs. Treated (cpm) ± 120 
vs. 136, n = 3; p > 0.05) or Effector CD4+CD25- T cell (Effector; Control vs. 
Treated (cpm) ± 3879 vs. 3668, n = 3; p > 0.05).   
Imiquimod also partially reduced the suppressive effect of Treg on CD8+ T 
cell proliferation (Figure 6.2B). Significant increases in proliferation were 
noted at the 1/5 fraction (Figure 6.2B; 1/5; Control vs. Treated (cpm) ± 19980 
vs. 20450, n = 3; p < 0.05) and the 1/10 fraction (Figure 6.2B; 1/10; Control 
vs. Treated (cpm) ± 12840 vs. 16030, n = 3; p < 0.05). As with the 
CD4+CD25- T cell assay, there was no change in the proliferation of Treg 
(Figure 6.2B; Treg; Control vs. Treated (cpm) ± 67 vs. 54.33, n = 3; p > 0.05). 
However, there was a significant increase in CD8+ T cell proliferation (Figure 
6.2B; CD8; Control vs. Treated (cpm) ± 19980 vs. 24780, n = 3, p < 0.05). 
The alteration in the suppressive phenotype of Treg and an increase in the 
proliferation of CD8+ T cells are key observations, both of which are 
advantageous in developing an anti-tumour immune response (86,87). After 
the above result the immediate objective was to observe whether there was a 
dose dependent effect on the abrogation of Treg suppressive activity. 
Figure 6.3 depicts the effect of a dose titration of Imiquimod on the 
suppressive activity of Treg. The proliferation of PHA-stimulated CD4+CD25- 
T cells in co-culture with a 1/5 fraction of Treg when treated with Imiquimod 
was assessed. A 1/5 fraction of Treg was used as this experimental group 
provided the greatest suppressive effect. Imiquimod demonstrated a dose-
dependent reversal of Treg suppression (Figure 6.3; 0.3 ± 30 µM, n = 3; p < 
0.05). Concentrations above 30 µM demonstrated no effect (Figure 6.3; 0 vs. 
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300 (cpm) ± 468 vs. 31, n = 3; p > 0.05) which could be contributed to 
excessive amounts of DMSO within the culture.           
It is not known exactly how the TLR triggering of Treg cells modulates their 
suppressive effects, and whether the triggering of different TLRs occurs 
through the same pathway or has the same effect on Treg function. One 
explanation could be the upregulation or downregulation of FOXP3 
expression following the different TLR stimulations (64,65), but how TLR-
signalling affects FOXP3 expression is still unclear. As discussed previously, 
the role of FOXP3 expression in human Treg is still under scrutiny (88-90) 
and so its relevance in Treg-TLR signalling is to be questioned. Another 
possibility to explain the abrogated regulatory function but enhanced 
proliferative capacity of Treg  after TLR7 stimulation corresponds with reports 
looking at TLR2 agonism indicating that Treg  rapidly lose their ability to 
inhibit proliferation after receiving strong activation signals (91).     
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Figure 6.2 ± Treg-mediated Suppression of Effector T cell Populations is 
Abrogated by 3 µM Imiquimod. A - CD4+CD25- Effector T cells stimulated by PHA.  
B ± CD8+ T cells stimulated by JPOĮ&'DQGJPOĮ&'. 3 µM Imiquimod 
reduces the suppressive effects of Treg where Treg were present at 1/5 and 1/10 
fraction of co-culture. Figures representative of the means of three independent 
experiments from the same donor. *=p<0.05. Statistical significance determined by a 
one-way ANOVA analysis with column comparisons using Tukey's Multiple 
Comparison Test. Error bars represents standard deviation. 
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Figure 6.3 ± Treg-mediated Suppression of Effector T cell Oopulations is Abrogated by Imiquimod in a dose-dependent manner. CD4+CD25- 
Effector T cells co-cultured with Treg where Treg were present at 1/5 fraction of co-culture. Suppressive effect of Treg reduced at concentrations 0.3, 3 and 
30 µM. Figure representative of the means of three independent experiments from three different donors. *=p<0.05. Statistical significance determined by a 
one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. Error bars represent standard deviation. 
 
275 
 
 
Figure 6.4 - Production of IL-10 and IFN-ȖIURP7FHOO6Xppression Assays Stimulated with PHA. Treatment with Imiquimod leads to an increase in IFN-
ȖDQGDGHFUHDVH LQ ,/-10 when  cells were co-stimulated with PHA.   A ± IFN-ȖFHOOV WUHDWHGZLWK ,PLTXLPRG± 300 µM), B ± IL-10; cells treated with 
Imiquimod (0 ± 300 µM). C- IFN- ȖFHOOVWUHDWHGZLWK'062± 10 % v/v) and D ± IL-10; cells treated with DMSO (0 ± 10 % v/v).  Figures representative of 
the means three independent experiments from different donors. Error bars represent standard deviation. *=p<0.05.  Detection limit = 40 pg/ml. Statistical 
significance determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. 
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The reduction in Treg-mediated suppression meant that the cytokine milieu 
produced during co-culture with CD4+CD25- T effector cells also changed, as 
seen in Figure 6.4. As expected, there was a significant, dose dependent 
increase in the amount of IFN-Ȗ)LJXUH$± 30 µM, n = 3; p < 0.05) 
and a decrease in IL-10 (Figure 6.4B; 0.3 ± 30 µM, n = 3; p < 0.05). The 
cytokine profile can be explained by the activation of NF-ț%GRZQVWUHDPRI
TLR7 activation (92). Interestingly, the decrease in IL-10 secretion has not 
previously been noted. As explained in Chapter 3, PHA acts on NF-ț%
leading to cytokine production. TLR agonism provides strong signals for pro-
inflammatory cytokine production (92). It could therefore be suggested that 
these pro-LQIODPPDWRU\ VLJQDOV µRXW-FRPSHWH¶ WKRVH VLJQDOV IRU IL-10 
production, thus demonstrating the behaviour seen in Figure 6.4.  
Having observed a significant change in the phenotype of Treg-mediated 
suppression, it was important to assess the co-culture system. This was in an 
attempt to delineate the mechanism by which Treg suppression was being 
abrogated. Figure 6.5 illustrates the proliferative effect of Imiquimod and 
Į&'Į&'VWLPXODWLRQRQERWK&'+ T cells and Treg.   The proliferation of 
Treg did not change under co-VWLPXODWLRQ ZLWK Į&'Į&' DQG D
concentration range of Imiquimod (Figure 6.5A; 0 ± 30 µM, n = 3, p > 0.05).  
,QWHUHVWLQJO\DVQRWHGHDUOLHULQ)LJXUH%Į&'Į&'-stimulated CD8+ T 
cells saw increased proliferation when treated with Imiquimod. This effect was 
dose dependent (Figure 6.5B; 0.03 ± 30 µM, n = 3, p < 0.05) with an 
Imiquimod concentration of 3 µM providing maximal stimulation (Figure 6.5B; 
0.03 vs. 0.3 vs. 3 vs. 30 µM; (cpm) ± 123 vs. 177 vs. 213 vs. 240 vs. 225, n = 
3; p < 0.05). The proliferative effect of TLR7 engagement on CD8+ T cells has 
been discussed previously (62,69,93).  The rationale for the lack of Treg 
277 
 
proliferation could be linked to the reported differences in proliferative 
pathways between effector populations and Treg as discussed in Chapter 3 
(94) (Figure 3.8). 
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Figure 6.5 ± Imiquimod Increases CD8+ T cells but not Treg Proliferation when 
co-VWLPXODWHGZLWKĮ&'Į&'IRUKRXUV$- Treg. Co-stimulation of Treg with 
JPOĮ&'DQGJPOĮ&'DQGYDU\LQJFRQFHQWUDWLRQVRI,PLTXLPRG± 30 
µM) showed no change in SUROLIHUDWLRQFRPSDUHGWR,PLTXLPRGRUĮ&'Į&'RQO\
B ± CD8+ T cell. Co-stimulation of CD8+ 7 FHOOV ZLWK  JPO Į&' DQG  JPO
Į&'DQGYDU\LQJFRQFHQWUDWLRQVRI,PLTXLPRG± 30 µM) showed an increase in 
proliferation when  compared to ImquimoGRUĮ&'Į&'DORQHp < 0.05 (n = 3).   
Figures representative of the means of three independent experiments from the 
different donors. Statistical significance determined by a one-way ANOVA analysis 
with column comparisons using Tukey's Multiple Comparison Test. Error bars 
represent standard deviation. 
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6.3.3 Cell Activation and IFN-Ȗ(xpression 
Figures 6.6 and 6.7 demonstrate the effect of Imiquimod on the activation 
status of CD8+ T cells. Firstly, in Figure 6.6, CD69 expression on CD8+ T cells 
VWLPXODWHG ZLWK HLWKHU ,PLTXLPRG RU LQ FRQMXQFWLRQ ZLWK Į&'Į&' ZDV
assessed using flow cytometric analysis. CD69 is an early membrane 
receptor transiently expressed on lymphocyte activation, not detected in 
resting lymphocytes, and selectively H[SUHVVHG LQ FKURQLF LQÀDPPDWRU\
LQ¿OWUDWHVDQGDWWKHVLWHVRIDFWLYHLPPXQHUHVSRQVHVin vivo (95). It is widely 
used as a marker for T cell activation and as such was used to monitor the 
activation of CD8+ T cells in response to stimuli. There was no change in 
CD69 expression when treated with Imiquimod only (0 ± 30 µM, n = 3, p > 
 Į&'Į&' DORQH FDXVHG DQ LQFUHDVH LQ CD69 expression (Figure 
6.6; 0 µM Imiquimod vs. Į&'Į&' (%) ± 7.70 vs. 9.65, n = 3, p < 0.05).  
However, on titration of Imiquimod, a significant increase in CD69 expression 
was seen (0.03 ± 30 µM, n = 3, p < 0.05). The effect was dose dependent 
with a FRPELQDWLRQ RI  0 ,PLTXLPRG DQG  JPO Į&' DQG  JPO
Į&' VWLPXODWLRQ SURYLGLQJ WKH KLJKHVW SHUFHQWDJH RI &'+CD69+ cells 
(Figure 6.6; 0.03 vs. 0.3 vs. 3 vs. 30 µM ; (CD69 %) ± 11.42 vs. 12.33 vs. 
14.26 vs. 14.04, n = 3; p < 0.05).  
Another common technique used for assessing activated T cells is 
intracellular cytokine staining for IFN-Ȗ (96).  Intracellular cytokine staining 
allows the assessment of individual cells within a population and does not rely 
on the detection of secreted cytokines. It can provide an insight into the 
processes underway within in a cell soon after stimulation/activation. Figure 
6.7 shows the level of intracellular IFN-ȖLQ&'+ T cells after stimulation with 
either Imiquimod or in conjunctLRQZLWKĮ&'Į&'7UHDWLQJ&'+ T cells 
with Imiquimod led to an increase in intracellular IFN-ȖH[SUHVVLRQ± 30 
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µM, n = 3, p   Į&'Į&' DORQH FDXVHG DQ LQFUHDVH LQ ,)1-Ȗ
expression (Figure 6.7; 0 µM Imiquimod vsĮ&'Į&' (IFN-Ȗ± 1.59 
vs. 5.413, n = 3, p < 0.05). As with the change in CD69 expression seen in 
Figure 6.6, titration of Imiquimod led to a significant increase in IFN-Ȗ± 
30 µM, n = 3, p < 0.05).  The effect was dose dependent with a combination 
of 30 0 ,PLTXLPRG DQG  JPO Į&' DQG  JPO Į&' VWLPXODWLRQ
providing the highest percentage of CD8+IFN-Ȗ+ cells (Figure 6.7; 0.03 vs. 0.3 
vs. 3 vs. 30 µM ; (IFN-Ȗ± 9.88 vs. 12.44 vs. 13.65 vs. 14.03, n = 3; p < 
0.05).  Ideally, Treg would have also been assessed for CD69 and 
intracellular IFN-Ȗ H[SUHVVLRQ +RZHYHU UHVWULFWLRQV RQ FHOO VL]H UHDJHQW
availability and cost meant that the decision was made to forgo these 
experiments. Although in Chapter 3, a method for expanding Treg was 
optimised, it would be difficult extract any useful information from CD69/IFN-Ȗ
experiments. The rationale for this statement is due to the continuous stimuli 
provided to Treg whilst expanding. High IL- DQG Į&' VXSHUDJRQLVW
treatment lead to activation and subsequent proliferation of Treg. Therefore, 
upon treatment, CD69 would be artificially elevated in the expanded 
population of Treg (97-100) and so the effect of Imiquimod would be less 
inferable. Recent work by Daniel et al. (101) suggests that a subset of 
CD4+CD25+FOXP3+ Treg possess the ability to express IFN-Ȗ.  Again, this 
could skew the inference of Imiquimod-induced IFN-ȖH[SUHVVLRQ 
To confirm the intracellular cytokine results seen in Figure 6.7, supernatants 
from the CD8+ T cell stimulation assays were assessed by IFN-ȖDQG ,/-10 
ELISA (Figure 6.8). Samples from Treg stimulation assays were also 
assessed. The data in Figure 6.8 validates those findings which were 
described earlier. Both Treg and CD8+ T cells demonstrate a dose-dependent 
increase in IFN-Ȗ)LJXUH; Treg, 0.3 ± 30 µM; CD8, 0.3 ± 30 µM, n = 3, p < 
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0.05) on Imiquimod treatment which was subsequently enhanced on the 
DGGLWLRQRIĮ&'Į&'7UHJ± 30 µM; CD8, 0.03 ± 30 µM, n = 3, p < 
  0 ,PLTXLPRG LQ FRPELQDWLRQ ZLWK  JPO Į&' DQG  JPO
Į&' H[KLELWHG WKH KLJKHVW FRQFHQWUDWLRQ RI ,)1-Ȗ VHFUHWLRQ LQ ERWK 7UHJ
and CD8+ T cells (Treg; 2.41 ng/ml, CD8; 4.68 ng/ml).  
A similar trend can be reported with regards to IL-10 secretion. Both Treg and 
CD8+ T cells demonstrate a dose-dependent increase in IL-10 (Treg, 0.03 ± 
30 µM; CD8, 0.3 ± 30 µM, n = 3, p < 0.05) on Imiquimod treatment which was 
VXEVHTXHQWO\HQKDQFHGRQWKHDGGLWLRQRIĮ&'Į&'7UHJ± 30 µM; 
CD8, 0.3 ± 30 µM, n = 3, p < 0.05). 30 µM Imiquimod, in combination with, 10 
JPOĮ&'DQGJPOĮ&'H[KLELWHGWKHKLJKHVWFRQFHQWUDWLRQRI,)1-Ȗ
secretion in both Treg and CD8+ T cells (Figure 6.8; Treg; 0.41 ng/ml, CD8; 
0.68 ng/ml). An interesting observation is that on treatment with 
Į&'Į&' 7UHJ GR QRW VHFUHWH ,/-10. It is only on the addition of 
Imiquimod that a significant increase in IL-10 can be detected (Figure 6.8; 0 
vs 0.03 vs. 0.3 vs. 3 vs. 30 µM; (IL-10 ng/ml) ± 0.04 vs. 0.07 vs. 0.07 vs. 
0.150 vs. 0.413, n = 3; p < 0.05). Another noticeable observation was that co-
VWLPXODWLRQRI7UHJZLWKĮ&'Į&'DQG0,PLTXLPRGOHDGVWRDIXUWKHU
increase in IL-10 secretion (Figure 6.8; Imiquimod vs. Imiquimod + 
Į&'Į&' (ng/ml); 0.19 vs. 0.41, n = 3, p < 0.05). This effect can be 
explained by work Baecher-Allan et al. (91) who suggested that TLR 
engagement and T cell stimulation provide strong activation signals which 
lead to the secretion of both IFN-ȖDQG,/-10.  
The data suggests that treatment with a TLR7 agonist leads to increased 
CD8+ T cell proliferation as well as increased CD69 and IFN-Ȗ
expression/secretion. There also appears to be a partial abrogation of the 
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suppressive activity of Treg against both CD4+CD25- and CD8+ effector T 
cells when treated with Imiquimod. This enhancement of effector T cell 
function and reduction in the suppressive effects of Treg are suggestive of the 
role Imiquimod could have in enhancing CD8+ T cell function. 
The next step is to assess the effect of Imiquimod on plasmacytoid dendritic 
cells. As mentioned previously, there is an increased presence of pDC at the 
tumour site (35). The isolation and phenotypic characterisation of pDC when 
stimulated with Imiquimod are critical in understanding whether these antigen 
presenting cells will be of assistance in generating an anti-tumour immune 
response.   
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Figure 6.6 ± Imiquimod Increases CD69 Expression on CD8+ T cells when Co-VWLPXODWHGZLWKĮ&'Į&'$  - FACS plot of CD3/CD69 expression 
on CD8+ T cells stimulated with Imiquimod for 24 hours. B - FACS plot of CD3/CD69 expression on CD8+ 7FHOOVVWLPXODWHGZLWKJPOĮ&'DQGJPO
Į&'IRUKRXUVC ± CD69 expression on CD8+ 7FHOOVVWLPXODWHGZLWKJPOĮ&'JPOĮ&'DQGYDU\LQJFRQFHQtrations of Imiquimod (0 ± 30 
03HDN&'H[SUHVVLRQZDVVHHQZLWKJPOĮ&'DQGJPOĮ&' DQG0 ,PLTXLPRG *=p<0.05; n = 3. CD69 expression determined in 
comparison to Mouse IgG-PE-Cy5 as isotype control.  Figures representative of the means of three independent experiments from the different donors. 
Statistical significance determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. Error bars represent 
standard deviation. 
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Figure 6.7 ± Imiquimod Increases Intracellular IFN-Ȗ([SUHVVLRQRQ&'7FHOOVZKHQ&o-VWLPXODWHGZLWKĮ&'Į&'$  - FACS plot of CD3/IFN-Ȗ
expression on CD8+ T cells stimulated with Imiquimod for 24 hours. B  - FACS plot of CD3/IFN-ȖH[SUHVVLRQRQ&'+ 7FHOOVVWLPXODWHGZLWKJPOĮ&'
DQG  JPO Į&' IRU  KRXUV C ± IFN-Ȗ H[SUHVVLRQ RQ &'+ 7 FHOOV VWLPXODWHG ZLWK  JPO Į&'  JPO Į&' DQG varying concentrations of 
Imiquimod (0 ± 30 µM) for 24 hours. Peak IFN-ȖH[SUHVVLRQZDVVHHQZLWKJPOĮ&'DQGJPOĮ&'DQG0,PLTXLPRG*=p<0.05; n = 3. IFN-Ȗ
expression determined in comparison to Mouse IgG-FITC as isotype control.  Figures representative of the means of three independent experiments from the 
different donors. Statistical significance determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. Error 
bars represent standard deviation. 
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Figure 6.8 ± Increased Production of IL-10 and IFN-Ȗ IURPoth CD8+ T cells and Treg when SWLPXODWHGZLWKĮ&'Į&'DQG ,PLTXLPRG  IFN-Ȗ
production is increased in both A- Treg and B- CD8+ 7FHOOVZKHQVWLPXODWHGZLWKJPOĮ&'JPOĮ&'DQGYDU\LQJFRQFHQWUDWLRQVRI,PLTXLPRG
0 ± 30 µM) for 24 hours. Peak IFN-ȖVHFUHWLRQVHHQLQERWK7UHJDQG&'+ 7FHOOVZKHQVWLPXODWHGZLWKJPOĮ&'JPOĮ&'DQG0,PLTXLPRG
IL-10 production is also increased in C ± Treg and D ± CD8+ 7FHOOVZKHQVWLPXODWHGZLWKJPOĮ&'JPOĮ&'DQGYDU\LQJFRQFHQWUDWLRQVRI
Imiquimod ( 0 ± 30 µM) for 24 hours. Peak IL-10 secretion seen in both Treg and CD8+ T cells when stimulated witKJPOĮ&'JPOĮ&'DQG0
Imiquimod.  Error bars represent standard deviation. *=p<0.05.. Detection limit = 40 pg/ml Figures representative of the means of three independent 
experiments from three different donors. Statistical significance determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple 
Comparison Test. 
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6.3.4 pDC Isolation and Stimulation with Imiquimod 
pDC make up a very small percentage of the total PBMC population (102). 
Therefore their isolation and use in downstream applications makes their use 
ex-vivo particularly challenging. Using CD304 microbeads, isolation of pDC 
from PBMCs was conducted. CD304 (BDCA-4/Neuropilin-1) is specifically 
expressed by pDCs in human blood (102-106), bone marrow (103), and cord 
blood (107). Exclusive expression of CD304 (BDCA-4/Neuropilin-1) on pDCs 
allows their direct isolation. In blood and bone marrow, CD304 (BDCA-
4/Neuropilin-1)+ pDCs are CD4+, CD45RA+, CD303 (BDCA-2)+, CD123+, 
CD141 (BDCA-3)dim, CD1c (BDCA-1)±, and CD2±. They lack expression of 
lineage markers (CD3, CD14, CD16, CD19, CD20, CD56) and neither 
express myeloid markers such as CD13 and CD33, nor Fc receptors such as 
&' &' RU )Fİ5, (103,104). Isolation of pDC was assessed via flow 
cytometry, using CD303 and CD123 as markers, an example of which is 
provided in Figure 6.9. The purity of pDC on isolation was 90.2% (85.3 ± 
94.6%).   
From Figure 6.1, pDC express TLR7. Therefore, it was important to examine 
the effect of Imiquimod on these cells and thus gain evidence either for or 
against being a target in generating an anti-tumour immune response. Figure 
6.10 illustrates the expression of the pDC maturation markers CD80, CD83 
and CD86 when treated with Imiquimod. These markers are widely used for 
assessing the maturation of dendritic cells (40,62).  
Treatment of pDC with Imiquimod causes the upregulation of CD80, CD83 
and CD86 in a dose-dependent manner (Figure 6.10; 0.3 ± 30 µM, n = 3, p < 
0.05).  Peak expression CD80 (Figure 6.10; 0.03 vs. 0.3 vs. 3 vs. 30 µM; 
(CD80%) ± 37.0 vs. 42.2 vs. 61.87 vs. 53.53, n = 3), CD83 (Figure 6.10; 0.03 
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vs. 0.3 vs. 3 vs. 30 µM; (CD83%) ± 10.49 vs. 11.93 vs. 22.56 vs. 18.63, n = 3) 
and CD86 (Figure 6.10; 0.03 vs. 0.3 vs. 3 vs. 30 µM; (CD86%) ± 36.67 vs. 
46.87 vs. 51.73 vs. 45.60, n = 3) was demonstrated when treated with 3 µM 
Imiquimod (p < 0.05). These results suggest that Imiquimod can aide pDC 
maturation. 
CD83 is highly expressed on mature DC, but is not detectable on APCs that 
do not prime naive T cells such as immature DCs, resting B cells, and 
monocytes (108). Critically, prolonged CD83 expression leads to increased 
priming of human CD8+ T cells (108,109). Therefore, the dose-dependent 
increase seen on treating pDC with Imiquimod is of importance as, along with 
the increase in CD80 and CD86 (110). CD80 and CD86 are  co-stimulatory 
molecules which play  key role in the priming and activation of naïve T cells 
(111). 
Increased co-stimulation of CD8+ T cells could potentiate an anti-tumour 
response. However, the increase in CD80 and CD86 could also potentiate 
Treg engagement and thus subsequent tolerisation through CTLA-4 
(112,113). From the results above, there is evidence to suggest that 
Imiquimod has an effect on Treg. The expression of CTLA-4 has not been 
looked at in this thesis. Therefore, the effect on Imiquimod on CTLA-4 would 
be of great interest in understanding the effects of TLR7 engagement.  
The supernatant of Imiquimod-stimulated pDC was analysed for their 
production of IFN-Į ,/-6 and TNF-ĮYLD(/,6$DV Lllustrated in Figure 6.11.  
pDC treatment of Imiquimod led to an increase in IFN-ĮSURGXFWLRQLQDGRVH
dependent manner (Figure 6.11A; 0.03 ± 30 µM, n = 3, p < 0.05).  Peak 
secretion of IFN-ĮZDVREVHUYHGZKHQWUHDWHGZLWK0,PLTXLPRG,)1-Į
(ng/ml) - 0.03 vs. 0.3 vs. 3 vs. 30 µM; ± 0.10 vs. 0.25 vs. 0.67 vs. 0.42, n = 3, 
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p < 0.05). pDC are regarded as professional type I interferon (IFN-ĮDQG,)1-
ȕSURGXFLQJFHOOV(114).  Moreover, type I IFN modulates several aspects of 
the immune response, including pDC survival, mDC  diơerentiation (115), 
modulation of Th1 and CD8+ T cell responses, cross-presentation and cross-
priming independent of CD4+ T helper cells (116), upregulation of MHC and 
co-stimulatory molecules, activation of NK, and induction of primary antibody 
responses (117).  
IL-6 is a pleiotropic cytokine involved in the physiology of virtually every organ 
system. pDC treatment of Imiquimod led to an increase in IL-6 production in a 
dose dependent manner (Figure 6.11B 0.03 ± 30 µM, n = 3, p < 0.05).  Peak 
secretion of IL-6 was observed when treated with 30 µM Imiquimod (Figure 
6.11; IL-6; (ng/ml) - 0.03 vs. 0.3 vs. 3 vs. 30 µM; ± 0.76 vs. 3.66 vs. 8.20 vs. 
13.31, n = 3, p < 0.05). Recent studies have demonstrated that IL-6 has a 
very important role in regulating the balance between IL-17-producing Th17 
cells and Treg. IL-6 induces the development of Th17 cells from naïve T cells 
together with TGF-ȕZKLOHLQKLELWLQJ7*)-ȕ-induced Treg differentiation (70). 
Given the critical role of IL-6 in altering the balance between Treg and Th17 
cells, increasing the amount of IL-6 within the tumour microenvironment is, 
potentially, an effective approach to further limit the suppressive effect of 
Treg.  
TNF-Į LV SURGXFHG GXULQJ WKH LQLWLDWLRQ RI LQIODPPDWRU\ UHVSRQVHV DQG LV
critical for maintenance of chronic inflammation (118,119). pDC treatment of 
Imiquimod led to an increase in TNF-Į SURGXFWLRQ LQ D GRVH GHSHQGHQW
manner (Figure 6.11C; 0.03 ± 30 µM, n = 3, p < 0.05).  Peak secretion of 
TNF-ĮZDVREVHUYHGZKHQWUHDWHGZLWK0,PLTXLPRG)LJXUH&71)-
Į QJPO - 0.03 vs. 0.3 vs. 3 vs. 30 µM; ± 0.43 vs.  vs. 0.69 vs. 1.228 vs. 
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1.043, n = 3, p < 0.05). Given its established role in chronic inflammation, 
angiogenesis, tissue remodelling, tumour growth and metastasis, TNF-Į LV
likely to be an important cytokine in a variety of cancers (120-122). There is 
also controversial evidence surrounding the effect of TNF-Į RQ 7UHJ
suppression. Valencia et al. (123) suggests that TNF-Į WUHDWPHQW RI 7UHJ
leads to a decrease in Foxp3 expression in mice with a subsequent reduction 
in suppression activity. Whereas Chen et al. (124), amongst others, suggests 
that TNF-ĮFDQDLGH7UHJH[SDQVLRQ(125).  
In addition to the above secreted cytokines pDC stimulated with viral-like 
ligands produce chemokines, such as CCL3, CCL4, CCL5, CXCL8 and 
CXCL10 which stimulate Th1, and NK cells migration to sites of inflammation 
(126,127). There is also evidence that pDC can induce significant IL-10 
production by Treg (35,92).  This indicates that pDC can be phenotypically 
and functionally modulated in the tumour microenvironment with either pro- or 
anti-inflammatory stimuli. On this basis, it would be advantageous to target 
pDC within the tumour microenvironment with Imiquimod. 
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Figure 6.9 - Flow Cytometry Analysis of pDC cells Isolated using Magnetic Selection. Cells were stained for CD303 and CD123 expression.  
Lymphocytes were identified from forward/side scatter plots before populations of interest were gated upon. Analysis confirms CD303+CD123+ cells are 
approximately 1 % of the total PBMC populations which agrees with current population statistics.  
291 
 
 
Figure 6.10 ± Imiquimod Increases Expression of CD80, CD83 and CD86 on pDC. FACS plots of pDC maturation markers after 24 hours of Imiquimod 
treatment. A  - CD80, B- CD83, C ± CD86. D ± Percentage expression of CD80, CD83 and CD86 on pDC stimulated with varying concentrations of 
Imiquimod (0 ± 30 µM). Peak CD80, CD83 and CD86 expression was seen at 3 µM Imiquimod, *=p<0.05; n = 3. Percentage expression determined in 
comparison to Mouse IgG-FITC/PE/PE-Cy5 respectively as isotype controls.  Figures representative of three independent experiments from the different 
donors. Statistical significance determined by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. Error bars 
represent standard deviation. 
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Figure 6.11 ± Increased Cytokine Production from pDC Treated with Imiquimod. 
Treatment with varying concentrations of Imiquimod (0 - 30 µM) for 24 hours leads to 
a dose dependent increase in IFN-Į,/-6 and TNF-Į A ± IFN-ĮB ± IL-6; C- TNF-Į
Control cells treated with DMSO (0 ± 10 % v/v). Peak concentrations of cytokines 
seen at the following concentrations of Imiquimod ± IFN-Į0 ,/-6 (30 µM) and 
TNF-Į  0 p < 0.05; n = 3.  Figure representative of the means of three 
independent experiments from three different donors. Error bars represent standard 
deviations. *=p<0.05. Statistical significance determined by a one-way ANOVA 
analysis with column comparisons using Tukey's Multiple Comparison Test. Detection 
limit = 40 pg/ml. 
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6.3.5 Stimulation of pDC on Administration of Imiquimod and Tumour-
associated Antigen 
Having seen an increase in cell maturation and the generation of a pro-
inflammatory cytokine milieu, it is now important to assess the effects of 
Imiquimod, in conjunction with a tumour associated antigen, on pDC. In 
Chapter 5, there was a demonstration of the release of the tumour associated 
antigen MUC1 on treatment with Camptothecin. As mentioned previously, the 
increase in available MUC1 should increase the possibility for antigen 
presentation, both at the tumour site (23,24) and at distal draining lymph 
nodes (1,11,128).  
With readily available antigen, the role of Imiquimod becomes critical in not 
only reducing the suppressive effect of Treg and potentiating CD8+ T cell 
proliferation and activation, but by inducing cross-presentation within pDC. In 
order to replicate this effect, pDC were treated with a combination of 
Imiquimod and an epitope derived from MUC1.  The rationale for using an 
epitope, rather than the native protein was due to the cost involved in 
screening for multiple antigenic epitopes. The epitope used (LLLLTVLTV) was 
one of two sequences first discovered by Brossart et al. (129) who, using the 
PAP program, identified peptides from MUC1 which had a high probability of 
being presented by HLA-A2. 
Figure 6.12 illustrates the expression of the pDC maturation markers CD80, 
CD83 and CD86 when treated with 3 µM Imiquimod and a concentration 
range of (0 ± 100 µg/ml) MUC1 peptide. The first observation to be made is 
that, on treatment with peptide only, there is a dose-dependent change in the 
expression of CD83 and CD86 but not CD80, suggesting there is uptake of 
exogenous antigen.  Maximal expression of CD83 (Figure 6.12B; Peptide; 0 
294 
 
vs 20 vs. 40 vs 60 vs. 80 vs. 100 µg/ml; (CD83%) ± 30.5 vs. 33.43 vs. 36.30 
vs. 25.30 vs. 16.62 vs. 13.26, n = 3; p < 0.05) and CD86 (Figure 6.12C; 
Peptide; 0 vs 20 vs. 40 vs 60 vs. 80 vs. 100 µg/ml; (CD86%) ± 31.17 vs. 
31.40 vs. 46.33 vs. 38.10 vs. 36.23 vs. 34.30, n = 3; p < 0.05) was observed 
at a peptide concentration of 40 µg/ml. Interestingly, as peptide concentration 
increased, the expression of CD80, CD83 and CD86 decreased. This could 
possibly be due to the development of immunological tolerance (130). Too 
much antigen can lead to quiescent activation of antigen presenting cells, 
leading to the induction of tolerant mechanisms, such as the induction of Treg 
(31,131-133).   
Co-administration of 3 µM Imiquimod saw an increase in the expression of 
CD83 and CD86. No change was seen in CD80 expression (p > 0.05). 
Treatment with Imiquimod did not alter the peak concentration of peptide 
required to provide maximal expression on CD83 (Figure 6.12B; Peptide + 3 
µM Imiquimod; 0 vs 20 vs. 40 vs 60 vs. 80 vs. 100 µg/ml; (CD83 %) ± 22.93 
vs. 43.90 vs. 50.47 vs. 36.33 vs. 25.67 vs. 18.63, n = 3; p < 0.05) and CD86 
(Figure 6.12C; Peptide+ 3 µM Imiquimod; 0 vs 20 vs. 40 vs 60 vs. 80 vs. 100 
µg/ml; (CD86 %) ± 33.10 vs. 51.22 vs. 60.47 vs. 52.80 vs. 47.13 vs. 46.47, n 
= 3; p < 0.05). Despite the significant elevated expression of these markers 
on peptide-pulsed pDC with Imiquimod, the antigen tolerance effect, 
mentioned above, still exists, albeit to a lesser extent.  These results suggests 
that co-stimulation of pDC with Imiquimod, when pulsed with antigen, can 
increase cell maturity and activation markers. The lack of CD80 upregulation 
is not of major concern as work by Elloso and Scott (134), demonstrated that 
costimulation involving CD80 or CD86 can result in the production of either 
Th1 or Th2 cytokines, rather than a preferential induction of one type of 
response.  
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The supernatant of peptide-pulsed pDC, co-stimulated with Imiquimod was 
analysed for their production of IFN-Į,/-6 and TNF-ĮYLD(/,6$DVLOOXVWUDWHG
in Figure 6.13.   In correlation with Figure 6.12, peptide-pulsed pDC, 
demonstrated a dose dependent increase in IFN-Į ,/-6 and TNF-Į )LJXUH
6.13; 20 ± 100 µg/ml, n = 3, p < 0.05). Peak secretion of  IFN-Į)LJXUH$
20 vs. 40 vs. 60 vs. 80 vs. 100 µg/ml; (IFN-ĮQJPO± 0.29 vs. 0.33 vs. 0.36 
vs. 0.18 vs. 0.04, n = 3), IL-6 (Figure 6.13B; 20 vs. 40 vs. 60 vs. 80 vs. 100 
µg/ml; (IL-6 ng/ml) ± 2.6 vs. 3.03 vs. 1.72 vs. 1.27 vs. 1.17, n = 3) and TNF-Į
(Figure 6.13C; 20 vs. 40 vs. 60 vs. 80 vs. 100 µg/ml; (TNF-ĮQJPO± 0.55 vs. 
0.77 vs. 0.43 vs. 0.34 vs. 0.25, n = 3) at 40 µg/ml of peptide.       
As before, 3 µM Imiquimod enhanced the production of these chemokines. 
Peak secretion of  IFN-Į)LJXUH$YV40 vs. 60 vs. 80 vs. 100 µg/ml; 
(IFN-ĮQJPO± 0.71 vs. 0.80 vs. 0.74 vs. 0.25 vs. 0.14, n = 3), IL-6 (Figure 
6.13B; 20 vs. 40 vs. 60 vs. 80 vs. 100 µg/ml; (IL-6 ng/ml) ± 9.27 vs. 8.99 vs. 
7.06 vs. 6.12 vs. 3.39, n = 3) and TNF-Į)LJXUH&YV40 vs. 60 vs. 
80 vs. 100 µg/ml; (TNF-ĮQJPO± 1.25 vs. 1.43 vs. 0.89 vs. 0.64 vs. 0.41, n = 
3) was demonstrated 20 µg/ml for IL-6 and 40 µg/ml for IFN-ĮDQG71)-Į 
These results are suggestive of pDC maturation and pro-inflammatory 
cytokine production when pulsed with antigen and Imiquimod. It could also be 
suggested that, contrary to some literature, the endocytic activity of pDC does 
exists (45-48), which improves upon co-stimulation with Imiquimod. Further 
work would need to be carried out on the degree of maturation that pDC 
undergo when treated with TLR7 agonists and to quantify their ability to 
endocytose antigen and present it efficiently. 
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Figure 6.12 ± Imiquimod Increases pDC Maturation Marker Expression when 
Co-administered with MUC1 Peptide.  Expression of A - CD80, B - CD83 and C - 
CD86 is increased in pDC when stimulated with 3 µM Imiquimod and varying 
concentrations of MUC1 peptide (0 ± 100 µg/ml) for 24 hours. Peak expression of 
CD80, CD83 and CD86 was seen at 40 µg/ml MUC1 peptide and 3 µM Imiquimod, p 
< 0.05; n = 3. Figure representative of the means of three independent experiments 
from three different donors. Error bars represent standard deviations.*=p<0.05. 
Statistical significance determined by a one-way ANOVA analysis with column 
comparisons using Tukey's Multiple Comparison Test. 
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Figure 6.13 ± Imiquimod Increases pDC Cytokine Production when Co-
administered with MUC1 Peptide. Combined treatment of pDC with 3 µM 
Imiquimod and varying concentrations of MUC1 peptide (0 ± 100 µg/ml) for 24 hours 
leads to a dose dependent increase in A - IFN-ĮB - IL-6 and C - TNF-Į 3HDN
concentrations of cytokines were seen at at 40 µg/ml MUC1 peptide and 3 µM 
Imiquimod.  Figure representative of the means three independent experiments from 
the same donor. Error bars represent standard deviations. *=p<0.05. Statistical 
significance determined by a one-way ANOVA analysis with column comparisons 
using Tukey's Multiple Comparison Test.. Detection limit = 40 pg/ml 
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Figure 6.14 ± Imiquimod Facilitates the Generation of MUC1+ CD8 T cells.  pDC, CD8 and Treg were co-cultured for 7 days. FACS plots of CD8+MUC1+ 
cells, A ±  Negative control, 0 µg/ml MUC1 peptide, B ± 40 µg/ml MUC1 peptide  C ± 40 µg/ml MUC1 peptide plus 3 µM Imiquimod, D - 40 µg/ml MUC1 
peptide plus Treg  E - 40 µg/ml MUC1 peptide plus Treg with 3 µM Imiquimod. Addition of 3 µM Imiquimod caused an increase in the number of CD8+MUC1+ 
T cells. F ± Cytokine output of CD8+MUC1+ T cell generation. Increases in IFN-Į,)1-Ȗ IL-6, IL-10 and TNF-ĮZHUHVHHQRQDGGLWLRQRI0,PLTXLPRG
Figure representative of the mean of one experiment run in triplicate. Error bars represent standard deviations. *=p<0.05. Statistical significance determined 
by a one-way ANOVA analysis with column comparisons using Tukey's Multiple Comparison Test. Detection limit = 40 pg/ml 
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6.3.6 Generation of CD8+MUC1+ T cells 
With limited time and reagents, and having demonstrated the role Imiquimod 
could have in mediating CD8+ T cell proliferation as well as maturation of 
pDC, a small scale MUC1+ T cell generation assay was assembled. Figures 
6.14A-E illustrates the percentage of CD8+MUC1+ T cells as identified using a 
MUC1-specific pentamer while Figure 6.14F depicts the corresponding 
cytokine output. The first observation to be made is from Figure 6.14B, where 
peptide-pulsed pDC and CD8+ T cells were co-cultured. 1.21 +/- 0.6 % of 
CD8+ T cells became positive for MUC1+ which suggests that pDC have some 
intrinsic cross-presentation activity. This effect was enhanced on the addition 
of 3 µM Imiquimod (Figure 6.14C), with 2.54 +/- 0.3 % of cells being 
CD8+MUC1+ T cells.  
On addition of Treg to the co-culture system, the percentage of MUC1+ cells 
fell to 0.46 +/- 0.2 % (Figure 6.14D), indicating that Treg had inhibited CD8+ T 
cell priming (135). However, on the re-introduction of Imiquimod to the 
system, the fraction of antigen-specific CD8+ T cells increased to 1.86 %.  
These CD8+MUC1+ T cells were sorted with the intention of using them in a 
cytotoxic T cell assay (136). However, when sorting, only 112 positive cells 
were collected. These were subsequently cultured under T cell expansion 
conditions as described in the methods section above. At the time of writing, 
these cells had now reached a total cell number of 4.8 x 104, which was not 
enough for use in an assay. 
The cytokine profiles of these assays demonstrated a similar trend. Treg 
significantly reduced the production of IFN-Į S'&&' YV Treg (ng/ml) ± 
9.35 vs. 7.26, n = 3, p < 0.05), IFN-ȖS'&&'YVTreg (ng/ml) ± 3.68 vs. 
0.91, n = 3, p < 0.05), IL-6 (pDC/CD8 vs. Treg (ng/ml) ± 8.47 vs. 7.72, n = 3, 
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p < 0.05), IL-10, (pDC/CD8 vs. Treg (ng/ml) ± 2.81 vs. 1.11, n = 3, p < 0.05) 
and TNF-ĮS'&&'YVTreg (ng/ml) ± 1.26 vs. 0.83, n = 3, p < 0.05).  
Yet on addition of Imiquimod, there was a partial reversal of this effect IFN-Į
(Figure 6.14F; Treg vs. Treg + 3 µM Imiquimod (ng/ml) ± 7.26 vs. 13.92, n = 
3, p < 0.05), IFN-Ȗ)LJXUH)7UHJYVTreg + 3 µM Imiquimod (ng/ml) ± 
0.91 vs. 8.09, n = 3, p < 0.05), IL-6 (Figure 6.14F; Treg vs. Treg + 3 µM 
Imiquimod (ng/ml) ± 7.72 vs. 11.68, n = 3, p < 0.05), IL-10, (Figure 6.14F; 
Treg vs. Treg + 3 µM Imiquimod (ng/ml) ± 1.11 vs. 5.31, n = 3, p < 0.05) 
and TNF-Į)LJXUH)7UHJYVTreg + 3 µM Imiquimod (ng/ml) ± 0.83 vs. 
2.10, n = 3, p < 0.05).  An interesting observation from Figure 6.14F was 
noted in that on treating the CD8/pDC/Treg co-culture there was a significant 
increase in all the cytokines measured. A possible explanation for this could 
be inferred from work carried out Sharma et al. (137) who described the use 
of a TLR9 ligand to reduce the suppressive effects of Treg. The key 
REVHUYDWLRQ ZDV WKDW WKHVH QHZO\ µQRQ-VXSSUHVVLYH¶ 7UHJ DFWHG OLNH
conventional T helper cells and improved the generation of antigen specific 
CD8+ T cells.        
These effects could be attributed to the evidence provided earlier in this 
chapter. TLR7 agonism lead to a decrease in the suppressive effects of Treg 
and an increase in CD8+ T cell activation and proliferation, pDC maturation 
and pro-inflammatory cytokine secretion, there is an increased possibility of 
aiding antigen specific CD8+ T cell generation. However, as this experiment 
was only executed once it is difficult to make any meaningful conclusions 
from it.  
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6.4 Conculsions 
This chapter sought to take advantage of MUC1 antigen release which would 
occur under the treatment of ovarian tumours with JPM137. Although 
successful release of antigen has been demonstrated, it is not adequate to 
assume that efficient MUC1-specific T cell priming will occur. Therefore, a 
method of potentiating the immune system such that antigen presentation, 
cytotoxic T cell proliferation and increasing the presence of pro-inflammatory 
cytokines was pursued. 
The expression of TLR7 on a variety of immune cell populations; including 
pDC and CD8+ T cells meant that this became an attractive target for use as 
part of the immunotherapeutic strategy being developed in this thesis. 
Evidence regarding the expression of TLR7 on Treg was conflicting; however 
flow cytometry demonstrated a clear expression of the receptor.  A TLR7 
agonist, Imiquimod, was selected and a subsequent investigation into its 
effects on the aforementioned cell populations began. The suppressive effect 
of Treg on both CD4+CD25- and CD8+ T cells were partially reversed with 
TLR7 engagement. Further investigation into the mechanism of how 
Imiquimod was acting suggested that an increase in CD8+ T cell proliferation 
combined with an altered cytokine profile; which had a greater pro-
inflammatory element, were both major contributors. Additional work on the 
change in FOXP3 (88,138) and CTLA-4 (139) expression  would add greater 
credence to the potential of TLR7-mediated abrogation of Treg function.  
The effect of Imiquimod was not just restricted to T cells. pDC are a subset of 
antigen presenting cells that are known for the Type I interferon secretion and 
poor antigen endocytosis and cross-presentation. Their prevalence and 
contribution to the immune suppressive milieu within ovarian tumours has 
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been recently documented (32), making them an interesting target for 
therapeutic innervation.  Treatment with Imiquimod induced pDC activation, 
maturation and the secretion of pro-inflammatory cytokines such as IFN-Į,/-
6 and TNF-Į  2Q WKH DGGLWLRQ RI ,PLTXLPRG S'& SXOVHG ZLWK D 08&
peptide, demonstrated a further increase in activation, maturation and 
cytokine release. Interestingly, an increase in pDC activation and cytokine 
release were seen on the addition of antigen only, suggesting that these cells 
do have the ability to present exogenous antigen, albeit in small amounts 
(140).  
An attempt was then made to combine the above observations into an assay 
to generate MUC1+ cytotoxic T cells. Imiquimod slightly increased the fraction 
of MUC1+CD8+ T cells and was able to partially reverse the suppressive effect 
of Treg on cytotoxic T cell generation.      
The above results suggest that Imiquimod would be of use in enhancing an 
anti-tumour response. The potential of TLR7 agonists to abrogate Treg 
function, as well as boost both pDC and CD8+ T cell activation would be 
advantageous in utilising the antigen which has become readily available on 
targeted tumour cell death. 
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Chapter 7 
General Conclusions and Future Work 
The idea that the immune system can affect either cancer development 
or clearance has been the subject of debate for over a century. In the 
early 1900s, Paul Ehrlich was perhaps the first to reason that cancer 
would be quite common in long-lived organisms if not for the protective 
effects of immunity. It is now recognised that the immune system plays 
at least two distinct roles in cancer: elimination or escape.  
In the elimination phase, innate and adaptive immunity work together to 
destroy developing tumours long before they become clinically apparent. 
Many of the immune molecules and cells that participate in the elimination 
phase, such as CD8+ T cells and Natural Killer cells have been identified. If 
this phase is successful, then the host remains free of cancer. However, a 
common occurrence is the avoidance of some cancer cells to immune-
mediated cytotoxicity. These cells are no longer recognised by the immune 
system through i) loss of antigen expression and presentation, (ii) become 
insensitive to immune effector mechanisms (through the increased fraction of 
Treg or other immune suppressive cells in the tumour-immune infiltrate, or (iii) 
induce an immunosuppressive state within the tumour microenvironment 
(through upregulation of immune suppressive mechanisms such as 
Indoleamine-2,3-dioxygenase and Adenosine). This thesis explores, in 
principle, a strategy to propagate an anti-ovarian cancer immune response by 
targeting three different facets of ovarian cancer immunity; Regulatory T cell 
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(Treg) migration, poor release of the tumour-associated antigen, MUC1 and 
reduced cytotoxic T cell (CTL) proliferation. 
 Before embarking on the development of this strategy, studies were 
conducted to develop a suitable method by which to characterise Treg both 
functionally and phenotypically. Although there is still much debate 
surrounding a truly reliable human Treg phenotype it was decided that 
CD4+CD25+FOXP3+ cells were to be used in all experiments on the basis that 
these were commonly used markers within the literature. On isolation of Treg 
from whole blooding using magnetic beads, it became clear that an expansion 
protocol needed to be devised in order to generate large populations of cells 
for downstream experiments. After comparing the cost/purity benefits of 
dLIIHUHQWVWLPXOLXVHGLQH[SDQVLRQLWZDVGHFLGHGWKDWDQĮ&'VXSHUDJRQLVW
would be used alongside high concentrations of IL-2. This allowed breakage 
of the anergic phenotype of Treg and thus provided suitably pure and large 
populations of cells.  Expanded Treg maintained their phenotype and 
suppressive properties. 
Treg demonstrated dose dependent suppression of both CD4+CD25- and 
CD8+ T cells which is an indicator for the impairment of an anti-tumour 
immune response.  Interestingly, the cytokine milieu generated by Treg 
suppression can be substantially altered, depending on the stimuli added. 
Mitogenic stimulation lead to the production of IFN-Ȗ DQG ,/-10 from Treg 
ZKHUHDV 7&5 HQJDJHPHQW ZLWK Į&'Į&' GRHV QRW 7KLV FRXOG EH
attributed to the altered proliferative pathways that exist within Treg. It also 
indicated that induction of certain molecular pathways, in particular the NF-ț%
pathway could offer a way to alter Treg function.  
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Dose-dependent Treg-mediated suppression suggested that their reduced 
prescene led to greater proliferation of effector populations. This observation, 
together with those found in literature suggests that strategies to either 
manipulate Treg function or decrease the number of Treg within the tumour 
microenvironment will be of clinical benefit (1).  
The evidence of increased Treg within tumour immune infiltrates being 
associated as a poor prognostic indicator gave credence to the theory that 
restricting Treg migration to the tumour site could help reduce the immune 
suppressive milieu. The clinical significance of increased Treg infiltration in 
progressively poorly prognostic ovarian cancer has been, in part, attributed to 
the chemokine-chemokine receptor axis CCL17/CCL22-CCR4. The 
expression of CCR4 and its specific chemokines has also been identified as a 
means for certain tumour types to undergo migration and metastatic seeding 
DWGLVWDQWVLWHV7KLVHYLGHQFHVXJJHVWVWKDWWKLVPHWKRGRIFHOOµUHFUXLWPHQW¶
may be a target for therapeutic intervention.  
Based on current literature and the data in this thesis,  CCL17 and CCL22 are 
both implicated in Treg migration. The propensity of ovarian cancer cells to 
produce CCL17 and CCL22 in response to pro-inflammatory stimuli was also 
observed. This suggests that the immunological time course of events within 
the solid tumour microenvironment starts with a pro-inflammatory period, i.e. 
an anti-tumour response, followed by an ensuing regulatory, or anti-
inflammatory, response. The release of CCL17 and CCL22 into the 
microenvironment could be considered part of that anti-inflammatory 
response; inducing the migration of Treg to dampen any local pro-
inflammatory event.  
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 The use of AZ1, a specific CCR4 antagonist demonstrated efficacy in 
reducing both Treg and ovarian cancer cell migration toboth chemokines. 
With no change in cell viability or the suppressive function of Treg, CCR4 
became the first target of the proposed treatment stratagem. The employment 
of AZ1 would be as an adjuvant. Evidence suggests that as the disease 
progresses there is an increase in Treg infiltration (2,3). This means that 
abrogating the chemotactic function of CCL17 and CCL22 would reduce Treg 
infiltrate over time as the disease progressed.  
The reduction in the infiltrating capacity of Treg would help in the propagation 
of an anti-tumour immune response. However, in order to potentiate this 
effect, it was theorised that an alteration in the suppressive capacity of Treg 
as well as an improvement the release and presentation of tumour-associated 
antigen would be necessary to gain real clinical benefit.  
To explore the facilitation of adequate antigen expression, the cytotoxic 
Camptothecin was used. In vitro, the treatment of ovarian cancer cells with 
this drug led to the release of the tumour-associated antigen MUC1.    This 
antigen has been shown to be highly expressed in ovarian cancer and thus its 
release into the extracellular environment could be advantageous in 
attempting to generate an anti-ovarian tumour immune response. However, it 
must be noted that a saturation of immune populations with antigen can lead 
to antigen-specific tolerance.  Clinically, despite a cytoreduction in tumour 
burden and the increase in MUC1 availability, the lymphodepletive effect of 
Camptothecin  would mean that generating a potent anti-tumour immune 
response would be difficult.  This was highlighted by the significant lack in 
PBMC proliferation but also in terms of a reduction in CD8+ T cell. 
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Interestingly, and in concordance with current literature, low doses of 
Camptothecin reduced the number of Treg from PBMC.  
In order to improve tumour targeting and thus reduce peripheral 
lymphodepletion, JPM137 was created. This novel drug delivery system, 
encapsulated Camptothecin within a hydrophilic polymer to improve its 
solubility and pharmacokinetic profile. The addition of the Leuteinizing-
hormone releasing hormone ligand (LHRH) gave the construct ovarian 
tumour specific targeting properties. JPM137 demonstrated similar but not 
superior cytotoxic  performance compared to Camptothecin while maintaining 
CD8+ T cell populations and reducing Treg.   Critically,  JPM137 would have 
an effect at the tumour site, depleting intra-tumoural Treg while maintaining 
CD8+ T cells whereas Camptothecin would cause peripheral, as well as 
localised immune suppression which would not be as advantageous or 
clinically beneficial.   
The release of MUC1 and subsequent maintenance of immune cell viability 
meant that there is a significant opportunity to induce an antigen specific anti-
tumour immune response. Due to a variety of immune suppressive 
mechanisms it is it is not adequate to assume that efficient MUC1-specific T 
cell priming will occur. Therefore a method of potentiating the immune system 
such that antigen presentation, cytotoxic T cell proliferation and the presence 
of pro-inflammatory cytokines increased was explained.    
The expression of Toll-like receptor 7 on a variety of immune cell populations; 
including pDC and CD8+ T cells meant that this became an attractive target 
for use as part of the immunotherapeutic strategy being developed in this 
thesis. Evidence regarding the expression of TLR7 on Treg was conflictive, at 
best; however flow cytometry demonstrated a clear expression of the 
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receptor. By using a TLR7 agonist, Imiquimod, the suppressive effect of Treg 
on both CD4+CD25- and CD8+ T cells was partially reversed with TLR7 
engagement. Further investigation into where and how Imiquimod was acting 
suggested that an increase in CD8+ T cell proliferation combined with an 
altered cytokine profile; which had a greater pro-inflammatory element, were 
both major contributors.  
The effect of Imiquimod was not just restricted to T cells. Plasmacytoid 
dendritic cells are a subset of antigen presenting cells that are known for their 
Type I interferon secretion and poor antigen endocytosis and cross-
presentation. Their prevalence and contribution to the immune suppressive 
milieu within ovarian tumours has been recently documented (9), making 
them an interesting target for therapeutic innervation.  Treatment with 
Imiquimod induced pDC activation, maturation and the secretion of pro-
inflammatory cytokines such as IFN-Į ,/-6 and TNF-Į 2Q WKHDGGLWLRQRI
Imiquimod, pDC pulsed with a MUC1 peptide, demonstrated a further 
increase in activation, maturation and cytokine release. Interestingly, an 
increase in pDC activation and cytokine release were seen on the addition of 
antigen only, suggesting that these cells do have the ability to present 
exogenous antigen, albeit in small amounts (10).  
An attempt was then made to combine the above observations into a model 
assay with which to generate MUC1+ cytotoxic T cells. Imiquimod slightly 
increased the fraction of cytotoxic T cells and was able to partially reverse the 
suppressive effect of Treg on cytotoxic T cell generation, although the 
cytotoxic effect of these MUC1+T cells was not evaluated.      
To improve the potential of this treatment strategy, key alterations can be 
made. The TLR7 agonist, Imiquimod could be replaced with its daughter 
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compound, Resiquimod. Resquimod has been shown to have activity against 
both TLR7 and TLR8 and is reportedly fifty times more potent than Imiquimod 
(11). This should further reduce the suppressive effect of Treg as well 
increase antigen processing and CD8+ T cell proliferation.  As mentioned in 
Chapter 5, the performance of JPM137 could be improved by modifying the 
prescence of LHRH on the constructs surface. This would allow for greater 
accumulation within the ovarian tumour site and thus improve cytotoxicity. 
The choice of cytotoxic could also be altered. Camptothecin was picked due 
to itself relative inexpensive cost and for the evidence regarding drug 
encapsulation into hydrophilic polymers. Current treatment regimens for 
ovarian cancer include Paclitaxel and Cisplatin (12) and it is not unreasonable 
to suggest that a similar approach could be taken with these drugs. 
In order to evaluate the proposed strategy more effectively, in vivo work is 
essential. In recent years, the development of syngeneic mouse models have 
provided a greater testing bed for chemo- and immuno-therapeutic strategies 
(13). However, one of the major issues with assessing the use of these 
models would be the effect of TLR7 agonists on Treg. As mentioned 
previously TLR7 engagement in mice leads to an increase in Treg 
suppressive activity (14). Standard human tumour xenografts such as those 
used by Dharap et al.(15) would be suitable for evaluating the cytotoxic effect 
of JPM137 as well determining the extent to which MUC1 is released 
peripherally on tumour cell death. The most suitable model would be an 
engraftment of HLA matched immune cells and tumour cells in an nude-
mouse (16), however their reliability and cost would make this difficult to use.    
Overall, this thesis has highlighted the potential importance of polypharmacy 
in treating ovarian cancer. The treatment stratagem employed herewith, has 
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demonstrated a reduction in the immune suppressive behaviour of Treg as 
well as its chemotaxis and reduction in tumour cell migration. The 
combination of chemo- and immunotherapy aides tumour debulking, release 
of the tumour-associated antigen MUC1 and the subsequent presentation and 
potential durable priming of antigen specific-cytotoxic T cells (Figure 7.1).  
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Figure 7.1 ʹ The Effect of JPM137, Imiquimod and AZ1 on Tumour Immunity. A ʹ JPM137 localises at the tumour site and cause cytolysis of the tumour. B- Tumour cell 
death leads to the release of tumour associated antigen. C ʹ Imiquimod activates dendritic cells at tumour draining- and peripheral- lymph nodes causing antigen uptake, 
improved antigen presentation and generation of antigen specific cytotoxic T cells. D ʹ Imiquimod induces the proliferation of CD8+ T cells and improves the production of 
pro-inflammatory cytokines (E). F ʹ Imiquimod reduces the suppressive effects of Treg while AZ1 blocks their migration to the tumour site (denoted by red crosses).   The 
net result is reduced tumour burden and a durable anti-tumour immune response. 
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